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ABSTRACT 
Phthalates are a category of chemicals that are commonly used in a wide range of consumer 
products, including plastics, building materials, medical devices, and personal care products. As a 
result, humans and animals are constantly exposed to phthalates daily. Metabolites of multiple 
phthalates frequently have been detected in human urine and blood samples, suggesting ubiquitous 
exposure to different phthalates. Studies have shown that women are exposed to phthalates at 
higher levels compared to men, likely due to the higher use of personal care products by women 
compared to men. This ubiquitous exposure to phthalates is of great concern because several 
phthalates have been shown to have endocrine disrupting abilities. 
The developing ovary is thought to be extremely vulnerable to toxicants. In mammals, 
females are born with a finite pool of primordial follicles, and the size of primordial follicle pool 
determines the reproductive lifespan. To form the finite pool of primordial follicles, germ cells 
must undergo mitosis, formation of germ cell nests, meiosis, and germ cell nest breakdown. Any 
disruption in the formation of the primordial follicle pool can affect female reproductive ability. 
In the mouse, the ovaries begin to develop around embryonic day (E) 10.5 and the pool of 
primordial follicles starts to form around birth. During the reproductive life span, some primordial 
follicles grow into primary follicles, then pre-antral follicles, and subsequently into antral follicles. 
The antral follicle is the major follicle type that is capable releasing an egg for fertilization and 
synthesizing sex steroid hormones such as estrogens. Thus, female fertility depends on normal 
prenatal ovarian development, the maintenance of a constant stream of growing follicles from the 
primordial to antral stage postnatally, and the health of antral follicles. Chemicals that interfere 
with developing ovaries, formation of a normal number of primordial follicles, and the quality of 
antral follicles will cause infertility. 
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Very limited information is available on the effects of phthalate mixtures on female 
reproduction, and even less information is available on the effects of an environmentally relevant 
phthalate mixture on female reproduction. Thus, the goal of my doctoral dissertation work was to 
examine the effects of an environmentally relevant phthalate mixture on female reproduction. 
Specifically, I examined the direct effect of in vitro phthalate mixture exposure on mouse antral 
follicles. Further, I examined the effects of in vivo prenatal phthalate mixture exposure on the first 
and subsequent generation of mice in a transgenerational study design.  
First, I tested the hypothesis that phthalate mixture exposure decreases antral follicle 
growth, compromises steroidogenic capacity, and induces atresia. Normal antral follicle growth, 
steroidogenic capacity, intact oocyte and somatic cells, and undisrupted cell cycles are important 
for female reproductive health and fertility. I found that the phthalate mixture decreased antral 
follicle growth starting at 24 hours compared to controls. The mixture also decreased several 
hormone levels in the steroidogenic pathway compared to control. Further, the mixture reduced 
atresia rating, but it induced more oocyte fragmentation compared to control. Additionally, the 
phthalate mixture adversely affected antioxidant enzymes, apoptotic factors, steroidogenic 
enzymes, and receptors. Interestingly, the mixture adversely affected several cell cycle regulators 
to induce cell cycle arrest, which in turn reduced atresia. 
Next, I tested the hypothesis that prenatal exposure to an environmentally relevant 
phthalate mixture adversely affects female reproduction in mice. Developing sex organs are very 
sensitive to chemical challenges. For example, prenatal exposure to several phthalates induces 
“phthalate syndrome” in male rodents to disrupt male reproduction. Similar in females, disrupting 
the developing female reproductive organs can result in disrupted puberty, irregular cyclicity, 
subfertility, or infertility. I found that prenatal exposure to the phthalate mixture significantly 
iv 
 
increased uterine weight and decreased anogenital distance at early ages, disrupted estrous 
cyclicity at multiple time points, and induced cystic ovaries at an old age. These observed adverse 
effects are probably the reason for the observed reduced fertility and increased breeding 
complications in phthalate mixture treated mice compared to controls.   
Further, I tested the hypothesis that prenatal exposure to an environmentally relevant 
phthalate mixture induces transgenerational disruption on female reproduction in mice. 
Multigenerational effects occur when the effects of a chemical are observed in more than one 
generation (F1 and F2). Transgenerational effects occur when the effects of a chemical is 
transmitted to the generations that are not directly exposed to the chemical, such as the F3 
generation. I found that prenatal exposure to the phthalate mixture induced multigenerational and 
transgenerational effects in female mice. Specifically, the phthalate mixture significantly increased 
body weight at different ages in F2 and F3 females, increased liver weights in F2 females, 
decreased anogenital distance in F2 and F3 females, increased uterine weight in F2 females, 
induced cystic ovaries in F2 females, and caused breeding complications in F2 and F3 females. 
Taken together, these data suggest that prenatal exposure to an environmentally relevant phthalate 
mixture disrupts many aspects of female reproduction in F2 and F3 female mice. Collectively, my 
doctoral dissertation data suggest that exposure to an environmentally relevant phthalate mixture 
directly acts on antral follicles to reduce the health and function of antral follicles, and exposure 
to this mixture prenatally causes fertility problems in the first and the subsequent generations of 
female mice.  
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CHAPTER I 
Overview 
1.1 Overview 
Humans are constantly exposed to endocrine disrupting chemicals (EDCs). Numerous 
studies have already indicated that EDCs, such as phthalates, can cause impaired reproductive 
function (reviewed in [1]). Phthalates are a family of structurally related chemicals used as 
plasticizers and additives in a wide range of common products, including various plastics, 
cosmetics, personal care products, polyvinyl chloride pipes, and vinyl flooring [2, 3]. However, 
most previous studies have only examined a single phthalate, and it is well known that humans 
and animals are exposed to mixtures of phthalates [4-6]. The limited number of studies conducted 
with chemical mixtures either used very high doses (over 100 times higher than human daily 
exposure) or the mixtures were not made based on actual phthalates present in humans. It is crucial 
to examine environmentally relevant doses of a phthalate mixture that mimics human daily 
exposure so that we can better understand the potential risks of phthalates on human and animal 
health.  
Previous studies have not determined the effects of an environmentally relevant phthalate 
mixture on the ovary. It is important to determine if phthalates cause toxicity in the ovary because 
ovarian toxicity can lead to infertility. The developing ovary is thought to be extremely vulnerable 
to toxicants. In the mouse, the ovaries begin to develop around embryonic day (E) 10.5 after the 
primordial germ cells migrate to the genital ridge [7-10]. The primordial germ cells then undergo 
mitotic proliferation while they are still connected to each other to form clusters called germ cell 
nests [8, 11]. This mitotic proliferation of the germ cells stops around E 13.5, when the germ cells 
enter meiosis to form oocytes. At E 17.5, the oocytes become arrested at the diplotene stage of 
2 
 
prophase in meiosis I [7-10]. Between E 17.5 to postnatal day (PND) 5, the germ cell nests break 
down, allowing the formation of individual primordial follicles. The primordial follicles formed 
during this time period represent the reproductive capacity for the female’s entire life span. During 
the reproductive life span, some primordial follicles grow into primary follicles, then pre-antral 
follicles, and subsequently into antral follicles. The antral follicle is the major follicle type that is 
capable releasing an egg for fertilization and synthesizing sex steroid hormones such as estrogens 
[7]. Thus, female fertility depends on normal prenatal ovarian development, the maintenance of a 
constant stream of growing follicles from the primordial to antral stage postnatally, and the health 
of antral follicles. Chemicals that interfere with developing ovaries, formation of a normal number 
of primordial follicles, and the quality of antral follicles will cause infertility. 
Thus, the overall goal of my doctoral dissertation work was to test the effects of a phthalate 
mixture on the ovarian antral follicle health and reproductive capability of female mice. The 
phthalate mixture that I used in my studies was made of 21% di-2-ethylhexyl phthalate (DEHP), 
35% diethyl phthalate (DEP), 15% dibutyl phthalate (DBP), 8% diisobutyl phthalate (DiBP), 5% 
benzylbutyl phthalate (BBzP), and 15% diisononyl phthalate (DiNP). This mixture is 
environmentally relevant because it was based on levels of phthalate metabolites present in human 
urine samples from pregnant women in Illinois (unpublished data from the iKids study). The 
specific goal of my doctoral dissertation work was to test the hypothesis that exposure to an 
environmentally relevant phthalate mixture decreases the growth and steroidogenic capacity of 
antral follicles and causes transgenerational fertility problems in female mice. 
To complete my dissertation work, I specifically tested the following three main 
hypotheses: 1) phthalate mixture exposure decreases antral follicle growth, compromises 
steroidogenic capacity, and induces atresia, 2) prenatal exposure to an environmentally relevant 
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phthalate mixture adversely affects female reproduction in mice, and 3) prenatal exposure to an 
environmentally relevant phthalate mixture induces transgenerational disruption on female 
reproduction in mice. To test these hypotheses, I completed the following specific aims: 
Specific Aim 1: Examine if phthalate mixture exposure decreases antral follicle growth, 
compromises steroidogenic capacity, and induces atresia.  
To complete this aim, I isolated and cultured antral follicles from adult cycling CD-1 mice 
with vehicle control (dimethyl sulfoxide, DMSO) or phthalate mixture (1-500 µg/ml) for 96 hours. 
During culture, antral follicle diameters were measured every 24 hours to monitor growth. After 
culture, media were subjected to measurements of sex steroid hormones and follicles were 
subjected to evaluation of gene expression and atresia. The data indicated that the phthalate 
mixture (100 and 500 µg/ml) decreased antral follicle growth starting at 24 hours compared to 
controls. The mixture at 10, 100, and 500 µg/ml also decreased androstenedione, testosterone, 
estrone, and estradiol levels compared to control. The mixture (10, 100, and 500 µg/ml) reduced 
atresia rating, but it induced more oocyte fragmentation compared to control. The phthalate 
mixture at different doses adversely affected cell cycle regulators, antioxidant enzymes, apoptotic 
factors, steroidogenic enzymes, and receptors. Collectively, these data indicate that exposure to an 
environmentally relevant phthalate mixture reduces antral follicle growth, induces oocyte 
fragmentation, and decreases hormone production by adversely affecting the expression of cell 
cycle regulators, apoptotic factors, steroidogenic enzymes, and receptors. These data are presented 
in Chapter III. 
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Specific Aim 2: Determine if prenatal exposure to an environmentally relevant phthalate 
mixture adversely affects female reproduction in mice. 
 To complete this aim, pregnant CD-1 dams were orally dosed with vehicle (tocopherol-
stripped corn oil) or a phthalate mixture (20 and 200 µg/kg/day, 200 and 500 mg/kg/day) daily 
from gestational day 10 to birth. Female mice born to the exposed dams were subjected to 
measurements of body and tissue weights, as well as tissue collections on postnatal day 1, 4, 8, 21, 
60 and 13 month. These females were also subjected to fertility tests at 3, 6, and 9 month of age. 
The data indicate that prenatal exposure to the phthalate mixture significantly increased uterine 
weight and decreased anogenital distance on postnatal days 8 and 60, induced cystic ovaries at 13 
months, disrupted estrous cyclicity, reduced fertility-related indices, and caused breeding 
complications at 3, 6, and 9 months of age. Collectively, these data suggest that prenatal exposure 
to an environmentally relevant phthalate mixture disrupts many aspects of female reproduction in 
mice. These data are presented in Chapter IV. 
Specific Aim 3: Test whether prenatal exposure to an environmentally relevant phthalate 
mixture induces transgenerational disruption on female reproduction in mice. 
  To complete this aim, I dosed pregnant dams from gestational day 10 until birth and used 
the female mice born to these dams to produce the next two generations. The dosed dams were 
considered to be the F0 generation. F0 mice were orally dosed with tocopherol-stripped corn oil 
(vehicle control) or different doses of phthalate mixture (20 and 200 µg/kg/day, 200 and 500 
mg/kg/day). The pups born to F0 were considered as the first generation (F1). The F1 generation 
was exposed to phthalate mixture as fetuses during dosing of the F0 dam. The F1 females were 
used to generate the second generation (F2) by breeding F1 female mice (3 months of age) with 
non-exposed adult proven male breeders. This F2 generation was exposed to phthalates as germ 
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cells when the F0 dams were dosed with the mixture. The F2 females were then used to generate 
the third generation (F3) by breeding F2 female mice (3 months of age) with non-exposed adult 
proven male breeders. This F3 generation was the first generation that was not exposed to phthalate 
mixture during the dosing of F0 dams. F2 and F3 female mice were subjected measurements of 
body and tissue weights, as well as to tissue collections on postnatal day 1, 4, 8, 21, 60 and 13 
month. These females were also subjected to fertility tests at 3, 6, and 9 month of age. The data 
indicate that prenatal exposure to the phthalate mixture significantly increased body weight at 
different age in F2 and F3 females, increased liver weight in F2 females, decreased AGD on PND 
21 in F2 and F3 females, increased uterine weight in F2 females, induced cystic ovaries at 13 
months in F2 females, and caused breeding complications in F2 and F3 females at 3, 6, and 9 
months of age. Collectively, these data suggest that prenatal exposure to an environmentally 
relevant phthalate mixture induces multigenerational and transgenerational disruption in many 
aspects of female reproduction in F2 and F3 female mice. These data are presented in Chapter V. 
 In summary, Chapter I describes the overview of my dissertation. Chapter II provides the 
information on common phthalates, phthalate exposure, and the effects of phthalates exposure on 
female and male reproduction. Chapter III describes the work that tested the hypothesis that 
phthalate mixture exposure decreases antral follicle growth, compromises steroidogenic capacity, 
and induces atresia. Chapter IV describes the work that tested the hypothesis that prenatal exposure 
to an environmentally relevant phthalate mixture adversely affects female reproduction in mice. 
Chapter V describes the work that tested the hypothesis that prenatal exposure to an 
environmentally relevant phthalate mixture induces transgenerational disruption on female 
reproduction in mice. Finally, Chapter VI summarizes the findings presented in the entire 
dissertation work and suggests the future study directions.  
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Chapter II 
The Effects of Phthalates on Reproduction1 
2.1 Abstract 
Phthalates are commonly used in a wide range of consumer products, including plastics, 
building materials, medical devices, and personal care products. As a result, humans and animals 
are constantly exposed to phthalates daily. This ubiquitous exposure to phthalates is of great 
concern because several phthalates have been shown to have endocrine disrupting abilities. This 
chapter discusses the known effects of phthalates that are commonly used in building materials, 
personal care products and cosmetics on reproduction. The reproductive endpoints that are of 
interest include the developing and mature sex organs, steroidogenic capacity and regulation, 
puberty, reproductive diseases and complications, fertility, pregnancy, and birth outcomes. Both 
human and animal studies are discussed in this chapter. 
 
 
 
 
 
 
 
 
 
 
1 Published in part in Zhou C. et al. Personal care products and cosmetics. In Reproductive and 
Developmental Toxicology. Editor: Ramesh Gupta. Academic Press/Elsevier, (in press).   
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2.2 Phthalates and exposure 
Phthalates are a family of structurally related chemicals used as plasticizers and additives 
in a wide range of common products, including personal care products (PCPs), plastics, cosmetics, 
polyvinyl chloride pipes, and vinyl flooring [1, 2]. They are divided into two groups, low and high 
molecular weight phthalates, based on the number of carbon atoms in their backbones (low 
molecular weight phthalates have 3-6 carbon atoms, high molecular weight phthalates have more 
than 6 carbons). Several phthalates, especially the low molecular weight phthalates, are commonly 
used as additives (e.g., humectants, emollients, and skin penetration enhancers) in PCPs [3, 4].  
Several studies have detected phthalates in PCPs, including some that have been banned 
by certain countries/regions [3, 5, 6]. A study conducted in Albany, New York showed that two 
phthalates (diethyl phthalate [DEP] and dibutyl phthalate [DBP]) were present in almost all tested 
perfumes, skin toners, and nail polishes [3]. Similarly, a study conducted in Tianjin, China detected 
DEP in PCPs, with the highest levels in hand and body lotions [5]. Another study in Canada found 
that DEP is the predominant phthalate in PCPs (especially in fragrances), followed by DBP 
(mainly in nail polishes), diisobutyl phthalate (DiBP), di-2-ethylhexyl phthalate (DEHP), and 
dimethyl phthalate (DMP) [1]. 
Phthalate exposure is widespread in infants and young children because of the use of baby 
care products, such as baby wipes, powder, and lotion. In a study conducted on wipes and wet 
toilet papers for children in Spain, DBP and DEHP (forbidden in the European Union) were present 
in 13 out of the 20 tested samples [6]. Urinary phthalate concentrations in infants and children 
reflect phthalate exposures, and such exposures have been shown to be associated with the use of 
baby care products. Studies showed that the use of lotion, powder, and shampoo is significantly 
associated with DEP, DMP, DiBP, benzyl butyl phthalate (BBzP), and DEHP metabolite levels in 
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infant urine samples [7, 8]. These associations may be due to the immature metabolic system and 
high dosage per unit body surface area in infants [8]. A number of studies have also examined 
phthalate exposure in young children and teenagers [9-11]. These studies indicate that girls have 
higher urinary phthalate metabolite levels (DEP, DEHP, DBP, and DiBP) than boys [9-11]. 
Adult phthalate exposures have been examined extensively around the world. Phthalate 
metabolites are commonly detected in urine samples and the levels of these metabolites are 
correlated with the usage of PCPs [12-16]. Metabolites of DEP, BBzP, DBP, DiBP, and DEHP 
have been detected in urine samples from women and have been positively associated with the 
number of PCPs used by women [12-14]. Studies have also shown that urinary monoethyl 
phthalate (MEP, metabolite of DEP) concentration is positively associated with the use of perfume, 
hair spray, nail polish, and deodorant [15, 16].  
Women are exposed to phthalates at higher levels compared to men, likely due to the higher 
number of products used and increased frequency of using PCPs in women compared to men [3, 
5, 6]. The use of different types of PCPs is closely associated with the exposure levels of phthalates 
in women. Women who use perfume have almost three times higher urinary concentrations of 
MEP than women who do not use perfume [16]. An increased urinary concentration of MEP is 
also associated with the use of hair spray, nail polish, and deodorant [16]. Although fewer PCPs 
are used by men compared to women, men who use cologne, lotion, and deodorant have higher 
urinary phthalate metabolite levels (DEP, DBP, BBzP, and DEHP)  than men who do not use these 
PCPs [17]. In both women and men, urinary MEP concentration increased with the number of 
PCPs used, especially the number of the fragranced products [16, 17]. A study that screened 
phthalates present in perfumes showed that the amounts of several phthalates (detection levels 
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from high to low: DEP, DMP, BBzP, DEHP, and DBP) were above the quantitation limits in the 
European Union [18].  
Phthalate exposure is of concern because epidemiological studies have shown that it is 
associated with increased human health risks [4]. PCPs are frequently and heavily used in human 
daily life; therefore, exposure through PCP use is a major phthalate exposure route. Several studies 
have shown that DEP, DMP, BBzP, DBP, DiBP, and DEHP are the most commonly detected 
phthalates present in PCPs [1, 3, 5, 16, 18]. The sections below describe the effects of phthalates 
present in PCPs on reproduction (study findings are summarized in Tables 2.1 to 2.4).  
2.3 The effects of phthalates on female reproduction 
Ovarian development 
Phthalates can target the developing ovaries to adversely affect the ovarian follicle reserve. 
In mammals, females are born with a finite pool of primordial follicles, and the size of primordial 
follicle pool determines the reproductive lifespan [19]. To form the finite pool of primordial 
follicles, germ cells  must undergo mitosis, formation of germ cell nests, meiosis, and germ cell 
nest breakdown [20]. Any disruption in the formation of the primordial follicle pool can affect 
female reproductive ability.  
Several studies show that phthalate exposure can interrupt primordial follicle formation. In 
vitro DEHP exposure (10 and 100 µM) from postnatal day (PND) 0 to PND 3 significantly reduced 
germ cell nest breakdown and primordial follicle pool formation by increasing oocyte apoptosis 
and reducing oocyte specific gene expression in mouse ovaries [21]. Studies conducted by 
injecting neonatal mice with DEHP (2.5, 5, and 10 μg/g/day, PND 0 to 4) or culturing embryonic 
ovaries with DEHP (25, 50, and 100 mM, from embryonic day 16.5 for 6 days) also showed that 
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DEHP adversely affected germ cell nest breakdown and primordial follicle formation [22]. Further, 
DEHP reduced expression of estrogen receptor beta (ESR2), progesterone receptor (PR), and 
Notch2 signaling factors, as well as reduced proliferation of pregranulosa precursor cells, further 
reducing primordial follicle formation [22]. 
Several studies show that prenatal exposure to phthalates can affect the follicular and 
ovarian structures of the exposed pups. In rats, single gestational exposure to DiBP (0.375, 0.75, 
and 1.25 ml/kg) on gestational day (GD) 10, 12, and 14 induced oocyte degeneration, formation 
of follicles without oocytes, prominent and congested blood vessels in the ovarian stroma, and 
widespread architectural disarray of the ovaries [23]. Prenatal exposure to DEHP from GD 14 to 
birth decreased the thickness of the theca cell layer (50 and 300 mg/kg/day) [24]. In mouse studies, 
DEHP increased the number of preantral follicles when mice were orally dosed (500 and 1000 
mg/kg/day) from GD 17 to 19 [25] or from GD 11 to birth (200 µg/kg/day and 500 mg/kg/day) 
[26]. DEHP exposure during gestation and lactation (0.05 and 5 mg/kg/day) also increased ovarian 
weight and decreased the number of oocytes that reached the metaphase II (MII) stage [27].  
Very limited information is available on the association between prenatal exposure to 
mixtures of phthalates and adverse ovarian outcomes. In one animal study, transgenerational 
effects were caused by a mixture of bisphenol A (BPA), DEHP, and DBP [28]. In that study, F0 
dams were dosed from GD 8 to 14 with the mixture (BPA 50 mg/kg/day, DEHP 750 mg/kg/day, 
and DBP 66 mg/kg/day, or exactly half of the doses) and exposure to the mixture induced 
significant loss of primordial follicles, reduced ovarian follicular reserve, and induced polycystic 
ovaries in both F1 and F3 generations in rats [28]. 
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Postnatal ovary 
Although the finite primordial follicle pool represents female reproductive potential, 
reproductive capacity depends on the quantity and quality of the antral follicles. This is because 
the antral follicle is the only follicle type that is able to ovulate an oocyte for fertilization, as well 
as produce large amounts of sex steroid hormones [19]. After females are born, primordial follicles 
are recruited to grow into more advanced follicle types. Primordial follicles consist of an oocyte 
surrounded by a single layer of flattened granulosa cells. Primordial follicles can grow into primary 
follicles, which contain an oocyte surrounded by a layer of cuboidal granulosa cells. Primary 
follicles then grow to the preantral stage. Preantral follicles have an oocyte surrounded by two or 
more layers of granulosa cells and an outer layer of thecal cells. Preantral follicles then grow into 
antral follicles, which have an oocyte, several layers of granulosa cells, two distinct layers of thecal 
cells, and a fluid filled antral space. Sex steroid hormones produced by antral follicles are required 
for normal estrous cyclicity, maintenance of the female reproductive tract, and the health of non-
reproductive systems such as cardiovascular, bone, and nervous systems [29-31].  
Several in vivo animal studies have shown that postnatal exposure to phthalates can 
adversely affect folliculogenesis in ovaries. When mice were exposed to DEHP daily (PND 7 to 
14) or every 5 days (PND 5 to 20 and PND 5 to 40) at doses of 20 and 40 µg/kg/day, DEHP 
accelerated the rate of follicle recruitment and decreased the number of primordial follicles [32]. 
It also reduced levels of imprinted gene methylation in oocytes and increased MII spindle 
abnormalities in oocytes matured in vitro [32]. In another study, DEHP exposure (20 and 200 
µg/kg/day, 20, 200, and 750 mg/kg/day) for 10 days accelerated primordial follicle recruitment via 
the phosphatidylinositol 3-kinase signaling pathway [33]. DEHP exposure in adult mice for two 
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or four weeks has also been shown to induce follicle atresia (1000 and 3000 mg/kg/day) as well as 
decrease corpora lutea numbers (3000 mg/kg/day) in vivo [34].  
In vitro studies conducted on mouse ovaries or antral follicles also show that phthalates or 
their primary metabolites directly target the postnatal ovaries. In mouse antral follicle cultures, 
DBP exposure (1000 µg/ml) suppressed follicle growth and triggered atresia via altering cell cycle 
regulator and apoptotic factor expression and decreasing estradiol production [35]. Several antral 
follicle culture studies have also shown that DEHP (1, 10, and 100 µg/ml, 0.36, 3.6, and 36 µM) 
and mono-ethylhexyl phthalate (MEHP) (0.1, 1, and 10 µg/ml) directly inhibit antral follicle 
growth and induce atresia by inhibiting steroidogenesis [36-39], inducing oxidative stress [40, 41], 
disrupting expression of cell cycle regulators [39, 41], and altering the expression of pro- and anti-
apoptotic factors [41]. A study conducted using a neonatal ovary culture system showed MEHP 
accelerates early folliculogenesis [38]. That study demonstrated that MEHP (0.2, 2, and 20 µg/ml) 
decreased the percentage of germ cells and increased the percentage of primary follicles in cultured 
mouse neonatal ovaries (cultured from PND 4 to 10) by decreasing phosphatase and tensin 
homolog levels and increasing phosphorylated protein kinase B levels [38]. 
Ovarian steroidogenesis 
The ovaries are responsible for sex steroid hormone production. The ovarian production of 
sex steroid hormones requires the presence of enzymes in both thecal and granulosa cells. Briefly, 
cholesterol is transported into the mitochondria in thecal cells by steroidogenic acute regulatory 
protein (STAR) and is converted to pregnenolone in the mitochondria by cytochrome-P450 
cholesterol side-chain cleavage (CYP11A1). Pregnenolone then diffuses out of the mitochondria 
and is transported to the smooth endoplasmic reticulum to be converted to progesterone by 3β-
hydroxysteroid dehydrogenase (HSD3B1), or to dehydroepiandrosterone (DHEA) by 17α-
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hydroxylase (CYP17A1). Next, progesterone and DHEA are converted to androstenedione by 
CYP17A1 and HSD3B1 in the thecal cells, respectively. Androstenedione is then converted to 
testosterone by 17β-hydroxysteroid dehydrogenase (HSD17B1) or to estrone by aromatase 
(CYP19A1) in the granulosa cells. Testosterone and estrone are then converted to estradiol by 
CYP19A1 and HSD17B1, respectively (reviewed in [42]). Any disruption in the expression or 
activity of these enzymes can adversely affect hormone production in the ovary. Normal growth 
and steroidogenic capacity of the antral follicle is important for both reproductive and non-
reproductive health. Proper steroidogenesis is required for follicle maturation and fertility [43], 
and the maintenance of cardiovascular, bone, and brain function [29-31]. The adverse effects of 
phthalates commonly present in PCPs on antral follicle steroidogenesis are discussed below. 
In vivo studies have shown that exposure to phthalates can affect normal steroidogenesis 
in rodents. In one study, DEHP exposure (100, 500, and 1000 mg/kg/day) from GD 17 to 19 
significantly altered the expression of Star and aromatase, as well as increased estradiol levels in 
mice at adulthood [25]. When mice were exposed to DEHP (0.05 and 5 mg/kg/day) through 
gestation and lactation, DEHP exposure significantly reduced the expression of steroidogenic 
enzymes (Cyp17a1 and Cyp19a1) in adulthood [27]. DEHP exposure at 20 and 40 µg/kg on PND 
5, 10, and 15 significantly reduced gene and protein expression of CYP17A1 and luteinizing 
hormone/choriogonadotropin receptor (LHCGR) in the thecal cells. It also reduced levels of 
progesterone, estradiol, androstenedione, and luteinizing hormone (LH) [44]. In another study, 
DEHP exposure via oral gavage for 10 days at 500 mg/kg/day decreased serum levels of 
progesterone and estradiol in rats, which may be the result of DEHP-induced decreases in the 
transportation of cholesterol into the mitochondria for steroidogenesis [45]. DEHP exposure (25 
mg/m3) through inhalation from PND 22 to 84, however, increased serum cholesterol and estradiol 
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levels as well as increased aromatase gene expression level in rats [46]. Further, DEHP exposure 
at doses from 20 µg/kg/day to 2 g/kg/day for 8 days to 16 weeks decreased the serum levels of 
several sex steroid hormones in rodents (reviewed in [47]).  
Similar to the effects of phthalates on steroidogenesis in vivo, studies also show that 
phthalates disrupt steroidogenesis in antral follicles in vitro. DBP at 1000 µg/ml significantly 
reduced estradiol production in cultured mouse antral follicles [35]. Similarly, DEHP at 1, 10, and 
100 µg/ml inhibited steroidogenesis by reducing estradiol levels in mouse antral follicles [36, 39]. 
Its metabolite, MEHP, had similar effects on steroidogenesis, but at lower doses (0.1, 1, and 10 
µg/ml) than DEHP [38, 39]. 
Uterine structure and function 
The uterus is an important organ in females because it is responsible for embryo 
implantation and maintaining pregnancy. The information on the effects of phthalates that are 
found in PCPs on the uterus is limited, but the available study results are summarized below. 
One study reported an association between phthalate exposure and uterine size in 
Taiwanese girls [48]. This study followed 133 children for 12 years who were prenatally exposed 
to phthalates and showed that DEHP exposure was significantly associated with reduced uterine 
size at the ages of 8 to 11 [48].  
Although information is limited, animal studies show that phthalate exposure adversely 
affects uterine health. When rats were exposed with BBzP at 500 mg/kg/day from PND 2 to 20, 
the female pups had increased relative uterine weight at the time of vaginal opening compared to 
controls [49]. In endometrial cells collected from cows that were treated with DEHP or MEHP 
(0.1, 1, and 10 ng/ml), phthalate exposure stimulated uterine prostaglandin F2 alpha (PGF2alpha) 
17 
 
secretion, but inhibited prostaglandin E2 (PGE2) secretion [50]. This altered ratio of PGF2alpha 
to PGE2 ratio is thought to disrupt the estrous cycle in cows [50]. A study on the effects of a 
phthalate mixture (BBzP, DBP, DEHP, DiBP and dipentyl phthalate, at the ratio of 3:3:3:3:1,) 
showed that the mixture at doses of 65, 130, 260, 520, and 720 mg/kg/day from GD 8 to 19 or GD 
14 to 19 significantly induced female reproductive malformations, including hydrometrocolpos 
and agenesis or complete aplasia of uterus at adulthood in rats [51]. In another mixture study, a 
mixture of BPA, DEHP, and DBP (BPA 50 mg/kg/day, DEHP 750 mg/kg/day, and DBP 66 
mg/kg/day, or exactly half of the aforementioned doses) from GD 8 to 14 significantly reduced 
uterine weights in the F1 and F3 generations in rats [28].  
Anterior pituitary gland 
 The pituitary, especially the anterior pituitary gland, is another key organ in the female 
reproductive system. The hypothalamic-pituitary-ovarian axis regulates menstrual/estrous 
cyclicity and the hormones produced in this axis act on the ovary, uterus, and other parts of the 
reproductive system to regulate female reproduction. The anterior pituitary gland synthesizes and 
secretes luteinizing hormone (LH) and follicle stimulating hormone (FSH) in response to 
gonadotropin releasing hormone (GnRH) synthesized by hypothalamus. The following section 
discusses the known effects of the phthalates present in PCPs on the pituitary.  
Not much is known about the effects of phthalates on the human pituitary. However, 
phthalate exposure has been shown to target pituitary and to affect gonadotropin levels in animal 
studies. DBP exposure from GD 15 to PND 21 through the diet changed the population of pituitary 
hormone-immunoreactive cells (200, 2000, and 10000 ppm) by increasing the percentages of LH-
positive and decreasing FSH and prolactin producing cells in rats [52]. It also decreased pituitary 
weights (10000 ppm at 11 weeks of age, 200 ppm at 20 weeks of age) and increased FSH-positive 
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cells in the pituitary at 11 weeks of age in female rats [52]. Prenatal exposure to DEHP from GD 
14 to birth (1, 50, and 300 mg/kg/day, [24]) or MEHP from GD 17 to 19 (1000 mg/kg/day, [25]) 
increased serum FSH levels when the mice reached adulthood. In another mouse study, DEHP 
exposure (0.05, 5, and 500 mg/kg/day) from gestation to weaning significantly increased 
gonadotropin subunit gene expression at PND 42 [27]. In rats, DEHP exposure (30 mg/kg/day) 
during gestation through PND 15 also increased gonadotropin serum levels [53]. Postnatal DEHP 
exposure (500 mg/kg/day) for 10 days starting at PND 20 significantly increased LH levels in rats 
[45]. DEHP exposure (25 mg/m3) through inhalation from PND 22 to 84 increased serum LH 
levels in rats [46]. Further, a study conducted in adult Manchega sheep showed that DEHP 
exposure three times per week for two months at a dose of 50 mg/kg significantly decreased basal 
LH levels and decreased the pulsatile LH secretion when compared to control [54].  
Puberty 
Several studies examined the association between phthalate exposure and the onset of 
puberty in humans. Studies conducted in Puerto Rican and Chinese girls found that DEHP levels 
were higher in girls with premature thelarche or precocious puberty than in girls without premature 
thelarche or precocious puberty (reviewed in [55]). This association between DEHP levels and 
precocious puberty, however, was not observed in girls in United States (reviewed in [55]). A case-
control study in Taiwan found that urinary levels of monomethyl phthalate (MMP, a metabolite of 
DMP) are associated with premature thelarche [56]. A study from Taiwan measured seven urinary 
phthalate metabolites (MMP, MEP, monobutyl phthalate [MBP], monobenzyl phthalate [MBzP], 
and three metabolites of DEHP) in girls with and without precocious puberty and found that 
urinary levels of all the measured phthalate metabolites were significantly higher in girls with 
precocious puberty compared to girls with normal onset of puberty [57]. In a study conducted in 
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Korea, girls with precocious puberty had higher plasma MBP levels when compared to girls with 
normal onset of puberty, but no associations were found between MEHP levels and precocious 
puberty [58]. In contrast, in a study conducted on 725 Danish girls, higher urinary phthalate levels 
(MBP, MBzP, and DEHP metabolites) were associated with delayed pubarche, but not thelarche 
[59]. Similarly, a study on 1239 girls from the United States showed that urinary levels of DEHP 
metabolites, but not low molecular weight phthalates, were associated with delayed pubarche [60]. 
A study conducted in Shanghai, China also showed that high levels of MBP, MEP, and MEHP in 
urinary samples were measured in children with constitutional delay of growth and puberty [61].  
Animal studies also demonstrate that phthalate exposures can adversely affect puberty. 
BBzP exposure has been shown to delay puberty onset in rats that were exposed through the diet 
(11250 ppm) [62] or by gastric intubation from GD 10 to birth (500 mg/kg/day) [63]. Similarly, 
BBzP exposure (500 mg/kg/day) from PND 2 to 20 decreased body weight at the time of vaginal 
opening (indicating puberty onset), as well as induced architectural changes in the mammary gland 
on PND 35 (500 mg/kg/day) in rats [49]. One study on DEP demonstrated that 10 week dietary 
exposure (15000 ppm) before mating significantly delayed vaginal opening in both F1 and F2 
female pups [64]. In another study, DBP exposure (500 mg/kg/day) in males for 8 weeks before 
mating delayed vaginal opening for 2.5 days in the female pups born to the exposed mice [65]. 
DBP exposure (0.5, 5, and 50 mg/kg/day) during neonatal (PND 1 to 5) and prepubertal (PND 26 
to 30) periods advanced puberty onset, accompanied with irregular estrous cyclicity in female rats 
[66]. The mechanism likely involves the ability of DBP to increase hypothalamic kisspeptin levels 
and GPR54 gene expression in females [66]. In contrast, one study showed that DBP exposure 
(250, 500, and 1000 mg/kg/day) from weaning through puberty, mating, and gestation did not 
affect the age at vaginal opening, time of first estrus, or estrous cyclicity in the female rat pups 
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[67]. In utero exposure to MEHP at 500 and 1000 mg/kg/day delayed estrous onset in the female 
mice [25]. DEHP exposure through inhalation at doses of 5 and 25 mg/m3 from PND 22 to 41 or 
84 (6 h/day, 5 consecutive days/week) advanced puberty onset in rats, characterized by earlier age 
of vaginal opening and age at first estrous cycle [46]. In another DEHP exposure study in which 
female pubertal rats were exposed for four weeks at 250, 500, and 1000 mg/kg/day of DEHP, 
exposure of DEHP significantly increased GnRH levels in the hypothalamus and the GnRH 
receptor levels in the uterus, which could further lead to uterine diseases later in life [68]. 
Menstrual/estrous cyclicity and fertility 
Numerous studies have shown that phthalates are gonadal toxicants and can disrupt normal 
folliculogenesis, follicle growth, and steroidogenesis (reviewed in [47]). These effects of 
phthalates can lead to abnormal menstrual/estrous cyclicity and reduced fertility/infertility. This 
section discusses the effects of phthalates on menstrual/estrous cyclicity and fertility. 
The effects of phthalates on menstrual cyclicity in women are not well characterized, 
however, animal studies have shown that exposure to phthalates alters estrous cyclicity. Exposure 
to DEHP at 3000 mg/kg/day for 4 weeks induced prolonged and irregular estrous cyclicity in rats 
[34]. In another study, DEHP exposure from PND 22 to 84 via inhalation at a dose of 25 mg/m3 
caused irregular estrous cyclicity in rats [46]. DEHP exposure for 10 and 30 days significantly 
disrupted estrous cyclicity (10 days exposure, 20 µg/kg/day, 20, 200, and 750 mg/kg/day; 30 days 
exposure, 200 mg/kg/day) in mice [33]. In contrast, DBP exposure (250, 500, and 1000 mg/kg/day) 
from weaning through puberty, mating, and gestation did not affect estrous cyclicity in the female 
pups [67]. 
21 
 
Fertility has been associated with phthalate exposure in both human and animal studies. In 
a study conducted in Italy, urinary phthalate metabolite levels (DEP, DEHP, BBzP, and DBP) 
were significantly higher in 56 couples who were recruited from assisted reproduction clinics than 
in 56 couples who were parents of more than one child by spontaneous conception [69]. In the 
Environment and Reproductive Health (EARTH) study in which 215 women seeking infertility 
care were recruited, urinary concentrations of DEHP metabolites were positively associated with 
decreased antral follicle numbers [70]. In another report from the EARTH study, which included 
256 women undergoing in vitro fertilization, urinary metabolites of DEHP were inversely 
associated with oocyte yield, clinical pregnancy, and live birth after in vitro fertilization [71]. In 
rats, DEHP exposure at 3000 mg/kg/day from two weeks prior to mating to GD 7 decreased 
pregnancy rate [34]. Prenatal exposure to DEHP in female mice at 200 µg/kg/day and 750 
mg/kg/day induced breeding complications, including longer time to become pregnant and loss of 
some or all pups at birth [26].  
Endometriosis and leiomyoma 
Phthalate exposures have been associated with several pathophysiological reproductive 
conditions, including endometriosis and leiomyoma. The associations between exposure to 
phthalates found in PCPs and these reproductive diseases/conditions are below. 
Several studies found possible correlations between phthalate exposure and endometriosis 
and leiomyoma. In a study that included women from 14 different locations across the United 
States, metabolite levels of DBP and DEHP were significantly associated with an almost two-fold 
increase in the odds of endometriosis diagnosis [72]. In a U.S. Pacific Northwest population, 
DEHP, but not DEP and BBzP, urinary metabolite levels, were significantly associated with 
endometriosis risk [73]. In a National Health and Nutrition Examination Survey study that focused 
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on data collected from 1999 to 2004, positive associations between urinary MBP levels and 
endometriosis and leiomyomata as well as inverse associations between MEHP levels and 
endometriosis were found in 1227 women aged 20 to 54 [74]. In a study conducted in Korea, 
significantly higher DEHP and MEHP plasma levels were found in advanced-stage endometriosis 
patients, suggesting that exposure to phthalates could lead to the establishment of endometriosis 
[75]. In another Korean study, women with or without leiomyoma were recruited in a case control 
study to assess the urinary levels of phthalates [76]. This study found that women with leiomyoma 
had higher levels of urinary DEHP metabolites compared to women without leiomyoma. In a 
Chinese case control study using 61 cases of leiomyoma and 61 age-matched controls, urinary 
metabolites of DiBP, DBP, and DEHP were positively associated with uterine leiomyoma [77]. In 
a Taiwanese study, increased urinary levels of MEHP, MBP, and MEP were associated with 
leiomyoma, and MBP and higher levels of and MEHP were associated with endometriosis [78, 
79]. However, in a study conducted in infertile Japanese women, no associations between urinary 
levels of MEP, MBP, and metabolites of DEHP and endometriosis were found [80].  
Not many in vitro studies are available to examine the underlying mechanisms by which 
phthalates are associated with endometriosis and leiomyoma. One study, however, showed that 
DEHP exposure may induce endometriosis by elevating invasive and proliferative activities in 
endometrial cells [81].  
Pregnancy and birth 
Adverse pregnancy outcomes and birth defects are significant problems worldwide. A wide 
range of factors can adversely affect female reproduction and in turn, affect pregnancy and birth. 
Below, the associations between phthalates found in PCPs and these outcomes are discussed.  
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Information on the association between phthalate exposure and early pregnancy loss in 
humans is limited due to the difficulty in detecting early pregnancy loss in women. Animal studies, 
however, have examined the effects of several phthalates on early pregnancy loss. BBzP, DBP, 
and MBP exposure in pregnant rat dams from GD 0 to 8 significantly increased preimplantation 
loss following successful mating (BBzP and MBP at 1000 mg/kg/day, DBP at 1250 and 1500 
mg/kg/day) and caused post-implantation loss (BBzP and DBP at 750, 1000, 1250, and 1500 
mg/kg/day, MBP at 1000 mg/kg/day) [82-84]. In addition, dietary exposure to DEHP (500 
mg/kg/day) in pregnant mice from GD 0.5 until the end of gestation caused a dramatic increase in 
the post-implantation losses of pups [27].  
Studies have examined the association between mid or late pregnancy loss and phthalate 
exposure in women. In a study on a Danish population, a higher occurrence of pregnancy loss was 
observed in women with higher urinary MEHP concentrations compared to women with lower 
urinary MEHP concentrations [85]. In a case-control study, where 150 cases of missed miscarriage 
and 150 matched normal pregnancies in China were included, urinary levels of DEHP and DMP 
metabolites were significantly associated with odds of missed miscarriage (in utero death of the 
embryo or fetus before it reaches 20 weeks of gestation with retained conception products), as well 
as lower maternal serum hormone levels [86].  
Similarly, animal studies have shown that phthalates induce pregnancy loss. 
Administration of DBP at 500 and 1000 mg/kg/day from weaning through puberty, mating, and 
gestation induced mid-pregnancy abortion and reduced the percentage of live pups delivered in 
rats [67]. Exposure to DEHP at 500 mg/kg/day for 8 weeks caused 100% abortion in mice [87]. 
Phthalate exposures have been shown to adversely affect pregnancy length (reviewed in 
[88]). In a Polish mother and child cohort study, urinary metabolite levels of DEP and DiNP were 
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inversely associated with pregnancy length and infant head circumferences, respectively [89]. In 
a Mexican birth cohort study, urinary levels of MBP, MBzP, and DEHP metabolites in the third-
trimester were higher among women who delivered preterm compared to women who delivered 
full term [90]. In a study conducted in Boston, Massachusetts, DEHP metabolite levels in the third 
trimester were strongly associated with spontaneous preterm birth [91]. Higher DEHP metabolite 
levels in the first trimester were also associated with placental preterm birth (preeclampsia or 
intrauterine growth restriction) [91].  
The association between phthalate exposure and birth outcomes is equivocal. Umbilical 
vein blood, maternal blood, and meconium levels of DBP and MEHP, but not DEP and DEHP, 
were associated with low birth weight (reviewed in [88]). Interestingly, urinary phthalate levels 
were associated with increased size at birth (reviewed in [88]). Furthermore, no associations were 
found between phthalate exposure and infant length, head circumferences, and birth weights 
(reviewed in [88]). In animal studies, when female mice were hypodermically injected with DEHP 
postnatally every 5 days from PND 5 to 40, DEHP (20 and 40 μg/kg) decreased F1 pup weights 
and litter size [32].  
2.4 The effects of phthalates on males 
Developing male sex organs 
The development of the male sex organs largely depends upon testicular hormones 
(testosterone and dihydrotestosterone), anti-Müllerian hormone (AMH), and insulin-like peptide 
3 (INSL3). Disruption of these key factors during development can result in malformation and 
dysfunction of the male reproductive system. Phthalates have been shown to have adverse effects 
on the development of male sex organs. The available information is summarized below.  
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Experiments on the effects of phthalates on human tissues or cells are limited. In one cell 
culture study that used human fetal male germ cells, MEHP exposure at 10−5 M for 3 days 
significantly increased apoptosis in exposed male germ cells [92]. 
Animal studies have shown that in utero exposure to phthalates disrupts reproductive 
development in males. In male rats, prenatal exposure to a number of phthalates (BBzP, DBP, and 
DEHP) caused phthalate syndrome, which consisted of malformation of the male reproductive 
organs, retention of nipples, and reduced anogenital distance (AGD) (reviewed in [93]). One study 
showed that DEHP and BBzP, but not DEP and DMP exposure at 0.75 g/kg/day from GD 14 to 
PND 3 shortened AGD, decreased testis weight, and caused formation of female-like 
areolas/nipples in male rat pups [94]. Gestational exposure to DBP (500 mg/kg/day) in rats, either 
from GD 12 to 20 ([95]) or from GD 13 to 20 ([96]) significantly decreased testosterone levels, 
induced Leydig cell clustering, and increased the number of multi-nucleated gonocytes compared 
to control group. MBP exposure (0.5 g/kg/day) in rats from GD 15 to 18 decreased testis weight, 
inhibited maturation of germ cells, and decreased testosterone production by the Leydig cells in 
the male pups at birth [97]. Exposure to DiBP (600 mg/kg/day) from GD 7 to 21 caused Leydig 
cell hyperplasia and Sertoli cell vacuolization and induced multi-nucleated gonocytes in rats [98]. 
Moreover, in utero exposure to DEHP at 0.1, 1, and 10 mg/kg/day from GD 1 to weaning reduced 
the development and the size of testes on PND 15 in mouse pups [99]. Prenatal and lactational 
exposure to DEHP at 500 mg/kg/day significantly reduced the weights of male sex organs (ventral 
prostate and seminal vesicle) in rats [100]. In another study, MEHP exposure (720 mg/kg/day) 
from GD 13.5 to 14.5 significantly increased apoptosis in mouse fetal testes [92]. In a study that 
examined the mechanism by which prenatal exposure to low doses of DEHP (5 or 50 μg/kg/day) 
affects sexual differentiation in rats, DEHP exposure significantly increased the protein levels of 
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sex-determining region Y-box 9 and AMH in the testis, two factors that are crucial for the sexual 
differentiation events in males [101]. In another study, prenatal DEHP exposure (100 mg/kg/day) 
from GD 12 to 19 induced testis dysgenesis and Leydig cell clustering in the interstitium, caused 
seminiferous cord malformation, and thickened basement membranes of seminiferous cords, 
accompanied with significantly reduced testosterone production in rats [102]. In that study, DEHP 
exposure also significantly altered levels of 23 different proteins, including decreasing the levels 
of proteins involved in testis testosterone production and increasing the levels of proteins related 
to small Leydig cell cluster formation [102].  
Phthalate mixtures have also been shown to affect the development of male sex organs. 
Coadministration of DEHP (150 mg/kg/day) and DBP (100 mg/kg/day) from GD 13 to 21 
significantly reduced testicular testosterone levels and increased the incidence of multinucleated 
gonocytes, the diameter of the seminiferous cords, and Leydig cell clusters in rats [103]. In another 
study, prenatal exposure to DBP, DEHP, and a mixture of DBP and DEHP (500 mg/kg/day for 
each chemical) in rats from GD 14 to 18 induced a greater than 50% increase in the incidence of 
several reproductive malformations (epididymal agenesis, reduced androgen-dependent organ 
weights) and decreased fetal testosterone and Insl3 and Cyp11a1 expression in the male offspring 
[104]. 
Postnatal male sex organs 
Postnatal exposure to phthalates has been shown to induce adverse effects on male 
reproduction. The results obtained from animal studies that focus on postnatal exposure to 
phthalates are discussed below. 
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Prepubertal DBP exposure from PND 4 to 14 at doses from 1 to 500 mg/kg/day reduced 
Sertoli cell proliferation, delayed spermatogenesis, and impaired Sertoli cell maturation in mice 
[105]. Postnatal exposure to DBP (500, 1000, and 1500 mg/kg/day) for 7 days induced oxidative 
stress in the testis and impaired spermatogenesis in adult mice [106]. In another study, DBP 
exposure (100 and 500 mg/kg/day) for 30 days caused maldevelopment of the testes and 
epididymis, severe atrophy of the seminiferous tubules, loss of spermatogenesis, abnormal levels 
of serum hormones, altered levels of proteins involved in spermatogenesis, and disrupted the 
function and number of Sertoli and Leydig cells in rats [107]. Eight weeks of exposure to DBP 
(2000 mg/kg, 3 days/week) before mating increased the incidence of sperm head malformations 
in F1 mice [65]. Eight weeks exposure to DBP (500 mg/kg and 2000 mg/kg, 3 days/week) 
diminished sperm motility and enhanced frequency of abnormal sperm heads in adult mice [108]. 
In another study, DBP exposure (500 mg/kg/day) disrupted tubule formation and germ cell 
differentiation and decreased the number of spermatogonia and Sertoli cells in Rhesus monkey 
testis fragments [109]. Dietary exposure to DEHP in rats at 5000 and 20000 ppm for 60 days 
reduced total body, testis, epididymis, and prostate weights, caused testicular degeneration, and 
decreased testicular zinc content in rats [110]. In another rat study, pubertal exposure to DEHP at 
250, 500, and 750 mg/kg/day for 30 days induced deformed seminiferous tubules, aggregated 
chromatin, multiple vacuoles, swollen mitochondria, apoptotic germ cells and Sertoli cells, but 
increased Leydig cell numbers [111]. In contrast, DEHP exposure at 300 mg/kg weekly between 
3 and 7 weeks of age did not affect testis morphology, the number of Sertoli and Leydig cells, or 
the incidence of germinal epithelial lesions in pigs [112].  
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Steroidogenesis 
The steroidogenic pathway is also a major target of phthalates in males. Information on the 
effects of phthalates on sex steroid hormone production is discussed below.  
Phthalate exposure has been associated with altered sex steroid hormone levels in humans. 
In a Mexican population, prenatal exposure to phthalates was associated with decreased 
dehydroepiandrosterone sulfate (DBP) and inhibin B levels (DEP) as well as increased sex 
hormone-binding globulin levels (BBzP, and DBP) in boys [113]. Additionally, childhood 
exposure to DEHP, BBzP, and di-n-octyl phthalate was associated with decreased testosterone 
levels and increased sex hormone-binding globulin in boys [113]. A longitudinal study showed 
that urinary MBzP levels were negatively associated with dehydroepiandrosterone sulfate levels 
at 11 years of age, but positively associated with testosterone levels at 13 years of age in boys in 
Denmark [114]. A study on 881 Danish men found that MEHP levels were negatively associated 
with free androgen levels, the ratio of testosterone/LH or FSH, total and free testosterone levels, 
and the ratio of testosterone/estradiol [115]. In a 2011-2012 National Health and Nutrition 
Examination Survey study that focused on the United States general population, levels of DEHP 
and DBP metabolites were associated with reduced testosterone levels in men in the 40 to 60 age 
group [116]. In a study conducted on 425 men that were recruited through an infertility clinic in 
the United States, urinary MEHP levels were inversely associated with the levels of testosterone, 
estradiol, and free androgen index [117]. In a Chinese population, occupational exposure to high 
levels of DBP and DEHP were significantly associated with lower free testosterone level in 
workers [118].  
Animal studies have shown that phthalate exposures affect the steroidogenesis pathway 
and reduce sex steroid hormone production. One study found that 10 weeks of dietary DEP 
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exposure (3000 and 15000 ppm) decreased serum testosterone levels in male rats [64]. In another 
study, DBP exposure (500 mg/kg/day) reduced steroidogenic enzyme gene expression in Rhesus 
monkey testis fragments [109]. Prepubertal DBP exposure (from 1 to 500 mg/kg/day) from PND 
4 to 14 reduced testosterone and other testicular androgen activities in mice [105]. Oral gavage 
with DiBP (600 mg/kg/day) from GD 7 to 21 significantly reduced Cyp11A1 protein levels and 
reduced testicular testosterone production in rats [98]. A single dose of DEHP (30, 100, and 300 
mg/kg) on GD 15 decreased the expression of testicular StAR gene and protein expression (100 
and 300 mg/kg) in rats [119]. Moreover, DEHP exposure (10 mg/kg/day) from PND 21 to 48 
significantly increased serum testosterone levels, whereas DEHP exposure at 750 mg/kg/day 
decreased serum testosterone levels compared to control in rats [120]. DEHP exposure (500 
mg/kg/day) for 14 weeks also significantly reduced steroidogenic enzyme gene expression in 
Rhesus monkey testis fragments [109]. An in vitro study showed that certain doses of MEHP had 
biphasic effects on Leydig cells [120]. MEHP exposure (100 µM) increased LH-stimulated 
testosterone production whereas a higher dose (10 mM) inhibited LH-stimulated testosterone 
production [120].  
The effects of a mixture of several phthalates on steroidogenesis have also been examined. 
Exposure to a mixture of five phthalates (BBzP, DBP, DEHP, DiBP, and dipentyl phthalate) from 
GD 8 to GD 18 reduced male fetal testosterone levels in a dose-additive manner in rats [121]. 
Other studies on mixtures of different anti-androgens, including phthalates, also showed that 
mixture exposure reduced fetal testis testosterone production in rats [122, 123]. 
Anogenital distance  
In males, anogenital distance (AGD) is the distance between the anus and the base of the 
penis. AGD is largely determined by prenatal testosterone levels and is frequently used as a 
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measurement of genital development and androgen status in reproductive toxicological studies. 
Studies show that phthalate exposure is associated with shorter AGD in humans. In one 
epidemiological study, median and 95th percentile exposure estimates for prenatal DBP, DEP, 
BBzP, and DEHP exposure were significantly associated with reduced AGD in the male infants 
[124]. Further, a comprehensive literature review on the effects of phthalates on male reproduction 
and development indicates that maternal urinary metabolite levels of DEHP, DBP, BBzP, DEP, 
and DiBP have been associated with decreased AGD in some, but not in all, studies [125].  
Phthalate exposure also can reduce AGD in rodents. BBzP exposure (3750 and 11250 ppm) 
through the diet reduced AGD in rats [62]. In another study, DBP exposure from GD 15 to PND 
21 decreased AGD in rats [52]. Prepubertal DBP exposure (1 to 500 mg/kg/day) from PND 4 to 
14 reduced AGD in mice [105]. Exposure to DiBP (600 mg/kg/day) from GD 7 to 21 reduced 
AGD in rats [98]. Interestingly, whereas individual DEHP or DBP treatment reduces AGD in the 
male offspring, a mixture of these two chemicals (DEHP at 150 mg/kg/day and DBP at 100 
mg/kg/day) from GD 13 to 21 did not affect AGD in rats [103].  
Hypothalamus and pituitary 
Similar to female reproduction, male reproduction is controlled by the hypothalamic-
pituitary-gonadal axis. This axis is responsible for regulating organ development and hormone 
production. Proper feedback, interaction, and regulation among the organs in this axis are crucial 
for normal male reproduction. Adverse effects on any of these organs could disrupt male 
reproduction. The information below describes what is known about the effects of phthalates on 
the hypothalamus and the pituitary. 
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In rodents, phthalate exposure affects male reproduction by acting on both the 
hypothalamus and pituitary. DBP exposure (10000 ppm) through the diet from GD 15 to PND 21 
increased the percentage of LH-positive cells and decreased the numbers of FSH and prolactin 
producing cells in rats [52]. DEHP exposure (30 mg/kg/day) from GD 0 to lactational day 15 
significantly decreased gamma-aminobutyric acid (hypothalamic inhibitory neurotransmitter) and 
increased aspartate (hypothalamic stimulatory neurotransmitter) in prepubertal male rat offspring 
[53]. As a result, phthalate exposure increased gonadotropin serum levels, potentially leading to 
further reproductive problems in rats [53]. In another study, prenatal DEHP exposure at 0.05, 5, 
and 500 mg/kg/day decreased expression of gonadotropin-receptor genes in the gonad and 
increased the gonadotropin subunit gene expression in the pituitary in the male offspring [27]. 
Pubertal exposure to DEHP at 250, 500, or 750 mg/kg/day for 30 days has been shown to disturb 
the hypothalamic-pituitary-testis axis by reducing serum testosterone, LH, and FSH levels in rats 
[111]. 
Puberty  
Although information is limited, phthalate exposures have been associated with disrupted 
pubertal onset in human epidemiological studies. In a Mexican population, prenatal exposure to 
some phthalates was associated with reduced odds of adrenarche (metabolites of DEHP, BBzP, 
DBP, DiBP, DEP, and di-n-octyl phthalate) and puberty (metabolites of DEHP, BBzP, DBP, and 
DiBP) in boys [113]. Further, a longitudinal study showed that urinary MBP levels were associated 
with younger age of pubarche [114]. 
Phthalate exposure delays or advances pubertal onset in animal studies, depending on the 
exposure windows and doses. BBzP exposure (3750 and 11250 ppm) through the diet delayed 
pubertal onset, induced nipple retention, and caused male reproductive system malformation 
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(11250 ppm only) in rats [62]. Pubertal DEHP exposure (300 and 900 mg/kg/day) from PND 22 
to 58 significantly delayed the onset of puberty and reduced androgen-dependent organ weights 
by acting on both Leydig and Sertoli cells in rats [126]. Moreover, DEHP exposure at 10 
mg/kg/day from PND 21 to 48 significantly advanced pubertal onset and DEHP exposure at 750 
mg/kg/day delayed pubertal onset in rats [120].  
Fertility 
Phthalate exposure has been associated with abnormal sperm parameters in human and 
animal studies, a scenario that could reduce fertility. A study conducted in over 1000 men in China 
showed that urinary MBP levels were positively associated with low sperm concentration and low 
total sperm count, and MEHP levels were associated with an increased percentage of abnormal 
sperm heads [127]. Another Chinese study conducted in 1066 men of reproductive age further 
showed that urinary MEHP levels were negatively associated with acrosin activity (aids in the 
penetration of the zona pellucida) and that MBP and MiBP levels were negatively associated with 
acrosin activity and normal sperm morphology, but positively associated with DNA fragmentation 
index [128]. In another Chinese study, metabolites of DBP and DEHP were associated with 
reduced semen volume, metabolites of DBP, DEHP and BBzP were associated with decreased 
sperm velocity, and a metabolite of BBzP was associated with increased percentage of abnormal 
sperm heads and tails [129]. In a multi-center study in the United States, in which partners of 
pregnant women were recruited from the prenatal clinics, urinary levels of metabolites of DiBP 
and BBzP were negatively associated with semen quality, indicated by the lower sperm 
concentration and motility [130]. In a study that included 501 couples in the United States, urinary 
levels of MEP, MBP, and MBzP in men were associated with longer time to pregnancy [131]. 
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Many animal studies have shown that phthalate exposure affects sperm and reproductive 
organs to reduce fertility. In mice, DBP exposure for 8 weeks (3 days/week, 500 and 2000 mg/kg) 
diminished sperm motility, increased the frequency of abnormal sperm heads in adults [108], 
caused pup growth-retardation, and increased the incidence of sperm head malformation in the 
male pups (only at 2,000 mg/kg/day) [65]. In rats, prenatal exposure to DBP (100 and 500 
mg/kg/day) on GD 1, 7, and 14 significantly decreased fertility by decreasing testicular 
steroidogenic enzyme activity levels, serum testosterone levels, sperm density, motile and viable 
sperm numbers, and by increasing sperm abnormalities [132]. In a study conducted by using p53-
deficient mice, DBP exposure (250 and 500 mg/kg/day) from GD 12 until birth significantly 
induced multi-nucleated germ cells in the male offspring [133]. Prenatal exposure to DEHP (0.045, 
0.405, and 405 mg/kg/day) from GD 6 to lactation day 21 reduced daily sperm production (0.045 
mg/kg/day and higher), increased serum testosterone levels, and decreased weight of seminal 
vesicles with coagulating glands (405 mg/kg/day) in rats [134]. Prenatal and lactational exposure 
to DEHP at 500 mg/kg/day significantly disrupted male sexual behavior, and reduced daily sperm 
production and epididymal sperm counts when male rats were examined during puberty and 
adulthood [100]. Another prenatal and lactational DEHP exposure study in mice and rats showed 
that exposure at 0.05 and 5 mg/kg/day reduced testis weights and caused 50% less concentrated 
semen in the male pups [135]. DEHP exposure from PND 7 to 49 reduced the quality and quantity 
of spermatozoa (at 20 and 40 µg/kg/day), decreased the number of germ cells entering meiosis (at 
40 µg/kg/day), and altered immature testis gene expression (at 5 µg/kg/day) in mice [136]. Dietary 
exposure to DEHP at 5000 and 20000 ppm for 60 days reduced epididymal sperm density and 
motility and increased the incidence of abnormal sperm at the higher exposure group in rats [110]. 
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Reproductive diseases and complications 
Phthalate exposures are associated with several male reproductive diseases/complications 
in both epidemiological and animal studies. In a United States study, mother and male infant pairs 
were recruited during the first trimester of pregnancy and urinary phthalate levels were measured 
during first trimester [137]. This study found that the incidence of a newborn male genital anomaly 
was positively associated with first trimester urinary DEHP metabolite levels. Hypospadia is a 
testosterone-mediated condition that is described as an incomplete urethral closure during the 
development of external genitalia, resulting in the opening of the urethra on the underside of the 
penis. Information from epidemiological studies is very limited, but 3 out of the 4 studies did not 
find an association with maternal or paternal phthalate exposures and hypospadias; the only study 
that showed positive association had a very small sample size (reviewed in [125]).  
In one animal study, phthalate mixture exposure induced formation of hypospadias. In that 
study, exposure to a mixture of anti-androgens (vinclozolin, procymidone, linuron, prochloraz, 
BBzP, DBP, and DEHP) from GD 14 to 18 significantly disrupted male reproductive tract 
differentiation, induced hypospadias and epididymal agenesis, and caused undescended testes at 
high doses (75% and 100% of a mixture of 15 mg/kg/day vinclozolin, 15 mg/kg/day procymidone, 
35 mg/kg/day prochloraz, 20 mg/kg/day linuron , and 150 mg/kg/day each of BBzP, DBP, and 
DEHP) in rats [138]. 
Another common defect of the male reproductive system is cryptorchidism. In this 
condition, one or both testes are undescended. Results from studies on the association between 
phthalate exposure and cryptorchidism in humans are inconsistent. Metabolites of DEHP have 
been associated with cryptorchidism in some studies, however, other studies indicate that the levels 
35 
 
of metabolites of DEP, DBP, DiBP, DMP, BBzP, or DEHP are not associated with the prevalence 
of cryptorchidism (reviewed in [125]).  
In animal studies, DBP exposure (500 mg/kg/day) from GD 13.5 to 21.5 has been shown 
to induce cryptorchidism [139]. The mechanism by which DBP induces these adverse effects is 
thought to be by reducing INSL3 and CPY11A1 protein expression during gestation, leading to 
disrupted development and malfunction in adult Leydig cell populations [139].  
DEHP and DBP have also been shown to have transgenerational effects on reproduction in 
rodents. One study that exposed F0 dam rats from GD 8 to 14 with a plasticizer compound mixture 
(BPA 50 mg/kg/day, DEHP 750 mg/kg/day and DBP 66 mg/kg/day) found transgenerational 
effects on several male reproductive diseases [28]. Specifically, the mixture increased the 
incidence of prostate disease and abnormalities in F1 male rats, decreased seminal vesicle and 
epididymal weights in the F3 generation, and caused testicular diseases in both the F1 and F3 
generations [28]. The adverse effects of this mixture are probably through mixture-induced sperm 
epimutation (differential DNA methylation regions in gene promoters) that promoted epigenetic 
transgenerational diseases [28].  
2.5 Conclusion  
People use PCPs and cosmetics on a daily basis. As a result, humans are constantly exposed 
to chemicals in PCPs and cosmetics. Phthalates are very commonly used in these products. Thus, 
exposures to these chemicals are inevitable. Many available studies on the chemicals that are 
commonly found in PCPs, especially phthalates, have already shown that these chemicals can 
adversely affect female and male reproduction in both human and animal studies (summarized in 
Tables 2.1 to 2.4).  However, results from human epidemiological studies vary with study 
population and analytical methods. Thus, future studies are needed to develop some reliable 
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approaches to assess the association between phthalate exposure and adverse human health 
outcomes. More information is needed on the effects of the chemicals used in PCPs on 
reproduction in both human and animal respects. Moreover, the mechanisms by which these 
chemicals cause adverse effects on reproduction are not well understood. Thus, future studies are 
needed to examine the mechanisms by which different chemicals found in PCPs affect 
reproduction, especially with a focus on environmentally relevant exposures.  
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Table 2.1 The effects of phthalates on female reproduction (experimental studies) 
Targets Phthalate Species Exposure Effects References 
Ovarian 
development 
DiBP Rat 
Single exposure on GD 
10, 12, and 14, 0.375, 
0.75, and 1.25 ml/kg 
Oocyte degeneration, follicle formation 
without oocytes, prominent and congested 
blood vessels in the ovarian stroma, 
widespread architectural disarray of the ovaries 
[23] 
 
DEHP 
Mouse 
In vitro ovary culture, 
PND 0 to 3, 10 and 100 
µM 
Reduced germ cell nest breakdown and 
primordial follicle pool formation 
[21] 
Mouse 
PND 0 to 4, 2.5, 5, and 10 
µg/g/day 
Reduced germ cell nest breakdown and 
primordial follicle pool formation by 
decreasing expression of ESR2, PR, and 
Notch2 signaling factors, reduced proliferation 
of pregranulosa precursor cells 
[22] 
Mouse 
In vitro ovary culture, GD 
16.5 for 6 days, 25, 50, 
and 100 mM 
Rat 
GD 14 to birth,  50 and 
300 mg/kg/day 
Decreased thickness of the theca cell layer [24] 
Mouse 
GD 17 to 19, 500 and 
1000 mg/kg/day 
Increased number of preantral follicles 
[25] 
Mouse 
GD 11 to birth, 200 
µg/kg/day and 500 
mg/kg/day 
[26] 
Mouse 
Gestation and lactation, 
0.05 and 5 mg/kg/day 
Increased ovarian weight and decreased 
number of oocytes that reach the MII stage 
[27] 
Mixture Rat 
GD 8 to 14, mixture of 
BPA, DEHP, and DBP 
(BPA 50 mg/kg/day, 
DEHP 750 mg/kg/day, 
and DBP 66 mg/kg/day, 
or half of the doses) 
Induced loss of primordial follicles, reduced 
ovarian follicular reserve, and polycystic 
ovaries in both F1 and F3 
[28] 
Postnatal 
ovary 
DBP Mouse 
Antral follicle culture, 
1000 µg/ml 
Suppressed follicle growth and triggered 
atresia via altering cell cycle and apoptotic 
[35] 
2.6 Tables  
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Postnatal 
ovary 
factor expression and decreasing estradiol 
production 
DEHP 
Mouse 
Injection, every 5 days, 
PND 5 to 40, 20 and 40 
µg/kg/day 
Accelerated follicle recruitment, decreased 
numbers of primordial follicles, reduced levels 
of imprinted gene methylation in oocytes, and 
increased MII spindle abnormalities in oocytes 
matured in vitro 
[32] 
Mouse 
Adult dosing for 10 or 30 
days, 20 and 200 
µg/kg/day, 20, 200, and 
750 mg/kg/day 
Accelerated primordial follicle recruitment via 
the phosphatidylinositol 3-kinase signaling 
pathway 
[33] 
Mouse 
Adult dosing for 2 or 4 
weeks, 1000 and 3000 
mg/kg/day 
Induced follicle atresia (1000 and 3000 
mg/kg/day) and decreased corpora lutea 
numbers (3000 mg/kg/day) 
[34] 
Mouse 
Antral follicle culture, 
DEHP (1, 10, and 100 
µg/ml, 0.36, 3.6, and 36 
µM) and MEHP (0.1, 1, 
and 10 µg/ml) 
Inhibited antral follicle growth and induced 
atresia by inhibiting steroidogenesis, inducing 
oxidative stress, disrupting expression of cell 
cycle regulators, and altering the expression of 
pro- and anti-apoptotic factors 
[36-41] 
Mouse 
Ovary culture, PND 4 to 
10, MEHP at 0.2, 2, and 
20 µg/ml 
Decreased the percentage of germ cells and 
increased the percentage of primary follicles 
by decreasing phosphatase and tensin homolog 
levels and increasing phosphorylated protein 
kinase B levels 
[38] 
 
 
Ovarian 
steroidogenesis 
 
 
DBP Mouse 
Antral follicle culture, 
1000 µg/ml 
Reduced estradiol production 
[35] 
DEHP Mouse 
Antral follicle culture, 1, 
10, and 100 µg/ml 
[36, 39] 
MEHP Mouse 
Antral follicle culture, 0.1, 
1, and 10 µg/ml 
[38, 39] 
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Ovarian 
steroidogenesis DEHP 
Mouse 
GD 17 to 19, 100, 500 and 
1000 mg/kg/day 
Altered expression of Star and aromatase, 
increased estradiol levels 
[25] 
Mouse 
Gestation and lactation, 
0.05 and 5 mg/kg/day 
Reduced expression of steroidogenic enzymes 
(Cyp17a1 and Cyp19a1) 
[27] 
Mouse 
Intraperitoneal injection at 
20 and 40 µg/kg on PND 
5, 10, and 15 
Deceased expression of LHCGR and 
CYP17A1, levels of progesterone, estradiol, 
androstenedione, and LH 
[44] 
Rat 
Prepubertal dosing for 10 
days, 500 mg/kg/day 
Decreased progesterone and estradiol levels in 
the serum, decreased transportation of 
cholesterol into the mitochondria 
[45] 
Rat 
Inhalation from PND 22 
to 84, 25 mg/m3 
Increased serum cholesterol and estradiol 
levels as well as increased aromatase gene 
expression levels 
[46] 
Rodent 
8 days to 16 weeks, from 
20 µg/kg/day to 2g/kg/day 
Decreased several serum sex steroid hormone 
levels 
Reviewed 
in [47] 
Uterine 
structure and 
function 
BBzP Rat 
PND 2 to 20, 500 
mg/kg/day 
Increased relative uterine weight at the time of 
vaginal opening 
[49] 
DEHP or 
MEHP 
Cow 
Endometrial cell culture, 
0.1, 1, and 10 ng/ml 
Stimulated uterine PGF2alpha secretion, but 
inhibited PGE2 secretion 
[50] 
Mixture Rat 
GD 8-19 or 14-19, 
mixture of BBzP, DBP, 
DEHP, DiBP and dipentyl 
phthalate, 65, 130, 260, 
520, and 720 mg/kg/day 
Induced hydrometrocolpos and agenesis or 
complete aplasia of uterus 
[51] 
Mixture Rat 
GD 8 to 14, mixture of 
BPA, DEHP, and DBP 
(BPA 50 mg/kg/day, 
DEHP 750 mg/kg/day, 
and DBP 66 mg/kg/day, 
or half of the doses) 
Reduced uterine weights in the F1 and F3 
generations 
[28] 
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 Table 2.1 (cont.) 
Anterior 
pituitary gland 
DBP Rat 
GD 15 to PND 21, diet 
exposure, 200, 2000, and 
10000 ppm 
Increased percentages of LH-positive and 
decreased FSH and prolactin producing cells. 
Decreased pituitary weights increased FSH-
positive cells in the pituitary 
[52] 
DEHP 
Mouse 
GD 14 to birth, 1, 50, and 
300 mg/kg/day 
Increased serum FSH levels 
[24] 
Mouse 
MEHP, GD 17 to 19, 
1000 mg/kg/day 
[25] 
Mouse 
Gestation to weaning, 
0.05, 5, and 500 
mg/kg/day 
Increased gonadotropin subunit gene 
expression 
[27] 
Rat 
Gestation to PND 15, 30 
mg/kg/day 
Increased gonadotropin serum levels [53] 
Rat 
PND 20 to 30, 500 
mg/kg/day 
Increased LH levels [45] 
Rat 
Inhalation from PND 22 
to 84, 25 mg/m3 
Increased serum LH levels [46] 
Sheep 
Adult dosing for 2 
months, 3 times/week, 50 
mg/kg 
Decreased basal LH levels and the pulsatile 
LH secretion 
[54] 
 
 
 
 
Puberty 
 
 
 
 
BBzP 
Rat Diet exposure, 11250 ppm 
Delayed puberty onset 
[62] 
Rat 
GD 10 to birth, 500 
mg/kg/day 
[63] 
Rat 
PND 2 to 20, 500 
mg/kg/day 
Decreased body weight at the time of vaginal 
opening, induced modification in architecture 
and proliferative index of the mammary gland 
[49] 
DEP Rat 
F0 10 weeks dietary 
exposure before mating, 
15000 ppm 
Delayed vaginal opening in F1 and F2 [64] 
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Puberty 
DBP 
Mouse 
Males were exposed 8 
weeks before mating, 500 
mg/kg/day 
Delayed vaginal opening for 2.5 days in 
female pups 
[65] 
Rat 
PND 1 to 5, PND 26 to 
30, 0.5, 5, and 50 
mg/kg/day 
Advanced puberty onset, induced irregular 
estrous cycles and increased hypothalamic 
kisspeptin levels and GPR54 gene expression 
[66] 
Rat 
Weaning through puberty, 
mating and gestation, 250, 
500, and 1000 mg/kg/day 
No effects on age at vaginal opening, time of 
first estrus, or estrous cyclicity 
[67] 
DEHP 
Mouse 
MEHP, in utero exposure, 
500 and 1000 mg/kg/day 
Delayed estrous onset [25] 
Rat 
Inhalation from PND 22 
to 84, 25 mg/m3 
Advanced puberty onset, age of vaginal 
opening, and age at first estrous cycle 
[46] 
Rat 
Oral gavage 4 weeks in 
puberty, 250, 500, and 
1000 mg/kg/day 
Increased GnRH level in hypothalamus and 
GnRH receptor in uterus 
[68] 
Estrous 
cyclicity 
DEHP 
Rat 4 weeks, 3000 mg/kg/day 
Induced prolonged and irregular estrous 
cyclicity 
[34] 
Rat 
Inhalation from PND 22 
to 84, 25 mg/m3 
Induced irregular estrous cyclicity [46] 
Mouse 
Adult dosing for 10 or 30 
days, 20 and 200 
µg/kg/day, 20, 200, and 
750 mg/kg/day 
Disrupted cyclicity depending on dose [33] 
DBP Rat 
Weaning through puberty, 
mating and gestation, 250, 
500, and 1000 mg/kg/day 
No effects on estrous cyclicity [67] 
 
Fertility DEHP Rat 
2 weeks before mating to 
GD 7, 3000 mg/kg/day 
Decreased pregnancy rate [34] 
42 
 
 Table 2.1 (cont.) 
 
 Fertility Mouse 
Prenatal exposure, 200 
µg/kg/day and 750 
mg/kg/day 
Induced breeding complications (longer time 
to become pregnant and loss of some or all 
pups at birth) 
[26] 
Endometriosis DEHP Human 
Endometrial cell culture, 
10−8M and 10−6M 
Induced endometriosis by elevating invasive 
and proliferative activities in endometrial cells 
[81] 
Pregnancy and 
birth 
BBzP Rat 
GD 0 to 8, 750, 1000, 
1250, and 1500 mg/kg/day 
Increased preimplantation loss occurred 
following successful mating and post-
implantation loss depend on dose 
[83] 
DBP Rat [82] 
MBP Rat [84] 
DBP Rat 
Weaning through puberty, 
mating and gestation, 500 
and 1000 mg/kg/day 
Induced mid-pregnancy abortion and reduced 
the percentage of live pups delivered 
[67] 
DEHP 
Mouse 
Diet exposure, GD 0.5 to 
birth, 500 mg/kg/day 
Increased post-implantation losses of pups [27] 
Mouse 
Adult exposure for 8 
weeks, 500 mg/kg/day 
Caused 100% abortion [87] 
Mouse 
Injection, every 5 days, 
PND 5 to 40, 20 and 40 
µg/g/day 
Decreased F1 pup weights and litter size [32] 
 
This table is a summation of the major effects of phthalates on female reproduction in experimental designed studies.  
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Table 2.2 The associations between phthalate exposure and reproduction in women 
Endpoints Population Phthalates Positively associated with References 
Uterine 
structure and 
function 
Taiwanese children who 
were exposed to 
phthalates prenatally 
DEHP Reduced uterine size at age of 8 to 11 [48] 
Puberty 
Puerto Rican and 
Chinese girls, but not in 
girls in United States 
DEHP 
Higher levels in girls with premature thelarche 
or precocious puberty 
[55] 
Taiwanese girls DMP Premature thelarche [56] 
Taiwanese girls 
DMP, DEP, DBP, 
BBzP, DEHP 
Higher levels in girls with precocious puberty [57] 
Korean girls 
DBP, but not 
DEHP 
Precocious puberty [58] 
Danish girls 
DBP, BBzP, and 
DEHP 
Delayed pubarche [59] 
United States girls 
DEHP, but not low 
molecular weight 
phthalates 
Delayed pubarche [60] 
Girls in Shanghai, China 
DBP, DEP, and 
DEHP 
Delayed growth and puberty [61] 
Fertility 
Italian couples 
DEP, DEHP, BBzP, 
and DBP 
Higher in couples who were recruited from 
assisted reproduction clinics than in couples 
who were parents of more than one child by 
spontaneous conception 
[69] 
United States women 
seeking infertility care 
DEHP Decreased antral follicle numbers [70] 
United States women 
seeking infertility care 
DEHP 
Lower oocyte yield, clinical pregnancy, and 
live birth following IVF 
[71] 
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Endometriosis 
and leiomyoma 
Women from 14 
locations in the United 
States 
DBP and DEHP Increased odds of endometriosis diagnosis [72] 
Us Pacific Northwest 
population 
DEHP, but not DEP 
or BBzP 
Endometriosis risk [73] 
National Health and 
Nutrition Examination 
Survey study 
DBP and DEHP 
Positive associations between urinary MBP 
levels and endometriosis and leiomyomata as 
well as inverse associations between MEHP 
levels and endometriosis 
[74] 
Korean women DEHP 
Higher DEHP and MEHP plasma levels in 
advanced-stage endometriosis patients 
[75] 
Korean women DEHP 
Leiomyoma group had higher urinary levels of 
DEHP metabolites 
[76] 
Chinese women 
DiBP, DBP, and 
DEHP 
Uterine leiomyoma [77] 
Taiwanese women 
DEP, DBP, and 
DEHP 
Increased urinary levels of MBP and MEHP 
levels associated with endometriosis; higher 
levels of MEHP, MBP, and MEP were 
associated with leiomyoma 
[78, 79] 
Infertile Japanese women 
DEP, DBP, and 
DEHP 
No association between urinary levels of MEP, 
MBP, and metabolites of DEHP and 
endometriosis 
[80] 
Pregnancy loss 
Danish women DEHP 
Higher occurrence of pregnancy loss in women 
with higher urinary MEHP levels 
[85] 
Chinese women DMP and DEHP 
Missed miscarriage and lower maternal serum 
hormone levels 
[86] 
 
 
Pregnancy 
length 
 
Polish mother and child 
cohort 
DEP and DiNP 
Third trimester urinary metabolite levels of 
DEP and DiNP were associated with decreased 
pregnancy length and head circumference 
[89] 
Mexican birth cohort 
DBP, BBzP, and 
DEHP 
Higher metabolite levels at third-trimester 
among women who delivered preterm 
[90] 
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Pregnancy 
length 
Boston population DEHP 
Metabolite levels in the first trimester 
associated with placental preterm birth, and 
associated with spontaneous preterm birth in 
the third trimester 
[91] 
Review Common phthalates 
Umbilical vein blood, maternal blood and 
meconium levels of DBP and MEHP, but not 
DEP and DEHP, associated with low birth 
weight, no associations between phthalate 
exposure and infant length, head 
circumferences, and birth size 
[88] 
 
This table is a summation of the major effects of phthalates on female reproduction in epidemiology studies.  
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Table 2.3 The effects of phthalates on male reproduction (experimental studies) 
Targets Phthalates Species Exposure Effects References 
 
 
 
 
 
 
 
 
 
 
 
 
Developing 
male sex organs 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEHP Human 
Human fetal male 
germ cell culture, 
MEHP exposure at 
10−5 M for 3 days 
Increased apoptosis [92] 
BBzP, 
DBP, and 
DEHP 
Rodent In utero exposure 
Phthalate syndrome: malformation of the male 
reproductive organs, retention of nipples, and 
reduced AGD 
Reviewed 
in [93] 
DEHP, 
BBzP, 
DEP, and 
DMP 
Rat 
GD 14 to PND 3, 
0.75/g/kg/day 
Shortened AGD, decreased testis weight, and 
formation of female like areolas/nipples (DEHP 
and BBzP, but not DEP and DMP) 
[94] 
DBP 
Rat 
GD 12 to 20, 500 
mg/kg/day 
Decreased testosterone levels, induced Leydig 
cell clustering, increased number of multi-
nucleated gonocytes 
[95] 
GD 13 to 20, 500 
mg/kg/day 
[96] 
Rat 
GD 15 to 18, MBP, 
500 mg/kg/day 
Decreased testis weight and inhibited 
maturation of germ cells and testosterone 
production by the Leydig cells 
[97] 
DiBP Rat 
GD 7 to 21, 600 
mg/kg/day 
Leydig cell hyperplasia and Sertoli cell 
vacuolization, and multi-nucleated gonocytes 
[98] 
DEHP 
Mouse 
GD 1 to weaning, 0.1, 
1, and 10 mg/kg/day 
Reduced the development and the size of testes [99] 
Rat 
Prenatal and 
lactational exposure, 
500 mg/kg/day 
Reduced the weights of ventral prostate and 
seminal vesicle 
[100] 
Mouse 
GD 13.5 to 14.5, 
MEHP 720 mg/kg/day 
Increased apoptosis in fetal testes [92] 
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Developing 
male sex organs 
Rat 
Prenatal, 5 and 50 
μg/kg/day 
Increased the protein levels of sex-determining 
region Y-box 9 and AMH in the testis 
[101] 
Rat 
GD 12 to 19, 100 
mg/kg/day 
Induced testis dysgenesis and Leydig cell 
clustering in the interstitium, seminiferous cord 
malformation, and thickened basement 
membranes of seminiferous cords, reduced 
testosterone production, levels of proteins 
involved in testis testosterone production, and 
increased levels of proteins related to small 
Leydig cell cluster formation 
[102] 
Mixture Rat 
Coadministration of 
DEHP (150 
mg/kg/day) and DBP 
(100 mg/kg/day), GD 
13 to 21 
Reduced testicular testosterone levels, 
increased the incidence of multinucleated 
gonocytes, the diameter of seminiferous cords, 
and Leydig cell clusters 
[103] 
Mixture Rat 
Mixture of DBP and 
DEHP (both at 500 
mg/kg/day), GD 14 to 
18 
Induced a greater than 50% increase in the 
incidence of many reproductive malformations 
(epididymal agenesis, reduced androgen-
dependent organ weights) and decreased fetal 
testosterone and Insl3 and Cyp11a1 expression 
[104] 
 
 
Postnatal male 
sex organs 
 
 
DBP 
Mouse 
PND 4 to 14, 1 to 500 
mg/kg/day 
Reduced Sertoli cell proliferation, delayed 
spermatogenesis, and impaired Sertoli cell 
maturation 
[105] 
Mouse 
Adult exposure for 7 
days, 500, 1000, and 
1500 mg/kg/day 
Induced oxidative stress and impaired 
spermatogenesis 
[106] 
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Postnatal male 
sex organs 
Rat 
Pubertal exposure for 
30 days, 100 and 500 
mg/kg/day 
Maldevelopment of the testes and epididymis, 
severe atrophy of the seminiferous tubules, loss 
of spermatogenesis, abnormal levels of serum 
hormones, altered expression of proteins 
involved in spermatogenesis, and disrupted 
function and number of Sertoli and Leydig cells 
[107] 
Mouse 
8 weeks before mating, 
2000 mg/kg/day, 3 
days/week 
Increased incidence of sperm head 
malformations in F1 
[65] 
Mouse 
8 weeks before mating, 
500 and 2000 
mg/kg/day, 3 
days/week 
Diminished sperm motility, enhanced 
frequency of abnormal sperm heads 
[108] 
Rhesus 
monkey 
Testes fragments 
grafted to mice 
exposed for 28 weeks, 
500 mg/kg/day 
Disrupted tubule formation and germ cell 
differentiation and decreased number of 
spermatogonia and Sertoli cells 
[109] 
DEHP 
Rat 
Dietary exposure for 
60 days, 5000 and 
20000 ppm 
Reduced testis, epididymis, and prostate 
weights, testicular zinc content, and caused 
testis degeneration 
[110] 
Rat 
Pubertal exposure for 
30 days, 250, 500, and 
750 mg/kg/day 
Induced deformed seminiferous tubules, 
aggregated chromatin, multiple vacuoles, 
swollen mitochondria, apoptotic germ cells and 
Sertoli cells, but increased Leydig cell numbers 
[111] 
Pig 
3 to 7 weeks of age, 
300 mg/kg weekly 
No effects on testes morphology, the number of 
Sertoli and Leydig cells, or the incidence of 
germinal epithelial lesion 
[112] 
 
Steroidogenesis 
 
DEP Rat 
Dietary exposure for 
10 weeks, 3000 and 
15000 ppm 
Decreased serum testosterone [64] 
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Steroidogenesis 
DBP 
Rhesus 
monkey 
Testes fragments 
grafted to mice 
exposed for 28 weeks, 
500 mg/kg/day 
Reduced steroidogenic gene expression [109] 
Mouse 
PND 4 to 14, 1 to 500 
mg/kg/day 
Increased inhibin in circulation, reduced 
testosterone and other testicular androgen 
activities 
[105] 
DiBP Rat 
GD 7 to 21, 600 
mg/kg/day 
Reduced Cyp11A1 protein levels and testicular 
testosterone production 
[98] 
DEHP 
Rat 
Single dose on GD 15, 
100 and 300 mg/kg 
Decreased expression and protein level of 
testicular STAR 
[119] 
Rat 
PND 21 to 48, 10 and 
750 mg/kg/day 
Increased serum testosterone levels at 10 
mg/kg/day, but decreased the levels at 750 
mg/kg/day 
[120] 
Rhesus 
monkey 
Testes fragments 
grafted to mice 
exposed for 14 weeks, 
500 mg/kg/day 
Reduced steroidogenic gene expression [109] 
Rat 
In vitro Leydig cell 
culture, MEHP 100 
µM and 10 mM 
Increased and inhibited LH stimulated 
testosterone production, depending on dose 
[120] 
Mixture Rat 
Mixture of BBzP, 
DBP, DEHP, DiBP 
(each 300 mg/kg/day), 
and dipentyl phthalate 
(100 mg/kg/day), GD 
8 to 18, 5, 10, 20, 40, 
60, 80, and 100% of 
the dose 
Reduced male fetal testosterone level in a dose-
additive manner 
[121] 
 
AGD BBzP Rat 
Dietary exposure, 
3750 and 11250 ppm 
Reduced AGD [62] 
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AGD 
DBP 
Rat 
Dietary exposure, GD 
15 to PND 21, 20 and 
10000 ppm 
Reduced AGD [52] 
Mouse 
PND 4 to 14, 1 to 500 
mg/kg/day 
Reduced AGD [105] 
DiBP Rat 
GD 7 to 21, 600 
mg/kg/day 
Reduced AGD [98] 
DBP Rat 
GD 13 to 21, 100 
mg/kg/day 
Reduced AGD 
[103] 
DEHP Rat 
GD 13 to 21, 150 
mg/kg/day 
Reduced AGD 
Mixture Rat 
GD 13 to 21, mixture 
of DEHP (150 
mg/kg/day) and DBP 
(100 mg/kg/day) 
No effects on AGD 
Hypothalamus 
and pituitary 
DBP Rat 
Diet exposure, GD 15 
to PND 21, 10000 ppm 
Increased percentages of LH-positive and 
decreased numbers of FSH and prolactin 
producing cells 
[52] 
DEHP 
Rat 
GD 0 to lactational day 
15, 30 mg/kg/day 
Decreased gamma-aminobutyric acid and 
increased aspartate, and gonadotropin serum 
levels 
[53] 
Mouse 
Prenatal exposure, 
0.05, 5, and 500 
mg/kg/day 
Reduced expression of gonadotropin-receptor 
genes in the gonad and increased the 
gonadotropin subunit gene expression in the 
pituitary 
[27] 
Rat 
Pubertal exposure for 
30 days, 250, 500, and 
750 mg/kg/day 
Decreased serum LH and FSH levels [111] 
 
Puberty 
 
BBzP Rat 
Dietary exposure, 
3750 and 11250 ppm 
Delayed puberty onset, induced nipple 
retention, and caused reproductive system 
malformation 
[62] 
 Table 2.3 (cont.) 
51 
 
 
 
Puberty DEHP 
Rat 
PND 22 to 58, 300 and 
900 mg/kg/day 
Delayed the onset of puberty and reduced 
androgen-dependent organ weights by acting 
on both Leydig and Sertoli cells in rats 
[126] 
Rat 
PND 21 to 48, 10 and 
750 mg/kg/day 
Advanced or delayed puberty onset, depending 
on dose 
[120] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fertility 
 
 
 
 
 
 
 
 
 
 
 
 
DBP 
Mouse 
Adult exposure, 3 
days/week for 8 
weeks, 500 and 2000 
mg/kg 
Diminished sperm motility, increased 
frequency of abnormal sperm heads 
[108] 
Mouse 
Exposed 8 weeks 
before mating, 2000 
mg/kg/day 
Pup growth-retardation, and increased 
incidence of sperm head malformation 
[65] 
Rat 
GD 1, 7, and 14, 100 
and 500 mg/kg/day 
Decreased fertility in the male offspring by 
decreasing testicular steroidogenic enzyme 
activity levels and serum testosterone levels, 
sperm density, motile and viable sperm 
numbers, and increasing sperm abnormalities 
[132] 
Mouse 
GD 12 to birth, 250 
and 500 mg/kg/day 
Induced multi-nucleated germ cells [133] 
DEHP 
Rat 
GD 6 to lactation day 
21, 0.045, 0.405, and 
405 mg/kg/day 
Reduced daily sperm production, increased 
serum testosterone levels, and decreased weight 
of seminal vesicle with coagulating glands 
[134] 
Rat 
Prenatal and 
lactational exposure, 
500 mg/kg/day 
Disrupted male sexual behavior, reduced daily 
sperm production and epididymal sperm counts 
[100] 
Mouse 
Prenatal and 
lactational exposure, 
0.05 and 5 mg/kg/day 
Reduced testis weights and caused 50% less 
concentrated semen 
[135] 
Mouse 
PND 7 to 49, 5, 20, 
and 40 µg/kg/day 
Reduced the quality and quantity of 
spermatozoa (at 20 and 40 µg/kg/day), 
decreased the number of germ cells entering 
meiosis (at 40 µg/kg/day), and altered 
[136] 
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Fertility 
immature testis gene expression (at 5 
µg/kg/day) 
Rat 
Dietary exposure for 
60 days, 5000 and 
20000 ppm 
Reduced epididymal sperm density and 
motility, and increased the incidence of 
abnormal sperm 
[110] 
Reproductive 
diseases and 
complication 
Mixture Rat 
GD 14 to 18, mixture 
of anti-androgens (15 
mg/kg/day vinclozolin, 
15 mg/kg/day 
procymidone, 35 
mg/kg/day prochloraz, 
20 mg/kg/day linuron , 
and 150 mg/kg/day 
each of BBzP, DBP, 
DEHP) 
Disrupted male reproductive tract 
differentiation, induced hypospadias and 
epididymal agenesis, and caused undescended 
testes 
[138] 
DBP Rat 
GD 13.5 to 21.5, 500 
mg/kg/day 
Induced cryptorchidism by reducing INSL3 and 
CPY11A1 protein expression during gestation, 
leading to the observed disrupted development 
and malfunction in adult Leydig cell population 
[139] 
Mixture Rat 
Plasticizer mixture 
(BPA 50 mg/kg/day, 
DEHP 750 mg/kg/day 
and DBP 66 
mg/kg/day), GD 8 to 
14 
Increased the incidence of prostate disease and 
abnormalities in F1 male rats, decreased 
seminal vesicle and epididymal weights in the 
F3 generation, and caused testicular diseases in 
both the F1 and F3 generations 
[28] 
 
This table is a summation of the major effects of phthalates on male reproduction in experimental designed studies.  
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Table 2.4 The associations between phthalate exposure and reproduction in men 
Endpoints Population Phthalates Positively associated with References 
Steroidogenesis 
Mexican population 
DEP, DBP, BBzP, 
di-n-octyl phthalate 
Decreased dehydroepiandrosterone sulfate 
(DBP) and inhibin B levels (DEP), increased 
sex hormone-binding globulin (BBzP, and 
DBP). Decreased testosterone levels and 
increased sex hormone-binding globulin in 
boys (DEHP, BBzP, di-n-octyl phthalate) 
[113] 
Danish boys BBzP 
Negatively associated with 
dehydroepiandrosterone sulfate levels at 11 
years of age, but positively associated with 
testosterone levels at 13 years of age 
[114] 
Danish men DEHP 
Negatively associated with free androgen 
levels, the ratio of testosterone/LH or FSH, 
total and free testosterone levels, and the ratio 
of testosterone/estradiol 
[115] 
United States general 
population 
DEHP and DBP 
Reduced testosterone levels in men in the 40 to 
60 age group 
[116] 
Men recruited in an 
infertility clinic in the 
United States 
DEHP 
Inversely associated with the levels of 
testosterone, estradiol, and free androgen index 
[117] 
Chinese population DBP and DEHP Lower free testosterone levels [118] 
AGD 
Multicenter pregnancy 
cohort study in United 
States 
DBP, DEP, BBzP, 
and DEHP 
Median and 95th percentile exposure estimates 
were significantly associated with reduced 
AGD in male infants 
[124] 
Review 
DEHP, DBP, 
BBzP, DEP, and 
DiBP 
Associated with decreased AGD in some 
studies, but not in others 
[125] 
 
Puberty Mexican population 
DEHP, BBzP, 
DBP, DIBP, DEP, 
Reduced odds of adrenarche (metabolites of 
DEHP, BBzP, DBP, DiBP, DEP, and di-n-
[113] 
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Puberty 
and di-n-octyl 
phthalate 
octyl phthalate) and puberty (metabolites of 
DEHP, BBzP, DBP, and DiBP) in boys 
Danish boys DBP Younger age of pubarche [114] 
Fertility 
Chinese population DBP and DEHP 
Urinary MBP levels were positively associated 
with low sperm concentration and low total 
sperm count, and MEHP levels were 
associated with increased percentage of 
abnormal sperm heads 
[127] 
Chinese population 
DBP, DEHP and 
DiBP 
Urinary MEHP level was negatively associated 
with INSL3 and acrosin activity, MBP and 
MiBP levels were negatively associated with 
acrosin activity and normal sperm 
morphology, and positively associated with 
DNA fragmentation index 
[128] 
Chinese population DBP, DEHP, BBzP 
Semen metabolites of DBP and DEHP 
associated with decreased semen volume, 
semen metabolites of BBzP and DEHP 
associated with sperm curvilinear velocity, and 
BBzP metabolite associated with abnormal 
sperm head and tails 
[129] 
United States population DiBP and BBzP 
Urinary levels of DiBP and BBzP negatively 
associated with sperm motility and counts 
[130] 
United States population 
DEP, DBP, and 
BBzP 
Urinary metabolite levels were positively 
associated with taking longer time to become 
pregnant 
[131] 
Hydrocele United States population DEHP 
Increased odds of newborn genital anomaly, 
especially hydrocele 
[137] 
 
Hypospadias 
 
Review 
DEP, DBP, DiBP, 
DMP, BBzP, and 
DEHP 
No association with maternal or paternal 
phthalate exposures and hypospadias in 3 of 4 
reports; the only study that showed positive 
association had very small sample size 
[125] 
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Cryptorchidism Review 
DEP, DBP, DiBP, 
DMP, BBzP, and 
DEHP 
Metabolites of DEHP were associated with 
cryptorchidism in some studies, however, 
metabolites of DEP, DBP, DiBP, DMP, BBzP, 
or DEHP were not associated with the 
prevalence of cryptorchidism in other studies 
[125] 
 
This table is a summation of the major effects of phthalates on male reproduction in epidemiology studies.  
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CHAPTER III 
Effects of an environmentally relevant phthalate mixture on 
 cultured mouse antral follicles2  
3.1 Abstract 
Phthalates are used in building materials, medical devices, and personal care products. 
Most studies on phthalates have focused on single phthalates, but it is important to study mixtures 
of phthalates because humans are exposed to such mixtures daily. We tested the hypothesis that 
phthalate mixture exposure decreases antral follicle growth, compromises steroidogenic capacity, 
and induces atresia. Antral follicles from adult CD-1 mice were cultured with vehicle control or 
phthalate mixture (1-500 µg/ml) for 96 hours. The mixture was made of 35% diethyl phthalate, 
21% di(2-ethylhexyl) phthalate, 15% dibutyl phthalate, 15% diisononyl phthalate, 8% diisobutyl 
phthalate, and 5% benzylbutyl phthalate. During culture, antral follicle diameters were measured 
every 24 hours to monitor growth. After culture, media were subjected to measurements of sex 
steroid hormones and follicles were subjected to evaluation of gene expression and atresia. The 
phthalate mixture (100 and 500 µg/ml) decreased antral follicle growth starting at 24 hours 
compared to controls. The mixture at 10, 100, and 500 µg/ml also decreased androstenedione, 
testosterone, estrone, and estradiol levels compared to control. The mixture (10, 100, and 500 
µg/ml) reduced atresia rating, but it induced more oocyte fragmentation compared to control. The 
phthalate mixture at different doses adversely affected cell cycle regulators, antioxidant enzymes, 
apoptotic factors, steroidogenic enzymes, and receptors.  
 
1 Reprinted, with permission, from Zhou C and Flaws JA. Effects of an environmentally 
relevant phthalate mixture on cultured mouse antral follicles. Toxicological Science. doi: 
10.1093/toxsci/kfw245.   
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Collectively, these data indicate that exposure to an environmentally relevant phthalate 
mixture reduces antral follicle growth, induces oocyte fragmentation, and decreases hormone 
production by adversely affecting the expression of cell cycle regulators, apoptotic factors, 
steroidogenic enzymes, and receptors. 
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3.2 Introduction  
Phthalates are a family chemicals used as plasticizers and additives in common products, 
including plastics, personal care products (PCPs), polyvinyl chloride pipes, and vinyl flooring [1, 
2]. As a result, humans and animals are exposed to phthalates through ingestion, inhalation, and 
dermal contact. Metabolites of phthalates are commonly detected in human urine samples. They 
also can be detected in serum, milk, and saliva [3]. Interestingly, phthalate metabolites have been 
detected in follicular fluid [4, 5], indicating that oocytes are directly exposed to phthalates.  
The most commonly used phthalates are diethyl phthalate (DEP), di-n-butyl phthalate 
(DBP), diisobutyl phthalate (DiBP), butyl benzyl phthalate (BBzP), di(2-ethylhexyl) phthalate 
(DEHP), diisononyl phthalate (DiNP), and diisodecyl phthalate (DiDP) [6]. Food intake is 
considered to be a major route of phthalate exposure [7]. Phthalates are also commonly used in 
PCPs and the urinary metabolite levels are correlated with the usage of PCPs [8-12]. Phthalate 
exposure is of concern because studies have shown that it is associated with increased human 
health risks [13]. Specifically, urinary DEHP metabolite (mono-ethylhexyl phthalate, MEHP) 
levels have been associated with pregnancy loss [14] and preterm birth [15]. Moreover, urinary 
levels of monobenzyl phthalate (MBzP), a metabolite of BBzP and mono-n-butyl phthalate (MBP), 
a metabolite of DBP, were associated with preterm birth [16]. Childhood exposure to BBzP, DBP, 
DiBP, and DEHP has been associated with decreased testosterone and dehydroepiandrosterone 
(DHEA) levels in boys [17]. Urinary MEHP levels have also been inversely associated with 
testosterone and estradiol levels in adult male patients from an infertility clinic [18].  
Numerous experimental studies have indicated that phthalates impair reproductive function, 
but such studies have mainly focused on male reproduction (reviewed in [19]). Exposure to 
phthalates during gestation results in adverse effects on the male rat reproductive tract by 
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suppressing the androgen pathway; thus, phthalates are known anti-androgenic chemicals [20]. In 
male rats, prenatal exposure to a number of phthalates causes “phthalate syndrome”, which is 
characterized by malformations in the male reproductive organs, retention of nipples, and reduced 
anogenital distance [21]. The effects of phthalates on female reproduction are less extensively 
studied (reviewed in [22]), but they indicate phthalates reduce the number of follicles, accelerate 
follicle recruitment, inhibit follicle growth, disrupt ovulation and corpus luteum formation, 
decrease steroidogenic enzyme expression, and alter sex steroid hormone production [23].  
Most previous studies have only examined a single phthalate, and it is well known that 
humans and animals are exposed to mixtures of phthalates [17, 24, 25]. Available mixture studies 
have focused on male animals. Exposure to a mixture of 5 phthalates from gestational day (GD) 8 
to18 in rats reduced male fetal testosterone levels in a dose-additive manner [26]. Exposure to a 
mixture of anti-androgens including phthalates from GD 14 to 18 in rats disrupted male 
reproductive tract differentiation, induced hypospadias and epididymal agenesis, and caused 
undescended testes [27]. Other studies on mixtures of different anti-androgens, including 
phthalates, also showed that mixture exposure reduced fetal testis testosterone production 
compared to control in rats [28, 29].  
Information on the effects of a mixture of phthalates on female reproduction is very limited. 
Prenatal exposure (GD 8-19) to a phthalate mixture caused uterine and vaginal malformations in 
rats [30]. Gestational and lactational exposure to a mixture of endocrine disrupting chemicals 
(including phthalates) significantly reduced follicle numbers, disrupted estrous cycles, and caused 
adverse effects in reproductive organs [31]. To our knowledge, no studies have been conducted to 
examine the direct effects of a phthalate mixture on ovarian antral follicles. The antral follicle is 
the only follicle type that is capable of releasing an egg for fertilization and synthesizing sex steroid 
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hormones such as estrogens [32]. Thus, in this study, we tested the hypothesis that phthalate 
mixture exposure decreases antral follicle growth, compromises steroidogenic capacity, and 
induces atresia.  
3.3 Methods 
Chemicals 
The mixture we used in our study contains 21% DEHP, 35% DEP, 15% DBP, 8% DiBP, 
5% BBzP, and 15% DiNP. This mixture is based on estimates of phthalate exposure in women, 
which were derived from levels of phthalate metabolites measured in urine samples from pregnant 
women in Illinois (unpublished data from iKids study). DEP, DEHP, DBP, DiBP, DiNP, BBzP 
(>98% purity) were purchased from Sigma-Aldrich (St. Louis, MO). To make 500 mg of pure 
phthalate mixture, weights of each phthalate were calculated according to the percentages. Then, 
the desired amount of each phthalate was carefully weighed and mixed thoroughly to make the 
mixture. The intended amount and actual amount of each of the phthalates are shown in Table 3.1. 
The pure mixture solution was stored at -20 °C for up to one month before experimental use. A 
stock solution of pure mixture was dissolved and diluted in dimethyl sulfoxide (DMSO) (Sigma-
Aldrich) to achieve the selected phthalate mixture treatment concentrations (1.33, 13.3, 133, and 
665 mg/ml) for final working concentrations of 1, 10, 100, and 500 µg of phthalate mixture per ml 
of culture medium. Using these treatment concentrations allowed each working concentration to 
contain the same volume of chemical and vehicle solution (0.75 µl of phthalate mixture/DMSO 
solution per ml of culture media). 
This is the first time this phthalate mixture has been tested. Thus, concentrations of 
phthalate mixture were chosen to cover a relatively wide range (1-500 µg/ml), to include a dose 
that mimics human exposure, and to include some of the doses of individual phthalates that have 
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been shown to disrupt folliculogenesis and steroidogenesis [33, 34]. Currently, two studies 
measured phthalate concentrations in the follicular fluid [4, 5], but only one of them included a 
large sample size [5]. In both studies, the median phthalate metabolite levels were below 10 ng/ml 
of follicular fluid, which is 100 times lower than our lowest dose (1 µg/ml) [4, 5]. However, in the 
study conducted by Du et al., the maximum detection of the single phthalates reached 415 ng/ml 
for MBP, a level higher than in our lowest dose (1 µg/ml of mixture contains 150 ng/ml of DBP, 
the parent compound for MBP) [5]. Our lowest doses is therefore within the high end of phthalate 
detection levels in humans. Previous studies have shown that in cultured antral follicles, DBP at 
10 µg/ml disrupted the expression of cell cycle regulators Ccne1 and Cdkn1a [33], and DEHP at 
10 µg/ml or higher disrupted expression of cell cycle regulators, apoptotic factors, and 
steroidogenic enzymes, and it induced atresia and decreased hormone production [34]. Further, 
studies have shown that medical exposure to DEHP can result in relatively high phthalate 
concentrations in blood compared to concentrations before medical procedures [35]. For example, 
DEHP concentrations in blood can be as high as 21.6 µg/ml after medical procedures in infants, 
and can reach 14 µg/ml in adults after medical procedures [35]. In our study, the chosen mixture 
doses contain approximately 0.21, 2.1, 21, and 105 µg/ml of DEHP; thus our lower doses were 
within the range of medical exposure levels to phthalates. 
Animals 
Adult, cycling female CD-1 mice were purchased from Jackson Laboratory (Bar Harbor, 
ME) and allowed to acclimate to the facility for at least two days before use. The mice were housed 
at the University of Illinois at Urbana-Champaign, Veterinary Medicine Animal Facility. Food 
(Harlan Teklad 8604) and water were provided for ad libitum consumption. Temperature was 
maintained at 22±1 °C, and animals were subjected to 12-h light-dark cycles. The Institutional 
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Animal Use and Care Committee at the University of Illinois at Urbana-Champaign approved all 
procedures involving animal care, euthanasia, and tissue collection. 
In Vitro Antral Follicle Culture 
Adult cycling female CD-1 mice were euthanized and their ovaries were carefully removed 
to isolate antral follicles. Antral follicles were isolated mechanically from ovaries and interstitial 
tissue was removed using fine watchmaker forceps as described previously [36, 37]. Antral 
follicles, diameters ranging from 250 to 400 µm, were selected to be placed individually in wells 
of 96-well culture plates. At least two to three mice were used for each separate culture to provide 
60-90 follicles per culture. Individual follicles were randomly selected for each treatment group (n 
= 6 separate cultures, 6-12 follicles/treatment/culture).  
Treatment groups for the antral follicle cultures included vehicle control (DMSO) and 
phthalate mixture (1, 10, 100, and 500 µg/ml) prepared in supplemented α-MEM. Supplemented 
α-MEM was prepared with: 1% ITS (10 ng/ml insulin, 5.5 ng/ml transferrin, 5.5 ng/ml selenium, 
Sigma-Aldrich), 100 U/ml penicillin (Sigma-Aldrich), 100 mg/ml streptomycin (Sigma-Aldrich), 
5 IU/ml recombinant follicle-stimulating hormone (FSH, Dr. A.F. Parlow, National Hormone and 
Peptide Program, Harbor-UCLA Medical Center, Torrance, CA), and 5% fetal bovine serum 
(Atlanta Biologicals, Lawrenceville, GA). The same volume of chemical (0.75 µg/ml of media) 
was added to each dose to control the amount of vehicle in each culture well to be 0.075%. Each 
follicle was cultured in 150 µl of medium for 96 hours in an incubator at 37 °C with 5% CO2. At 
the end of the 96 hour cultures, media were collected and stored at -80 °C. Some antral follicles 
were collected, snap frozen, and then stored at -80 °C for gene expression, others were fixed in 
Dietrich’s solution for histological evaluation of atresia as described below. 
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Analysis of Antral Follicle Growth 
Follicles were cultured for 96 hours and the growth was examined every 24 hours by 
measuring follicle diameters. Follicle diameters were measured across perpendicular axes with an 
inverted microscope equipped with a calibrated ocular micrometer. The sizes of follicles in each 
treatment group within each experiment were averaged first and then converted to percentage of 
the initial follicle size at the start of the culture. Then, percent data were averaged and analyzed 
across different experiments (n = 6 separate cultures). 
Antral Follicle Culture Hormone Measurements 
Culture media were collected at 96 hours from 6 separate antral follicle cultures, and 
subjected to enzyme-linked immunosorbent assays (ELISAs, DRG International Inc., Springfield, 
NJ) for measurement of progesterone, androstenedione, testosterone, estrone, and estradiol. 
Assays were run according to the manufacturer’s instructions. Samples were diluted and run in 
duplicate for measurements of progesterone (1:5 dilution), androstenedione (1:5 dilution), 
testosterone (1:5 dilution), estrone (no dilution), and estradiol (1:10 dilution) to match the dynamic 
range of each ELISA kit.  
Histological Evaluation of Antral Follicles and Atresia Rating 
After 96 hours of culture, some antral follicles were collected for histological evaluation. 
Supplemented α-MEM was removed from each well and Dietrich’s solution (for 5100 ml final 
volume, 250 ml of 40% formaldehyde, 712.5 ml of 100% ethanol, 1537.5 mg water, and 50 ml 
glacial acetic acid) was added to the wells to fix the follicles. Then, the follicles were processed 
for histological analyses of atresia as described previously [37, 38]. Follicles were dehydrated and 
prepared for plastic embedding by using Technovit 7100 plastic embedding system (Electron 
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Microscopy Science), and serial sectioned at 2 µm. Sections were mounted on glass slides and 
stained with Lee’s methylene blue-basic fuchsin. Sections with oocytes were randomly selected 
and scored for apoptotic bodies and oocyte fragmentation (5 sections per follicle, n = 12 
follicles/treatment group, from 3 separate cultures). Based on the amount of apoptotic bodies 
present in the follicles, follicles were scored on a 1 to 4 scale as described previously [37, 38]. A 
score of 1 indicated the presence of apoptotic bodies encompassing 0-3% of the total area of follicle, 
a score of 2 indicated the presence of apoptotic bodies encompassing 4-10% of total area of follicle, 
a score of 3 indicated the presence of apoptotic bodies encompassing 11-30% of total area of 
follicle, and a score of 4 indicated >30% of apoptotic bodies of the total area of follicle. Atresia 
scores were reported based on the average of all five scores from the same follicle, and then 
analyzed across different treatment groups. Oocyte fragmentation was scored as “Yes” or “No” 
for each follicle. The percentage of follicles with fragmented oocytes compared to the total number 
of follicles was calculated. All scoring of atresia and oocyte fragmentation was performed without 
knowledge of treatment group.  
Gene expression analysis 
For quantitative polymerase chain reaction (qPCR) analyses, follicles were collected after 
culture, snap-frozen in liquid nitrogen, and then stored at -80 °C until RNA extraction. Total RNA 
was then isolated from follicles (n = 3, 9-12 follicles per pool for antral follicle cultures) using an 
RNeasy Micro kit (Qiagen, Inc., Valencia, CA) following the manufacturer's instructions. RNA 
was eluted in 14 μl of RNase-free water and the concentration was determined using a NanoDrop 
(λ = 260/280 nm; ND 1000; Nanodrop Technologies Inc., Wilmington, DE). Total RNA (100 ng) 
was reverse transcribed to complementary DNA (cDNA) using the iScript RT kit (Bio-Rad 
Laboratories, Inc., Hercules, CA) according to the manufacturer’s protocol. Analysis of qPCR was 
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conducted using the CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., 
Hercules, CA) and accompanying CFX Manager Software according to the manufacturer’s 
protocol. The machine quantifies the amount of PCR product generated by measuring 
SsoFastEvaGreen dye (Bio-Rad Laboratories, Inc., Hercules, CA) that fluoresces when bound to 
double-stranded DNA. Specific qPCR primers (Integrated DNA Technologies, Coralville, IA) for 
all the genes of interest are listed in Table 3.2.  All qPCR reactions were done in triplicate using 1 
μl cDNA, forward and reverse primers (5 pmol) for 18S ribosomal RNA (Rn 18S), superoxide 
dismutase 1 (Sod1), catalase (Cat), glutathione peroxidase (Gpx), glutathione reductase (Gsr), B 
cell leukemia/lymphoma 2 (Bcl2), Bcl2-associated X protein (Bax), caspase 3 (Casp3), caspase 8 
(Casp8), steroidogenic acute regulatory protein (Star), cytochrome-P450 cholesterol side-chain 
cleavage (Cyp11a1), cytochrome P450 steroid 17-α-hydroxylase 1 (Cyp17a1), 3β-hydroxysteroid 
dehydrogenase (Hsd3b1), 17β-hydroxysteroid dehydrogenase 1 (Hsd17b1), cytochrome P450 
aromatase (Cyp19a1), cyclin A2 (Ccna2), cyclin B1 (Ccnb1), cyclin D2 (Ccdn2), cyclin E1 
(Ccne1), cyclin-dependent kinase 4 (Cdk4), cyclin-dependent kinase inhibitor 1a (Cdkn1a),  
cyclin-dependent kinase inhibitor 1c (Cdkn1c),  cyclin-dependent kinase inhibitor 2a (Cdkn2a),  
estrogen receptor α (Esr1), estrogen receptor β (Esr2), follicle stimulating hormone receptor (Fshr), 
androgen receptor (Ar), peroxisome proliferator-activated receptor α (Pparα), and peroxisome 
proliferator-activated receptor γ (Pparγ) and SsoFastEvaGreen Supermix for a final reaction 
volume of 10 μl. The qPCR program consisted of an enzyme activation step (95 °C for 1 min), an 
amplification and quantification program (40 cycles of 95 °C for 10 sec, 60 °C for 10 sec, single 
fluorescence reading), a step of 72 °C for 5 min, a melt curve (65 °C–95 °C heating, 0.5 °C/sec 
with continuous fluorescence readings), and a final step at 72 °C for 5 min per the manufacturer's 
protocol. Rn 18S mRNA expression was used in qPCR analyses as a housekeeping gene. All gene 
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expression data were normalized to the housekeeping gene. Relative fold changes were calculated 
as the ratio to DMSO group level and were analyzed by using a mathematical model for relative 
quantification of real-time PCR data developed by Pfaffl [39].  
Statistical Analysis 
All data analyses were performed using SPSS statistical software (SPSS Inc., Chicago, IL). 
Data were expressed as means ± SEM from at least three separate experiments. Multiple 
comparisons between normally distributed experimental groups were made using one-way 
analysis of variance (ANOVA) followed by Dunnett post-hoc comparison, if equal variances were 
assumed, or Games-Howell post-hoc comparisons if equal variances were not assumed. If data 
were not normally distributed, comparison between two groups was done using Kruskal-Wallis H 
test for several independent samples and Mann-Whitney U two-independent sample tests. For 
oocyte fragmentation, we assigned each follicle a score of “0” or “1”. “0” indicates no oocyte 
fragmentation was observed in all sections examined and “1” indicates at least 1 section of the 
follicle had a fragmented oocyte. Then, we utilized Chi-square test to compared treatment groups 
to control. Statistical significance was assigned at p < 0.05. 
3.4 Results 
Effects of the mixture on antral follicle growth 
To determine whether phthalate mixture reduces antral follicle growth, individual antral 
follicles were cultured with either control (DMSO) or different doses of phthalate mixture (1 to 
500 µg/ml). Follicles in control groups showed significant growth at 96 hours (Figure 3.1, n = 6 
cultures, 6-12 antral follicles/treatment/culture). Phthalate mixture at 1 and 10 µg/ml did not 
significantly affect growth compared to control at any time point (Figure 3.1, n = 6 cultures, 6-12 
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antral follicles/treatment/culture). However, phthalate mixture at 100 µg/ml significantly inhibited 
growth starting at 48 hours and mixture at 500 µg/ml significantly inhibited antral follicle growth 
starting at 24 hours when compared to control (Figure 3.1, n = 6 cultures, 6-12 antral 
follicles/treatment/culture). The phthalate mixture-induced inhibition of follicle growth persisted 
throughout the 96-hour culture (Figure 3.1).  
Effects of the mixture on cell cycle regulators 
Cell cycle regulators play an important role in regulating follicle growth, and many cell 
cycle regulators are also the targets of phthalates (reviewed in [23]). Thus, we compared expression 
of several cell cycle regulators in control and phthalate mixture-treated follicles. Our results show 
that phthalate mixture exposure did not affect the expression of Cdk4, Ccna2, Ccnb1, and Ccne1 
(Figure 3.2 A, B, C, and E, n = 3, p > 0.05), but it (500 µg/ml) decreased the expression of Ccnd2 
compared to control (Figure 3.2 D, n = 3, p < 0.05). For selected cell cycle inhibitors, phthalate 
mixture at 100 and 500 µg/ml significantly decreased expression of Cdkn1a (Figure 3.2 F, n = 3, 
p < 0.05), it (500 µg/ml) borderline decreased expression of Cdkn1c (Figure 3.2 G, n = 3, p = 0.08), 
and it (500 µg/ml) significantly increased the expression of Cdkn2a compared to control (Figure 
3.2 H, n = 3, p < 0.05). 
Effects of the mixture on antral follicle histology  
The phthalate mixture-induced reduction in follicle growth may also be the result of follicle 
atresia. Thus, we evaluated atresia in control and phthalate mixture treated follicles. In control 
follicles, some apoptotic bodies were normally present after 96 hours of culture, and the oocytes 
appeared to be intact (Figure 3.3 A). In the phthalate mixture-treated follicles, the oocytes were 
frequently fragmented (Figure 3.3 C, E, G, H, and I). When we compared the percentage of 
follicles with fragmented oocytes in control and phthalate mixture-treated follicles, our results 
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indicated that 33.3% of the follicles in the control group, 16.7% of the follicles in the 1 µg/ml 
group, 33.3% follicles in the 10 µg/ml group, 58.3% in the 100 µg/ml group, and 75% in the 500 
µg/ml group had fragmented oocytes (n = 12 different follicles/treatment group; p < 0.05 for 
control vs. 500 µg/ml). Interestingly, in phthalate mixture-treated follicles, the presence of 
apoptotic bodies decreased with the occurrence of oocyte fragmentation (Figure 3.3). Specifically, 
the presence of apoptotic bodies for phthalate mixture-treated follicles (10, 100, and 500 µg/ml) 
was lower than control follicles as indicated by the atresia ratings (Figure 3.3 J, n = 12, p < 0.05).  
Effects of the mixture on apoptotic factors 
Next, we expanded our findings on the effects of the mixture on atresia by comparing the 
expression of key apoptotic factors in control and mixture-treated follicles. Our results show that 
phthalate mixture at the three lowest doses did not affect the expression of the pro-apoptotic factor 
Bax and the anti-apoptotic factor Bcl2 (Figure 3.4 A and B, n = 3, p > 0.05), but phthalate mixture 
at 500 µg/ml decreased the expression of Bax (Figure 3.4 A, n = 3, borderline significance, p = 
0.058) and significantly increased the expression of Bcl2 compared to control (Figure 3.4 B, n = 
3, p < 0.05). The mixture at 500 µg/ml also decreased the ratio of Bax/Bcl2, indicating decreased 
apoptosis (Figure 3.4 C, n = 3, * p < 0.05, ^ p = 0.09). Further, although the phthalate mixture did 
not affect the expression of pro-apoptotic factor Casp3 (Figure 3.4 D, n = 3, p > 0.05), it (100 and 
500 µg/ml) significantly reduced the expression of pro-apoptotic factor Casp8 (Figure 3.4 E, n = 
3, p < 0.05), indicating reduced apoptosis in these follicles compared to control. 
Effects of the mixture on antioxidant enzymes 
Phthalates have been shown to cause oxidative stress in the ovary (reviewed in [23]) and 
oxidative stress has been shown to regulate atresia [40]. To determine whether the phthalate 
mixture altered oxidative stress, the expression of four key antioxidant enzymes were compared 
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between control and mixture-treated follicles. Our results show that phthalate mixture reduced 
expression of all the selected antioxidant enzymes (Figure 3.5, n = 3, p < 0.05). Specifically, at 96 
hours, phthalate mixture at 10, 100, and 500 µg/ml significantly reduced the expression of Sod1 
(Figure 3.5 A), phthalate mixture at 10 µg/ml reduced expression of Cat (Figure 3.5 B), and 
phthalate mixture at 500 µg/ml significantly reduced the expression of Gpx (Figure 3.5 C) and Gsr 
(Figure 3.5 D) compared to control (n = 3, p < 0.05). 
Effects of the mixture on hormone production  
The effects of phthalate mixture on steroidogenesis in antral follicles were tested by 
comparing the sex steroid hormone levels in culture media from control and mixture-treated 
follicles after 96 hours of culture. The most upstream precursor sex steroid hormone that we were 
able to measure was progesterone. The phthalate mixture did not affect the level of progesterone 
compared to control (Figure 3.6 A, n = 6). However, the phthalate mixture at 10, 100, and 500 
µg/ml significantly reduced the levels of androstenedione compared to control (Figure 3.6 B, n = 
6, p < 0.05). Further, the phthalate mixture at 10 and 500 µg/ml significantly reduced testosterone 
levels and the mixture at 100 µg/ml showed a borderline significance of reducing testosterone 
levels compared to control (Figure 3.6 C, n = 6, * p < 0.05, ^ p = 0.06). Moreover, phthalate 
mixture at 100 and 500 µg/ml significantly reduced estrone production compared to control 
(Figure 3.6 D, n = 6, p < 0.05). Finally, phthalate mixture at 10, 100, and 500 µg/ml significantly 
reduced estradiol levels compared to control (Figure 3.6 E, n = 6, p < 0.05). 
Effects of the mixture on steroidogenic enzymes 
Given that the phthalate mixture reduced several sex steroid hormones, we next compared 
the expression of steroidogenic enzymes in control and phthalate mixture-treated follicles. STAR 
is the enzyme that transports cholesterol into thecal and granulosa cells. Our results show that 
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phthalate mixture at 10, 100, and 500 µg/ml significantly reduced the expression of Star compared 
to control (Figure 3.7 A, n = 3, p < 0.05). CYP11A1 converts cholesterol into pregnenolone. The 
phthalate mixture at 500 µg/ml significantly decreased the expression of Cyp11a1 compared to 
control (Figure 3.7 B, n = 3, p < 0.05). Pregnenolone is converted to DHEA by CYP17A1 in the 
thecal cells. The phthalate mixture did not affect the expression of Cyp17a1 compared to control 
(Figure 3.7 C, n = 3, p > 0.05). HSD3B1 converts pregnenolone to progesterone in both thecal and 
granulosa cells and it converts DHEA into androstenedione in the thecal cells. Our results showed 
that phthalate mixture at 500 µg/ml significantly reduced the expression of Hsd3b1 compared to 
control (Figure 3.7 D, n = 3, p < 0.05). HSD17A1 is the enzyme that converts androstenedione to 
testosterone in the thecal cell and converts estrone into estradiol in the granulosa cells. The 
phthalate mixture did not significantly affect the expression of Hsd17a1 compared to control 
(Figure 3.7 E, n = 3, p > 0.05, ^ p = 0.075). In the granulosa cells, CYP19A1 is responsible for 
converting androstenedione into estrone and testosterone into estradiol. Phthalate mixture at 100 
and 500 µg/ml significantly reduced the expression of Cyp19a1 compared to control (Figure 3.7 
F, n = 3, p < 0.05). 
Effects of the mixture on receptors 
Previous studies have shown that several hormone receptors and peroxisome proliferator-
activated receptors (PPARs) are targets of some phthalates (reviewed in [23]). Therefore, we 
compared the expression of several key receptors in control and phthalate mixture-treated follicles. 
Our results show that after 96 hours of culture, phthalate mixture exposure at 500 µg/ml 
significantly reduced the expression of Esr1 (Figure 3.8 A, n = 3, p < 0.05), but it did not affect 
the expression of Esr2 compared to control (Figure 3.8 B, n = 3, p > 0.05). Moreover, phthalate 
mixture at 500 µg/ml significantly reduced the expression of Fshr and phthalate mixture at 100 
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µg/ml trended to reduce the expression compared to control (Figure 3.8 C, n = 3, * p < 0.05, ^ p = 
0.07). The phthalate mixture did not significantly affect Ar expression compared to control (Figure 
3.8 D, n = 3, p > 0.05), but it (500 µg/ml) significantly reduced Pparα expression (Figure 3.8 E, n 
= 3, p < 0.05). Finally, phthalate mixture did not affect the expression of Pparγ at any doses 
compared to control (Figure 3.8 F, n = 3, p > 0.05). 
3.5 Discussion  
In the current study, we developed a phthalate mixture based on the phthalate levels 
detected in women and our results show that this mixture reduces follicle growth, steroidogenic 
capacity, and the health of antral follicles in mice. Previous studies indicate that exposure to single 
phthalates, like DEHP, inhibits antral follicle growth by 48h [23, 41]. Thus, we expected that the 
phthalate mixture would also reduce antral follicle growth in culture. Interestingly, our results 
showed that the phthalate mixture significantly decreased antral follicle growth as early as 24 hours 
in culture. It is likely that we observed decreased follicle growth at an earlier time point than with 
single phthalates because our highest dose of the mixture contains a higher amount of DEHP than 
in the DEHP study mentioned above. In the 500 µg/ml mixture, the DEHP concentration is 
approximately 105 µg/ml. Thus, the concentration of DEHP is higher than that used in studies with 
DEHP alone (10 and 100 µg/ml) [41].  
Reduced follicle growth is likely due to disrupted cell cycle regulation. DBP and DEHP 
cause defects in the cell cycle by affecting the gene expression levels of cell cycle regulators 
(reviewed in [23]). Therefore, we tested the gene expression levels of the key cell cycle regulators. 
In antral follicles, the majority of the cells are granulosa cells and granulosa cells are actively 
proliferating in growing antral follicles. As a result, the expression of the selected genes reflects 
the expression in granulosa cells. Our results show that phthalate mixture exposure decreased 
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Ccnd2 expression. Cyclin D2 is crucial for granulosa cell proliferation in response to FSH 
stimulation [42]. In our experiments, we added equal amounts of FSH to each culture well. Thus, 
it is likely that the reduced expression of Ccnd2 decreases the response of granulosa cells to FSH, 
leading to inhibition of granulosa cell proliferation. Moreover, phthalate mixture exposure 
decreased the expression of Cdkn1a and increased the expression of Cdkn2a. CDKN1A (p21) 
inhibits the CDK1-cyclin A complex to establish the G1 phase [43]. Our results showed that the 
mixture reduced Cdkn1a expression, indicating that the establishment of the G1 phase for follicular 
cells in these follicles was reduced compared to control. CDKN2A (p16) binds to CDK4 and 
CDK6 to prevent G1-S transition [43]. Phthalate mixture significantly increased the expression of 
Cdkn2a compared to control, indicating that the cell cycle was arrested and follicular cells were 
not able to transit from G1 to S phase. This finding is similar to those of Craig et al., in which 
more DBP-treated follicular cells were arrested at G1 stage compared to controls [33].Taken 
together, these data suggest that because phthalate mixture dramatically increased the expression 
of Cdkn2a and decreased the expression of Ccnd2, follicular cells were likely arrested at G1 phase, 
the cell cycle could not progress, and the expression of Cdkn1a was decreased to try to possibly 
compensate for the effects of Ccnd2 and Cdkn2a. However, this compensatory effect was probably 
not enough to overcome the cell cycle arrest, resulting in reduced proliferation of follicular cells, 
which further led to reduced antral follicle growth. 
Previous studies suggest that reduced antral follicle growth may also due to increased 
atresia [33, 34]. The reduction of antral follicle growth in the 500 µg/ml group was dramatic, thus, 
we expected that follicles in this treatment group were undergoing atresia. Surprisingly, we 
observed fewer apoptotic bodies in the three higher treatment groups (10, 100, and 500 µg/ml) 
compared to control. However, the presence of oocyte fragmentation in these groups was more 
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frequent compared to control. Our gene expression results confirmed these histological findings. 
We observed an increased expression of anti-apoptotic factor Bcl2 and decreased ratio of Bax/Bcl2, 
indicating a dominant effect of anti-apoptotic factor Bcl2, which further protects the cell from 
apoptosis. Moreover, our results on the expression of Casp8 also support the histological findings, 
indicating reduced cell death. These findings differ from those reported in studies using single 
phthalates. DEHP (10 and 100 µg/ml) and DBP (100 µg/ml) increase antral follicle atresia in 
culture [33, 34]. Thus, it is likely that the phthalate mixture acts via different mechanisms to induce 
different effects than single phthalates. The reason that we observed decreased atresia in the 
mixture treated follicles may be because studies have shown that cells at G1/S transition are 
susceptible to undergoing apoptosis and cells at G1 stage are relatively resistant to apoptosis [44]. 
In our experiments, granulosa cells of antral follicles in the phthalate treatment groups were 
arrested at the G1 stage, whereas the granulosa cells of antral follicles in the control groups were 
not arrested in G1. As a result, control follicles increased in size and acquired apoptotic bodies due 
to normal granulosa cell proliferation and G1/S transition. The absence or reduced amount of 
atretic bodies in phthalate mixture treated groups is likely due to the resistance of apoptosis 
because of the cell cycle arrest.  
In vitro antral follicle studies also showed that oxidative stress is likely a mechanism via 
which individual phthalates inhibit follicle growth (reviewed in [23]). We measured expression of 
important antioxidant enzymes to determine whether phthalate mixture induces oxidative stress in 
our study. Our results show that phthalate mixture significantly reduced expression of antioxidant 
enzymes compared to control, indicating less availability of anti-oxidant enzymes in the exposed 
follicles, which could potentially increase oxidative stress in these follicles. Future examinations 
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of reactive oxygen species levels are needed to further confirm that the phthalate mixture induces 
oxidative stress.  
Antral follicles are the major producers of the sex steroid hormones required for female 
reproductive and non-reproductive health [45-47]. Thus, we examined the effects of the mixture 
of steroidogenic capacity. The phthalate mixture reduced androstenedione, testosterone, estrone, 
and estradiol production compared to control. Moreover, the mixture disrupted the enzymes 
involved in steroidogenesis pathway. Collectively, these data indicate that the phthalate mixture 
disrupts the steroidogenesis pathway by affecting steroidogenic enzymes.  
We also examined the effects of phthalate mixture on selected receptors. Estrogen receptors 
are important in folliculogenesis. Estrogens act through ESR1 to induce follicular cell proliferation 
and act via ESR2 to promote differentiation [48]. The phthalate mixture significantly reduced the 
expression of Esr1 compared to control, but it did not affect expression of Esr2. Reduced 
expression of Esr1 could lead to reduced follicular cell proliferation, a scenario observed in our 
study. In addition, phthalate mixture reduced the expression of Fshr compared to control, 
indicating that follicles in these groups had impaired FSH-stimulated downstream effects. These 
impaired FSH-stimulated downstream effects include reduced granulosa cell proliferation and sex 
steroid hormone production, which have also been observed in single phthalate treatment [49, 50]. 
Androgen receptors also play an important role in folliculogenesis and steroidogenesis (reviewed 
in [51]). Our results show that the phthalate mixture did not affect the expression of Ar. Thus, it is 
likely that phthalate mixture did not act through the androgen receptor to induce adverse effects. 
PPARs regulate transcription of several genes in the ovary and studies have shown that MEHP 
acts through PPARα and PPARγ to decrease the hormone production in rats [50]. The phthalate 
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mixture decreased expression of Pparα, indicating that it is likely that some doses of the phthalate 
mixture act on the PPARs to reduce steroidogenesis in mouse antral follicles.  
In summary, our study shows that direct exposure to a phthalate mixture adversely affects 
antral follicle health in vitro. Specifically, the phthalate mixture decreases antral follicle growth, 
induces oocyte fragmentation, and disrupts steroidogenesis by arresting cell cycle, inducing 
oxidative stress, reducing sex steroid hormone production and steroidogenic enzyme expression, 
and decreasing receptor expression. We hypothesize that phthalate mixture disrupts cell cycle and 
hormone receptor expression to reduce the antral follicle growth and induce oxidative stress, which 
further reduces steroidogenesis and induces oocyte fragmentation. However, further investigations 
are needed to test our hypothesis. Future studies should investigate the effects of this phthalate 
mixture in vivo because phthalates are quickly transformed into their metabolites after they enter 
the body [13, 52]. Moreover, metabolites of some phthalates have been shown to act via different 
mechanisms than the parent compounds and to induce adverse effects at lower concentrations [41, 
53, 54]. We also observed that the phthalate mixture causes oocyte fragmentation. Oocyte 
fragmentation has been reported to occur because of disruption in intracellular Ca2+ concentrations, 
the PI3K/Akt/mTOR pathway, and cytoplasmic polyadenylation element [55-57]. Future studies 
should examine that if phthalate mixture interferes with these processes to cause oocyte 
fragmentation. 
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3.6 Tables and Figures 
Table 3.1 The amount of each phthalate used in the phthalate mixture. 
Phthalates 
Intended 
Percentage 
Intended 
Weights 
(g) 
Actual 
Weights 
(g) 
Actual 
Percentage 
DiBP 8% 0.04 0.043 8.60% 
DiNP 15% 0.075 0.0754 15.10% 
DEHP 21% 0.105 0.105 21.00% 
BBzP 5% 0.025 0.0256 5.10% 
DEP 35% 0.175 0.1759 35.20% 
DBP 15% 0.075 0.0745 14.90% 
 
The amount of each phthalate used in the mixture in this experiment. 
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Table 3.2 Sequence of primer sets used for gene expression analysis. 
Gene name Symbol Forward primer Reverse primer 
18S ribosomal RNA  Rn 18S 5’-TCGGCGTCCCCCAACTTCTTA-3’ 5’-GGTAGTAGCGACGGGCGGTGT-3’ 
Superoxide dismutase 1 Sod1 5'-TTCCGTCCGTCGGCTTCTCGT-3' 5'-CGCACACCGCTTTCATCGCC-3' 
Catalase Cat 5'-GCAGATACCTGTGAACTGTC-3' 5'-GTAGAATGTCCGCACCTGAG-3' 
Glutathione peroxidase Gpx 5'-CCTCAAGTACGTCCGACCTG-3' 5'-CAATGTCGTTGCGGCACACC-3' 
Glutathione reductase Gsr 5'- CAGTTGGCATGTCATCAAGCA-3' 5'-CGAATGTTGCATAGCCGTGG-3' 
B cell leukemia/lymphoma 2 Bcl2 5'- ATGCCTTTGTGGAACTATATGGC-3' 5'- GGTATGCACCCAGAGTGATGC-3' 
Bcl2-associated X protein Bax 5'- TGAAGACAGGGGCCTTTTTG-3' 5'- AATTCGCCGGAGACACTCG-3' 
Caspase 3 Casp3 5’-TGGTGATGAAGGGGTCATTTATG-3’ 5’-TTCGGCTTTCCAGTCAGACTC-3’ 
Caspase 8 Casp8 5'- CGAGAGGAGATGGTGAGAGAGC-3' 5'- CAGGCTCAAGTCATCTTCCAGC-3' 
Steroidogenic acute regulatory protein  Star 5’-CAGGGAGAGGTGGCTATGCA-3’ 5’-CCGTGTCTTTTCCAATCCTCTG-3’ 
Cytochrome-p450 cholesterol side-chain cleavage  Cyp11a1 5’-AGATCCCTTCCCCTGGTGACAATG-3’ 5’-CGCATGAGAAGAGTATCGACGCATC-3’ 
Cytochrome P450 steroid 17-α-hydroxylase 1 Cyp17a1 5’-CCAGGACCCAAGTGTGTTCT-3’ 5’-CCTGATACGAAGCACTTCTCG-3’ 
3β-hydroxysteroid dehydrogenase  Hsd3b1 5’-CAGGAGAAAGAACTGCAGGAGGTC-3’ 5’-GCACACTTGCTTGAACACAGGC-3’ 
17β-hydroxysteroid dehydrogenase 1  Hsd17b1 5’-ACTGTGCCAGCAAGTTTGCG-3’ 5’-AAGCGGTTCGTGGAGAAGTAG-3’ 
Cytochrome P450 aromatase Cyp19a1 5’-CATGGTCCCGGAAACTGTGA-3’ 5’-GTAGTAGTTGCAGGCACTTC-3’ 
Cyclin A2  Ccna2 5’-GCTCTACTGCCCGGAGGCTGA-3’ 5’-TGGCCTACATGTCCTCTGGGGAA-3’ 
Cyclin B1  Ccnb1 5’-TGCATTCTCTCAGTGCCCTCCACA-3’ 5’-AGACAGGAGTGGCGCCTTGGT-3’ 
Cyclin D2  Ccnd2 5’-CCTTTGACGCAGGCTCCCTTCT-3’ 5’-ACCCTGGTGCACGCATGCAAA-3’ 
Cyclin E1  Ccne1 5’-GGTGTCCTCGCTGCTTCTGCTT-3’ 5’-CCGGATAACCATGGCGAACGGA-3’ 
Cyclin-dependent kinase 4  Cdk4 5’-AGAAACCCTCGCTGAAGCGGCA-3’ 5’-TGGGGGTGAACCTCGTAAGGAGA-3’ 
Cyclin-dependent kinase inhibitor 1a  Cdkn1a 5’-TTAGGCAGCTCCAGTGGCAACC-3’ 5’-ACCCCCACCACCACACACCATA-3’ 
Cyclin-dependent kinase inhibitor 1c  Cdkn1c 5’-CTGGACAGGACAAGCGATCC-3’ 5’-GCTGTTCTGCTGCGGAGGTA-3’ 
Cyclin-dependent kinase inhibitor 2a  Cdkn2a 5’-GCTCTGGCTTTCGTGAACAT-3’ 5’-CGAATCTGCACCGTAGTTGA-3’ 
Estrogen receptor α Esr1 5’-CCGTGTGCAATGACTATGCC-3’ 5’-GTGCTTCAACATTCTCCCTCCTC-3’ 
Estrogen receptor β Esr2 5’-GGAATCTCTTCCCAGCAGCA-3’ 5’-GGGACCACATTTTTGCACTT-3’ 
Follicle stimulating hormone receptor Fshr 5’-GCAGATGTGTTCTCCAACCTACC-3’ 5’-GGAGAGACTGGATCTTGTGAAAGG-3’ 
Androgen receptor Ar 5’-GGCGGTCCTTCACTAATGTCAACT-3’ 5’-GAGACTTGTGCATGCGGTACTCAT-3’ 
Proliferator-activated receptor α Pparα  5’-TGAACAAAGACGGGATG-3’ 5’-TCAAACTTGGGTTCCATGAT-3’ 
Proliferator-activated receptor  γ Pparγ  5’-TGTGAGACCAACAGCCTGACGG-3’ 5’-GTCCTGAATATCAGTGGTTCACCGC-3’ 
 
Sequence of primer sets used for gene expression analysis in this experiment. 
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Figure 3.1 Effects of the phthalate mixture on antral follicle growth in culture. 
 
 
Effects of the phthalate mixture on antral follicle growth in culture. Antral follicles were isolated 
from mouse ovaries and treated with vehicle (DMSO) or phthalate mixture (1-500 µg/ml) for 96 
hours. Follicle growth was measured every 24 hours. The graphs represent means ± SEM from 6 
separate cultures (n = 6-12 follicles/treatment/culture). Asterisks (*) indicate significant 
differences from the control (p < 0.05). 
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Figure 3.2 Effects of the phthalate mixture on the expression of cell cycle regulators. 
 
 
Effects of the phthalate mixture on the expression of cell cycle regulators. Antral follicles were 
isolated from mouse ovaries and treated with vehicle (DMSO) or phthalate mixture (1-500 µg/ml) 
for 96 hours. Follicles were collected and subjected to qPCR analyses for the expression of Cdk4 
(A), Ccna2 (B), Ccnb1 (C), Ccnd2 (D), Ccne1 (E), Cdkn1a (F), Cdkn1c (G), and Cdkn2a (H). 
Relative fold changes of each gene normalized to Rn18s are shown. Graphs represent means ± 
SEM from 3 separate experiments (n = 9-12 follicles/treatment/experiment). Asterisks (*) indicate 
significant differences from the control (p < 0.05). ^ indicates borderline significance compared to 
control, p = 0.08. M = mixture.  
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Figure 3.3 Effect of the phthalate mixture on antral follicle atresia. 
 
 
Effect of the phthalate mixture on antral follicle atresia. Antral follicles were isolated from mouse 
ovaries and treated with vehicle (DMSO) or phthalate mixture (1-500 µg/ml) for 96 hours. 
Following culture, antral follicles were processed for histological evaluation of atresia. A 
representative image of a DMSO treated follicle is found in panel A, representative apoptotic 
bodies were circled in black. Representative images of mixture at 1, 10, and 100 μg/ml with intact 
oocytes are shown in B, D, and F, respectively. Representative images of mixture at 1, 10, and 
100 μg/ml with fragmented oocytes are shown in C, E, and G, respectively, Panel H and I are 
images of oocytes in the 500 μg/ml treatment group. All scale bars indicate 50 μm. Atresia scores 
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Figure 3.3 (cont.) 
are shown in panel J. A score of 1 indicates the presence of apoptotic bodies encompassing 0-3% 
of the total area of follicle, a score of 2 indicates the presence of apoptotic bodies encompassing 
4-10% of total area of follicle, a score of 3 indicates the presence of apoptotic bodies encompassing 
11-30% of total area of follicle, and a score of 4 indicates >30% of apoptotic bodies of the total 
area of follicle. Graph represents means ± SEM from 3 separate experiments, with 12 
follicles/treatment group in each experiment. Asterisks (*) represent significant difference from 
the control (p < 0.05). 
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Figure 3.4 Effects of the phthalate mixture on the expression of apoptotic factors. 
 
 
Effects of the phthalate mixture on the expression of apoptotic factors. Antral follicles were 
isolated from mouse ovaries and treated with vehicle (DMSO) or phthalate mixture (1-500 µg/ml) 
for 96 hours. Follicles were collected and subjected to qPCR analyses for the expression of Bax 
(A), Bcl2 (B), Casp3 (D), and Casp8 (E). Relative fold changes of each gene normalized to Rn18s 
are shown. Ratio of the gene expression was calculated and is shown for Bax/Bcl2 (C). Graphs 
represent means ± SEM from 3 separate experiments (n = 9-12 follicles/treatment/experiment). 
Asterisks (*) indicate significant differences from the control (p < 0.05). ^ indicates borderline 
significance compared to control, p = 0.06 for panel A, p = 0.09 for panel C. M = mixture.  
99 
 
Figure 3.5 Effects of the phthalate mixture on the expression of antioxidant enzymes. 
 
 
Effects of the phthalate mixture on the expression of antioxidant enzymes. Antral follicles were 
isolated from mouse ovaries and treated with vehicle (DMSO) or phthalate mixture (1-500 µg/ml) 
for 96 hours. Follicles were collected and subjected to qPCR analyses for the expression of Sod1 
(A), Cat (B), Gpx (C), and Gsr (D). Relative fold changes of each gene normalized to Rn18s are 
shown. Graphs represent means ± SEM from 3 separate experiments (n = 9 -12 
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Figure 3.5 (cont.) 
follicles/treatment/experiment). Asterisks (*) indicate significant differences from the control (p < 
0.05). M = mixture.  
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Figure 3.6 Effect of the phthalate mixture on antral follicle-produced sex steroid hormone 
levels. 
 
 
Effect of the phthalate mixture on antral follicle-produced sex steroid hormone levels. Antral 
follicles were isolated from mouse ovaries and treated with vehicle (DMSO) or phthalate mixture 
(1-500 µg/ml) for 96 hours. Following culture, media were pooled per treatment group and were 
subjected to ELISAs for the measurements of progesterone (panel A), androstenedione (panel B), 
testosterone (panel C), estrone (panel D), and estradiol (panel E). Graph represents means ± SEM 
from 6 separate experiments, with medium from 6-12 wells/treatment group in each experiment. 
Asterisks (*) indicate significant differences from the control (p < 0.05). ^ indicates borderline 
significance compared to control, p = 0.06. M = mixture.  
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Figure 3.7 Effects of the phthalate mixture on the expression of steroidogenic enzymes. 
 
 
Effects of the phthalate mixture on the expression of steroidogenic enzymes. Antral follicles were 
isolated from mouse ovaries and treated with vehicle (DMSO) or phthalate mixture (1-500 µg/ml) 
for 96 hours. Follicles were collected and subjected to qPCR analyses for the expression of Star 
(A), Cyp11a1 (B), Cyp17a1 (C), Hsd3b1 (D), Hsd17a1 (E), and Cyp19a1 (F). Relative fold 
changes of each gene normalized to Rn18s are shown. Graphs represent means ± SEM from 3 
separate experiments (n = 9-12 follicles/treatment/experiment). Asterisks (*) indicate significant 
differences from the control (p < 0.05) ^ indicates borderline significance compared to control, p 
= 0.075. M = mixture.  
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Figure 3.8 Effects of the phthalate mixture on the expression of receptors. 
 
 
Effects of the phthalate mixture on the expression of receptors. Antral follicles were isolated from 
mouse ovaries and treated with vehicle (DMSO) or phthalate mixture (1-500 µg/ml) for 96 hours. 
Follicles were collected and subjected to qPCR analyses for the expression of Esr1 (A), Esr2 (B), 
Fshr (C), Ar (D), Pparα (E), and Pparγ (F). Relative fold changes of each gene normalized to 
Rn18s are shown. Graphs represent means ± SEM from 3 separate experiments (n = 9-12 
follicles/treatment/experiment). Asterisks (*) indicate significant differences from the control (p < 
0.05). ^ indicates borderline significance compared to control, p = 0.07. M = mixture. 
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CHAPTER IV 
Prenatal exposure to an environmentally relevant phthalate mixture disrupts reproduction 
in F1 female mice3 
4.1 Abstract 
Phthalates are used in a large variety of products, such as building materials, medical devices, 
and personal care products. Most previous studies on the toxicity of phthalates have focused on 
single phthalates, but it is also important to study the effects of phthalate mixtures because 
humans are exposed to phthalate mixtures. Thus, we tested the hypothesis that prenatal exposure 
to an environmentally relevant phthalate mixture adversely affects female reproduction in mice. 
To test this hypothesis, pregnant CD-1 dams were orally dosed with vehicle (tocopherol-stripped 
corn oil) or a phthalate mixture (20 and 200 µg/kg/day, 200 and 500 mg/kg/day) daily from 
gestational day 10 to birth. The mixture was based on the composition of phthalates detected in 
urine samples from pregnant women in Illinois. The mixture included 35% diethyl phthalate, 
21% di(2-ethylhexyl) phthalate, 15% dibutyl phthalate, 15% diisononyl phthalate, 8% diisobutyl 
phthalate, and 5% benzylbutyl phthalate. Female mice born to the exposed dams were subjected 
to tissue collections and fertility tests at different ages. Our results indicate that prenatal exposure 
to the phthalate mixture significantly increased uterine weight and decreased anogenital distance 
on postnatal days 8 and 60, induced cystic ovaries at 13 months, disrupted estrous cyclicity, 
reduced fertility-related indices, and caused some breeding complications at 3, 6, and 9 months 
of age. Collectively, our data suggest that prenatal exposure to an environmentally relevant 
phthalate mixture disrupts many aspects of female reproduction in mice.  
3 Reprinted, with permission, from Zhou C. et al. Prenatal exposure to an environmentally 
relevant phthalate mixture disrupts reproduction in the F1 female mice. Toxicology and Applied 
Pharmacology (In press).  
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4.2 Introduction 
Phthalates are synthetic chemicals that are widely used in common consumer products, 
including various plastics, cosmetics, personal care products, polyvinyl chloride pipes, and vinyl 
flooring [1, 2]. Because of the ubiquitous characteristics of phthalates, humans at all ages are 
constantly exposed to phthalates through ingestion, inhalation, and dermal contact. Of particular 
concern, phthalates and their metabolites are present in pregnant women and can affect the health 
of the mothers as well as their offspring. Metabolites of many phthalates such as di(2-ethylhexyl) 
phthalate (DEHP), diethyl phthalate (DEP), dimethyl phthalate, dibutyl phthalate (DBP), benzyl 
butyl phthalate (BBzP), and diisobutyl phthalate (DiBP) have been frequently detected in urine 
samples from pregnant women [3-5].  Moreover, urinary levels of DEHP and its metabolite, mono-
ethylhexyl phthalate (MEHP), have been detected in maternal plasma and urine samples, and have 
been associated with decreased gestational age [6, 7]. Phthalate metabolites are also commonly 
found in fetal samples such as amniotic fluid and cord blood samples [8-10]. Collectively, these 
studies suggest that humans are constantly exposed to phthalates and that this exposure starts as 
early as fetal life.  
Fetal life is considered to be one of the most sensitive periods to toxicants because of the 
critical developmental events that occur during this time period. Prenatal phthalate exposure has 
been shown to induce “phthalate syndrome” in male rodents [11, 12]. This “phthalate syndrome” 
is characterized by malformations in the male reproductive organs, retention of nipples, and 
reduced anogenital distance (AGD) [11, 12]. Moreover, gestational exposures to different 
phthalates have been shown to reduce fertility in male rodents by decreasing steroidogenic capacity, 
sperm quality and quantity, and sexual behaviors [13-16]. However, the effects of prenatal 
phthalate exposure on female reproduction in the offspring are less extensively studied. Published 
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studies have shown that gestational exposure to DEHP affects folliculogenesis [17], reduces oocyte 
quality [18], decreases steroidogenic capacity [18, 19], delays puberty [19], and decreases fertility 
[17, 18].  
Although studies on prenatal exposure to a single phthalate provide important information 
on phthalate toxicity, it is important to study mixtures of phthalates because humans are exposed 
to mixtures. Prenatal exposure to a mixture of DBP, DEHP, and bisphenol A reduced ovarian 
follicular reserve and induced polycystic ovaries in female offspring [20]. Prenatal exposure to a 
phthalate mixture (BBzP, DBP, DEHP, DiBP, and dipentyl phthalate) induced uterine 
malformations in female offspring [21]. Prenatal exposure to a mixture of phthalates, pesticides, 
UV-filters, bisphenol A, butylparaben, and paracetamol significantly impaired female 
reproductive function in the offspring by reducing follicle numbers, disrupting estrous cycles, and 
decreasing ovarian weights [22]. Only one of these previous studies, however, used a mixture that 
was based on human exposure, but the lowest dose used in the study was 100 times greater than 
the estimates of human exposure [22]. Thus, there is a need for studies conducted using 
environmentally relevant phthalate mixtures at doses relevant to human exposure levels. Therefore, 
in our study, we developed a phthalate mixture based on estimates of phthalate exposure in 
pregnant women and we used this phthalate mixture at environmentally relevant doses to test the 
hypothesis that prenatal exposure to a phthalate mixture adversely affects reproductive outcomes 
in the F1 female offspring.  
4.3 Materials and Methods 
Chemicals 
DEP, DEHP, DBP, DiBP, diisononyl phthalate (DiNP), and BBzP (>98% purity) were 
purchased from Sigma-Aldrich (St. Louis, MO). A pure phthalate mixture was made by calculating 
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and combining the appropriate amount of each phthalate according to the following percentages: 
21% DEHP, 35% DEP, 15% DBP, 8% DiBP, 5% BBzP, and 15% DiNP. The percentages were 
derived from levels of phthalate metabolites measured in urine samples from pregnant women in 
Illinois (unpublished data from the iKids study). Then, the phthalate mixture was mixed thoroughly 
before dilution in tocopherol-stripped corn oil (vehicle control).  
The doses used for this study were 20 µg/kg/day, 200 µg/kg/day, 200 mg/kg/day, and 500 
mg/kg/day. This is the first time this phthalate mixture has been tested in vivo. Thus, doses of 
phthalate mixture were chosen to cover a wide environmentally relevant range and to include some 
of the doses of individual phthalates that have been shown to adversely affect reproductive health 
during prenatal exposure [17-19, 23]. The estimated general population daily exposure level of 
DEHP is 3-30 µg/kg/day [24]. According to these estimates, the two lower doses used in our study 
mimic daily human exposure because they contain approximately 4 and 40 µg/kg/day of DEHP, 
respectively. We also included two high doses of mixture (200 and 500 mg/kg/day, which contain 
approximately 40 and 100 mg/kg/day of DEHP, respectively) to test the effects of this mixture at 
a level higher than human expose range and to compare our results with available information 
from single phthalate studies that used doses close to this level. Previous studies have shown that 
gestational exposure to DEHP decreased the thickness of thecal cell layers at 50 and 300 
mg/kg/day [23], disrupted steroidogenic enzyme gene expression and increased estradiol levels at 
100 mg/kg/day [19], increased preantral follicle numbers at 200 µg/kg/day and 500 mg/kg/day 
[17], increased ovarian weights at 0.05 and 5 mg/kg/day [18], and induced breeding complications 
at 200 µg/kg/day and 750 mg/kg/day [17].  
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Animals 
Adult cycling female and adult male CD-1 mice were purchased from Jackson Laboratory 
(Bar Harbor, ME) and allowed to acclimate to the facility for at least two weeks before use. The 
mice were housed at the University of Illinois at Urbana-Champaign, Veterinary Medicine Animal 
Facility in polysulfone cages. Food (Harlan Teklad 8604) and water (reverse osmosis filtered) were 
provided for ad libitum consumption. Temperature was maintained at 22±1 °C, and animals were 
subjected to 12-h light-dark cycles. The Institutional Animal Care and Use Committee (IACUC) 
at the University of Illinois at Urbana-Champaign approved all procedures involving animal care, 
euthanasia, and tissue collection. 
Study Design 
At two months of age, 60 females were mated with untreated proven breeder male mice. 
Successful mating was confirmed by the presence of vaginal sperm plug. Gestational day (GD) 1 
was set as the day of the presence of vaginal sperm plug. Once the vaginal sperm plug was 
observed, female mice were separated and singly housed. These dams were considered to be the 
F0 generation, and their body weights were monitored every three days to confirm pregnancy. On 
GD 10, F0 dams were assigned to five different treatment groups (12 F0 dams/treatment group) 
and then were dosed once a day until they give birth. F0 dams were orally dosed by pipetting 
tocopherol-stripped corn oil (vehicle control) or different doses of phthalate mixture (20 µg/kg/day, 
200 µg/kg/day, 200 mg/kg/day, and 500 mg/kg/day) into the mouth from GD 10 to birth.  
The route of exposure was selected to mimic the major route of exposure in humans [25]. 
The exposure window was chosen because it is a critical period for ovarian development in the 
mouse. All doses were given in 28-44 µl based on their body weights. Dams were allowed to give 
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birth naturally and the number of total and live pups, body weights of live pups, and sex ratio of 
the F1 pups were recorded on postnatal day (PND) 0. 
Tissue Collection, Body Weights, and Organ Weights 
On PNDs 1, 4, 8, and 21, at least one female F1 pup per litter (n = 10-12 dams/treatment 
group) was randomly chosen for tissue collections. On PND 60 and 13 months of age, the 
remaining F1 female pups were euthanized and their tissues were collected during diestrus. At 
each time point, sera, ovaries, uteri, and livers were collected, organ weights and body weights 
were recorded, and anogenital distances (AGD) were measured. Organ weights were recorded as 
whole organ weights in grams, AGD was recorded in millimeters (mm), and ovaries from the same 
pup were measured together and recorded as one weight for PND 1-60. At 13 months of age, 
ovarian weights were based on one healthy ovary per mouse. The presence of cystic ovaries was 
recorded. We normalized AGD to cubic root of body weight to account for body size effects [26]. 
Sera were stored for measurement of hormone levels in future studies. Ovaries, uteri, and liver 
were snap-frozen or fixed for molecular or histological analyses in future studies.  
Onset of Puberty  
After weaning, one F1 female per litter (n = 11-12 litters/treatment group) was kept for 
analyses of onset of puberty, estrous cyclicity, and fertility. Vaginal opening was used as a sign of 
onset of puberty and was monitored every morning after weaning. Body weights were recorded on 
the day of weaning and on the day of vaginal opening. After vaginal opening, estrous cyclicity was 
monitored every morning by examining vaginal smears daily for 30 consecutive days.  
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Fertility Tests 
One F1 female per litter (n = 7-12 litters/treatment group) was subjected to fertility tests at 
3, 6, and 9 months of age. For each fertility test, estrous cyclicity was monitored every morning 
for 14 consecutive days prior to mating. Then, female mice were housed with untreated proven 
breeder male mice for maximum of 2 weeks to evaluate fertility of F1 females. Once a vaginal 
sperm plug was present, female mice were singly housed. Body weights were recorded twice a 
week starting from the first day of estrous cyclicity examination until the birth of pups. 
Maintenance or loss of pregnancy were monitored by body weight gain. For every female, the 
presence of a vaginal sperm plug, days to pregnancy, the ability to become and maintain pregnancy, 
and pregnancy lengths were recorded. The ability to deliver live pups, size of the litter, average 
live pup birth weight, and pup sex ratios were also recorded to evaluate the birth outcomes.  
To examine fertility, we used several equations to calculate mating index, pregnancy rate, 
fertility index, and gestation index as previously described [27] and as follows: 
Pregnancy rate = number of pregnant females / number of breeding pairs × 100 
Mating index = number of females with vaginal sperm plugs / number of breeding pairs × 
100 
Fertility index = number of pregnant females / number of females with vaginal sperm plugs 
× 100 
Gestational index = number of females who delivered / number of pregnant females × 100 
Statistical Analyses 
Data analyses were conducted using SPSS statistical software (SPSS Inc., Chicago, IL). 
One-way analysis of variance (ANOVA) was used to conduct multiple comparisons between 
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normally distributed experimental groups, then followed by Dunnett post-hoc comparisons if equal 
variances were assumed, or Games-Howell post-hoc comparisons if equal variances were not 
assumed. Kruskal-Wallis H tests were used for comparison between groups if data were not 
normally distributed, followed by Mann-Whitney U two-independent sample tests. Statistical 
significance was assigned at p < 0.05. 
4.4 Results 
Effect of Phthalate Mixture Exposure on F0 Fertility Outcomes 
The phthalate mixture did not affect the number of F0 females that gave birth to live litters 
(n = 10-12 dams/treatment group, p > 0.05, data not shown). The phthalate mixture also did not 
cause any effects on F0 body weight, ovary weight, uterine weight, liver weight, or relative organ 
weight compared to vehicle control (n = 11-12 dams/treatment group, p > 0.05, data not shown). 
Further, the phthalate mixture did not affect the number of total pups, number of live pups, average 
live pup body weights, and sex ratio of the F1 generation compared to the control groups (n = 10-
12 dams/treatment group, p > 0.05, data not shown).  
Effect of Prenatal Phthalate Mixture Exposure on F1 Female Pup Tissues 
Prenatal exposure to phthalate mixture did not affect the body and liver weights of F1 
females compared to controls on PND 1 and 4 (Table 4.1, n = 10-12 dams/treatment). Prenatal 
exposure to phthalate mixture at 500 mg/kg/day significantly decreased AGD in F1 females 
compared to controls on PND 8 (Table 4.1, n = 8-12 dams/treatment, p < 0.05). Moreover, prenatal 
exposure to phthalate mixture (20 µg/kg/day) increased uterine weight in the F1 females compared 
to controls on PND 8 (Table 4.1, n = 8-12 dams/treatment, p < 0.05). Prenatal exposure to phthalate 
mixture did not affect body weight, liver weight, ovary weight, uteri weight, or AGD in F1 females 
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compared to controls on PND 21 or at 13 months of age (Table 4.1, n = 6-11 dams/treatment). 
However, prenatal exposure to phthalate mixture at 20 and 200 µg/kg/day significantly decreased 
AGD in F1 females and it (500 mg/kg/day) increased uterine weight in F1 females compared to 
controls on PND 60 (Table 4.1, n = 5-9 dams/treatment, p < 0.05).  
Interestingly, prenatal exposure to the phthalate mixture caused cystic ovaries in F1 
females at 13 months of age (Figure 4.1). In controls, none of the F1 females had cystic ovaries, 
but females in all phthalate treated groups had cystic ovaries with enlarged fluid or blood filled 
cysts (Table 4.2).  
Effect of Prenatal Phthalate Mixture Exposure on F1 Pubertal Outcomes 
Prenatal exposure to phthalate mixture at 20 µg/kg/day decreased F1 body weights at 
vaginal opening compared to controls (Figure 4.2A, n = 10-12, p < 0.05), but it did not significantly 
affect the age at vaginal opening in F1 females compared to controls (Figure 4.2B, n = 10-12). 
However, prenatal exposure to phthalate mixture at 200 µg/kg/day borderline significantly reduced 
the days between vaginal opening and the first estrus in F1 females compared to controls (Figure 
4.2C, n = 10-12, p = 0.061). 
Prenatal phthalate mixture exposure did not affect the time mice spent in proestrus in the 
30 days after vaginal opening in F1 females compared to control (Figure 4.3A, n = 10-12). 
However, at all doses, prenatal phthalate mixture exposure increased the time F1 mice spent in 
estrus and decreased the time they spent in metestrus and diestrus combined in the 30 days after 
vaginal opening compared to control (Figure 4.3A, n = 10-12, *p < 0.05, ^p = 0.057 for estrus , ^p 
= 0.063 for metestrus/diestrus). 
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Effect of Prenatal Phthalate Mixture Exposure on F1 Body Weights and Cyclicity over Time 
Prenatal phthalate mixture exposure did not affect F1 body weights at 3, 6, 9, and 13 
months of age compared to controls (Table 4.3, n = 7-12). At 3 months, prenatal exposure to 
phthalate mixture did not affect the time F1 mice spent in proestrus (Figure 4.3B, n = 11-12), but 
it increased the time spent in estrus and decreased the time spent in metestrus/diestrus combined 
at all doses in F1 females compared to controls (Figure 4.3B, n = 11-12, ^p = 0.077 for estrus, ^p 
= 0.059 for metestrus/diestrus). At 6 months, prenatal exposure to phthalate mixture at 20 
µg/kg/day, 200 mg/kg/day, and 500 mg/kg/day significantly decreased the time F1 mice spent in 
proestrus, but at 500 mg/kg/day, it increased the time F1 mice spent in estrus compared to control 
(Figure 4.3C, n = 10-12, p < 0.05). At 13 months, prenatal exposure to phthalate mixture did not 
affect F1 estrous cyclicity compared to control (Figure 4.3D, n = 7-9).  
Effect of Prenatal Phthalate Mixture Exposure on F1 Fertility over Time  
At 3 months, prenatal exposure to phthalate mixture at 200 mg/kg/day significantly 
increased the number of days the F1 mice needed to become pregnant compared to controls (Figure 
4.4A, n = 11-12, p < 0.05), but it did not affect pregnancy length in F1 females compared to 
controls (n = 10-12, data not shown). At this time point, prenatal exposure to phthalate mixture 
also caused breeding complications in the F1 females. Specifically, one F1 female in the control 
group lost her pregnancy. One F1 female in the 200 mg/kg/day group successfully mated, but did 
not become pregnant and one F1 female in the same treatment group lost her pregnancy. One F1 
female in the 500 mg/kg/day group successfully mated, but did not become pregnant. This resulted 
in a reduced pregnancy rate and fertility index in the 200 and 500 mg/kg/day treatment groups 
compared to control (Table 4.4, n = 10-12). Overall, the percentage of fertile F1 females was 91% 
in control, 83% in the 200 mg/kg/day group, 91% in the 500 mg/kg/day group, and 100% in 20 
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and 200 µg/kg/day groups (Table 4.4, n = 10-12). As far as birth outcomes, the phthalate mixture 
did not affect live and total F2 pup numbers, average F2 pup birth weight, or percent F2 females 
compared to control ( n = 9-11, data not shown). 
At 6 months of age, prenatal exposure to the phthalate mixture did not affect the time F1 
mice needed to become pregnant (Figure 4.4B, n = 10-12). Phthalate mixture exposure also did 
not affect pregnancy length compared to controls (n = 10-12, data not shown). At this time point, 
prenatal exposure to phthalate mixture caused some breeding complications in F1 females. 
Specifically, one F1 female in the 20 µg/kg/day group successfully mated, but did not become 
pregnant, and two F1 females in the 200 µg/kg/day group successfully mated, but did not become 
pregnant and one F1 female in this group lost her pregnancy. Further, two F1 females in the 200 
mg/kg/day group successfully mated, but did not become pregnant and two F1 females in the same 
group lost their pregnancy. In addition, one F1 female in the 500 mg/kg/day group successfully 
mated, but did not become pregnant and one F1 female in the same group experienced dystocia. 
In contrast, only one F1 female in the control group lost her pregnancy. Taken together, this 
resulted in a reduced pregnancy rate and fertility index in the phthalate mixture treated groups 
compared to controls (Table 4.4, n = 10-12). As far as birth outcomes, the phthalate mixture at 200 
µg/kg/day significantly decreased the number of live and total F2 pups born to the F1 females 
compared to control animals (Figure 4.5A, n = 7-10, p < 0.05), but it did not affect average F2 pup 
birth weight or percent of F2 females compared to control (Figure 4.5B and 4.5C, n = 7-10). 
At 9 months of age, the phthalate mixture did not affect the time F1 mice needed to become 
pregnant (Figure 4.4C, n = 7-11). Phthalate mixture exposure also did not affect pregnancy length 
compared to controls (n = 7-11, data not shown). However, prenatal exposure to phthalate mixture 
caused breeding complications in F1 females. Specifically, one F1 female in the 20 µg/kg/day lost 
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her pregnancy and two F1 females in the same group experienced dystocia. Further, three F1 
females in the 200 µg/kg/day group lost their pregnancies. In addition, one F1 female in the 200 
mg/kg/day group lost her pregnancy and one female in the same group never mated. One F1 female 
in the 500 mg/kg/day group lost her pregnancy and two F1 females in the same group experienced 
dystocia. In contrast, only one F1 control female did not become pregnant after a successful mating. 
Taken together, this resulted in a reduced mating index and gestational index in the phthalate 
mixture treated groups compared to controls (Table 4.4, n = 7-11). As far as birth outcomes, the 
phthalate mixture did not affect F2 live and total pup numbers, average F2 pup birth weight, or 
percent F2 females compared to control (n = 7-11, data not shown). 
4.5 Discussion 
Previous animal studies have shown that exposure to phthalates during different exposure 
windows causes various reproductive and developmental defects in both male and female animals 
(reviewed in [28, 29]). Most of these previous studies were conducted using single phthalates and 
the doses used in these studies were usually much higher than human exposure levels (reviewed 
in [28, 29]). Given that humans and animals are exposed to a mixture of different phthalates on 
daily basis, it is important to study the effects of phthalate mixtures on reproductive outcomes. 
Thus, this study was designed to determine if exposure to an environmentally relevant phthalate 
mixture at doses comparable to human exposure levels during a critical ovarian developmental 
window has adverse effects on female reproduction throughout reproductive life. To our 
knowledge, this is the first study to provide information on the effects of an environmentally 
relevant phthalate mixture on female reproduction. In our study, we found that prenatal exposure 
to the phthalate mixture decreased AGD, increased uterine weight, disrupted estrous cyclicity, 
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reduced fertility-related indices, caused some breeding complications, and induced cystic ovaries 
in the F1 female mice (Table 5).  
Our data indicate that phthalate mixture exposure did not cause gestational complications 
in F0 females. F0 female mice in all treatment groups successfully gave birth to live litters, and 
the birth outcomes in the phthalate mixture exposed animals were comparable to controls. This 
indicates that phthalate mixture exposure did not cause fetal toxicity or overt maternal toxicity, 
which could lead to reduced litter size and birth defects in the pups. These findings differ from 
previous studies on gestational exposure to BBzP, DBP, and DEHP, which showed that these 
individual phthalates induced pregnancy loss and reduced litter size in rats and mice [18, 30-32]. 
The reasons for differences in our mixture study versus previous studies using single phthalates 
are probably due to the lower doses used in our study compared to previous studies. The dose 
range we included in our study was from 20 µg/kg/day to 500 mg/kg/day, however, the lowest 
doses that caused adverse effects used in the aforementioned studies was 500 mg/kg/day (doses 
used in these previous studies ranged from 0.05 to 1500 mg/kg/day for a single phthalate)  [18, 30-
32]. In addition, differences in our results from previous studies could be due to the differences in 
exposure window. In our study, we exposed the pregnant dam during the second half of gestation, 
however, in the studies in which pregnancy loss and reduced litter size were observed, the exposure 
windows were either only during the first half of the gestation [30, 31] or throughout the whole 
gestation period [18, 32].  
Our data showed that prenatal exposure to the phthalate mixture increased uterine weight 
on PND 8 and 60. Uterine weight is affected by sex steroid hormone levels. Thus, it is possible 
that in the phthalate mixture exposed F1 females, steroidogenesis was disrupted by the mixture 
exposure. On PND 8, the pups still depend on the dams and are sexually immature. The 
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hypothalamus-pituitary-ovary axis is not fully functioning on PND 8, and as a result, the hormone 
levels in F1 females are heavily influenced by the hormone levels in the dams. Studies have shown 
that exposure to single phthalates affects steroidogenesis in female mice [18, 33, 34]. Thus, it is 
possible that the phthalate mixture exposure adversely affected sex steroid hormone levels in the 
dams and in turn induced differences in uterine weights in the PND 8 pups. Moreover, our data 
showed that prenatal exposure to phthalate mixture also increased uterine weight on PND 60 in F1 
females. At this age, mice have a functional hypothalamus-pituitary-ovary axis and the uteri are 
responsive to hormone actions. Thus, it is possible that at this age, the phthalate mixture induced 
disruption in steroid hormone levels in the exposed F1 females and this led to an increase in uterine 
weight in the F1 pups. Increased uterine weight has been observed in F1 females prenatally 
exposed to DEHP and altered steroidogenesis has been observed in follicles exposed to DEHP [17, 
35]. Thus, future studies should examine the effects of the phthalate mixture on sex steroid 
hormone levels and determine if the phthalate mixture induced increase in uterine weight is due to 
altered sex steroid hormone levels.   
Prenatal exposure to the phthalate mixture reduced AGD on PNDs 8 and 60. Phthalates 
have been shown to reduce AGD in male offspring after prenatal exposure in both singular and 
mixture forms [11, 36, 37]. Similar to results obtained from prenatal phthalate exposure studies in 
males, our results show that the phthalate mixture reduces AGD in F1 females. This outcome is 
likely due to the mixture reducing maternal testosterone levels in the F1 females because AGD is 
determined by maternal testosterone levels. Future studies are needed to measure the serum sex 
steroid hormone levels of pregnant F0 dams to further confirm our hypotheses.  
In phthalate mixture exposed F1 females, we frequently observed enlarged ovaries with 
fluid or blood filled cysts, whereas enlarged cystic ovaries were not observed in any control 
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animals. The presence of ovarian cysts is often a sign of reproductive aging [38]. Similar 
phenotypes have been observed in aged mice, transgenic mice, and ovarian diseases mouse models 
[39-41]. Specifically, one study showed that CD-1 mice develop ovarian inclusion cysts starting 
at 6 months of age, but enlarged ovarian cysts were observed in a 9 month old animal [39]. In a 
transgenic mouse model with conditionally activated Notch1, enlarged ovarian cysts developed in 
8 month old animals [40]. In a transgenic mouse model for the study of ovarian endosalpingiosis, 
enlarged ovarian cysts similar to the cysts observed in our study were observed in animals at 8 
months of age or older [41]. Because we only observed the ovarian cysts in phthalate mixture 
treated F1 females, it is likely that phthalate mixture advanced reproductive senescence, or the 
mixture triggered other pathological changes indicated by the transgenic or induced ovarian 
diseases mouse models. Based on origin, ovarian cysts can be divided into follicular cysts, rete 
ovarii cysts, paraovarian cysts, luteal cysts, luteinized follicle cysts, and unspecified cysts [42]. 
Based on appearance, the cysts that we observed in the phthalate mixture treated F1 females are 
likely to be epithelial cysts or rete ovarii cysts, but it is difficult to distinguish epithelial ovarian 
cysts and rete ovarii cysts based on appearance alone [42]. Thus, further histological evaluations 
are needed to determine the origin of the cysts in the phthalate mixture treated F1 mice.  
In our study, prenatal exposure to phthalate mixture did not affect age at vaginal opening 
and age of first estrus. This is similar to previous study results on prenatal exposure to DEHP, in 
which no effects of DEHP were observed on the age at vaginal opening, weight at vaginal opening, 
or age at first estrus at any doses (20 µg/kg/day to 750 mg/kg/day) [17]. In contrast, prenatal 
exposure to BBzP or MEHP have been shown to delay puberty onset [19, 43]; however, the doses 
that were reported to delay puberty onset (≥ 500 mg/kg/day) were much higher than any of the 
individual phthalates used in the mixture in our study. 
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Our estrous cyclicity data indicate that prenatal exposure to the phthalate mixture 
significantly disrupted estrous cyclicity in F1 females. We observed that prenatal phthalate mixture 
exposure at all doses significantly prolonged the stage of estrus at peripuberty and at 3 months of 
age. This differs from previous studies which showed that prenatal exposure to DEHP did not 
affect estrous cyclicity at the peripubertal stage [17]. However, our results are similar to a study 
that showed that adult exposure to DEHP increased the time mice spent in estrus compared to 
controls [44]. Further, a prepubertal DEHP exposure study has shown that DEHP exposure affects 
ovarian steroidogenesis [45], which could lead to disrupted estrous cyclicity. In addition, we 
speculate that phthalate mixture could affect the establishment of hypothalamic-pituitary-ovarian 
axis, possibly by affecting hypothalamic kisspeptin levels, to disrupt estrous cyclicity. This 
speculation is supported by both animal and epidemiology studies, which showed that phthalates 
exposure interferes with kisspeptin levels [45-47]. Disrupted estrous cyclicity often indicates 
disrupted ovarian function and sex steroid hormone levels and it may also indicate early 
reproductive senescence [38]. Our results on estrous cyclicity are in accordance with our 
observation of cystic ovaries at 13 months of age in the phthalate mixture exposed females, in 
which the presence of the cysts may indicate disrupted ovarian function and ovarian aging.  
Prenatal exposure to the phthalate mixture affected fertility-related indices in F1 females 
at 3, 6, and 9 months of age. At 3 months of age, our results showed that F1 females in the 200 
mg/kg/day group took longer to become pregnant compared to control. This is likely due to the 
disruption of estrous cyclicity by the phthalate mixture at 3 months of age. Many phthalates have 
been shown to induce breeding complications and pregnancy loss [17, 18, 30-32, 48]. In our study, 
phthalate mixture exposed F1 females experienced many breeding complications, including failure 
to mate, failure to become pregnant after successful mating, loss of pregnancy, and dystocia. 
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Several of these complications became more apparent as the animals aged. Specifically, we 
observed more pregnancy loss and dystocia at 6 and 9 months of age than at 3 months of age, even 
at the lower doses. It is possible that prenatal exposure to phthalate mixture disrupted the 
development and functionality of the uterine tissues, and as a result, accelerated uterine aging. It 
could also due to the disrupted production of hormones that are required to maintain pregnancy. 
Further investigations on the uterine tissue and pregnancy related hormone levels are needed to 
elucidate the causes of pregnancy loss. It is difficult to distinguish early pregnancy loss and 
implantation failure based on the body weight alone. In our study, we defined pregnancy loss as 
more than 4g of weight loss during gestation. As a result, the rate of pregnancy loss might be 
higher than what we reported.  
In conclusion, our data indicate that prenatal exposure to an environmentally relevant 
phthalate mixture disrupts female reproduction in the F1 offspring in mice. Specifically, prenatal 
exposure to the phthalate mixture affects organ weights, induces pathological changes in ovaries, 
disrupts estrous cyclicity, reduces fertility-related indices, and causes some breeding 
complications in F1 female mice. To our knowledge, this is the first study that uses a phthalate 
mixture mimicking human exposure and examines the effects on female reproduction. However, 
our study did not provide mechanistic evaluation of the phthalate mixture induced effects. Thus, 
future analyses are needed to determine the underlying mechanisms of action of this phthalate 
mixture. Additionally, many endocrine disrupting chemicals have been shown to have 
transgenerational effects [27-29]; thus, it is of great interest to determine if a mixture of phthalates 
could induce transgenerational effects on female reproduction. 
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4.6 Tables and Figures 
Table 4.1 The effects of prenatal exposure to phthalate mixture on body and organ weights and AGD in F1 females.  
  Age of pups (F1)    
 Treatment PND 1 PND 4 PND 8 PND 21 PND 60 13 months 
Body weight (g) 
Corn oil 1.8279 ± 0.0456 3.3657 ± 0.1362 6.1867 ± 0.3138 14.9986 ± 1.2510 30.4500 ± 0.9917 44.3971 ± 2.2984 
20 µg/kg/day 1.7677 ± 0.0404 3.3603 ± 0.1277 6.0878 ± 0.1271 15.1017 ± 0.4504 28.6614 ± 0.8763 46.6067 ± 2.6242 
200 µg/kg/day 1.8442 ± 0.0487 3.3253 ± 0.0883 6.5079 ± 0.1839 15.7880 ± 0.2801 29.1700 ± 1.5292 46.8811 ± 2.2391 
200 mg/kg/day 1.7742 ± 0.0490 3.2851 ± 0.1237 5.9298 ± 0.1863 14.8082 ± 0.5059 29.2856 ± 1.0320 48.4640 ± 1.9372 
500 mg/kg/day 1.7737 ± 0.0395 3.1211 ± 0.1512 5.9311 ± 0.1121 15.4883 ± 0.3072 31.1767 ± 1.3363 44.8367 ± 3.7498 
                    
Liver weight (g) 
Corn oil 0.0776 ± 0.0024 0.1220 ± 0.0063 0.2031 ± 0.0149 0.8298 ± 0.0922 1.9251 ± 0.1499 2.6497 ± 0.1789 
20 µg/kg/day 0.0705 ± 0.0013 0.1186 ± 0.0075 0.1941 ± 0.0115 0.8415 ± 0.0393 1.6657 ± 0.1016 2.6943 ± 0.1463 
200 µg/kg/day 0.0766 ± 0.0027 0.1195 ± 0.0042 0.2131 ± 0.0063 0.9101 ± 0.0221 1.8083 ± 0.0918 2.5070 ± 0.1086 
200 mg/kg/day 0.0737 ± 0.0019 0.1137 ± 0.0038 0.1875 ± 0.0090 0.8169 ± 0.0403 1.8529± 0.0986 2.6211 ± 0.1209 
500 mg/kg/day 0.0760 ± 0.0020 0.1128 ± 0.0067 0.1918 ± 0.0039 0.8800 ± 0.0405 1.8505 ± 0.1512 2.5688 ± 0.1192 
                    
AGD (mm)/ 
∛Body weight (g) 
Corn oil       0.7162 ± 0.0669 1.7418 ± 0.0822 2.1497 ± 0.1105 1.6733 ± 0.0545 
20 µg/kg/day       0.6714 ± 0.0365 1.5916 ± 0.0501   1.7781 ± 0.0769* 1.7680 ± 0.0671 
200 µg/kg/day       0.6711 ± 0.0414 1.6945 ± 0.0592   1.8112 ± 0.0772* 1.7481 ± 0.0533 
200 mg/kg/day       0.7343 ± 0.0432 1.6683 ± 0.0567 1.9686 ± 0.0641 1.8108 ± 0.0450 
500 mg/kg/day         0.5899 ± 0.0253* 1.6103 ± 0.0120 1.9055 ± 0.0620 1.6997 ± 0.0843 
                    
Uterine weight 
(g) 
Corn oil       0.0065 ± 0.0006 0.0409 ± 0.0066 0.0902 ± 0.0119 0.2365 ± 0.0316 
20 µg/kg/day         0.0071 ± 0.0002* 0.0384 ± 0.0042 0.1119 ± 0.0093 0.2419 ± 0.0271 
200 µg/kg/day       0.0067 ± 0.0002 0.0448 ± 0.0035 0.0902 ± 0.0093 0.2201 ± 0.0221 
200 mg/kg/day       0.0064 ± 0.0003 0.0392 ± 0.0031 0.1120 ± 0.0096 0.2779 ± 0.0597 
500 mg/kg/day       0.0064 ± 0.0002  0.0391 ± 0.0019   0.1411 ± 0.0201* 0.3144 ± 0.0742 
                    
Ovary weight (g) 
Corn oil        0.0048 ± 0.0004 0.0169 ± 0.0015 0.0096 ± 0.0012 
20 µg/kg/day        0.0045 ± 0.0002 0.0135 ± 0.0014 0.0096 ± 0.0008 
200 µg/kg/day        0.0044 ± 0.0004 0.0138 ± 0.0011 0.0118 ± 0.0018 
200 mg/kg/day        0.0045 ± 0.0003 0.0157 ± 0.0020 0.0094 ± 0.0011 
500 mg/kg/day        0.0051 ± 0.0004 0.0151 ± 0.0014 0.0102 ± 0.0014 
This table summarized the body weight, liver weight, AGD, uterine weight, and ovary weight of F1 female mice at different age.  
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Table 4.2 The effects of prenatal exposure to phthalate mixture on the occurrence of cystic ovaries in F1 females. 
Treatment 
Total number 
of females 
Number of 
females with 
cystic ovaries 
Number of 
females with 1 
cystic ovary 
Number of 
females with 2 
cystic ovaries 
Number of 
females with 
blood filled cysts 
Number of 
females with 
fluid filled cysts 
Corn oil 7 0 0 0 0 0 
20 µg/kg/day 9 5 5 0 0 5 
200 µg/kg/day 9 7 4 3 3 4 
200 mg/kg/day 10 5 4 1 1 4 
500 mg/kg/day 9 2 1 1 2 0 
 
This table summarized the information of cystic ovaries in the F1 females at 13 months of age. 
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Table 4.3 The effects of prenatal exposure to phthalate mixture on body weight in F1 
females. 
Treatments 
Age of pups (F1) 
3 months (g) 6 months (g) 9 months (g) 13 months (g) 
Corn oil 32.34 ± 1.23 39.37 ± 1.08 44.86 ± 1.50 46.07 ± 2.42 
20 µg/kg/day 32.23 ± 0.78 39.14 ± 1.99 43.66 ± 1.28 48.00 ± 2.56 
200 µg/kg/day 32.71 ± 0.85 40.16 ± 0.97 44.84 ± 1.60 49.95 ± 2.13 
200 mg/kg/day 33.95 ± 0.79 41.39 ± 0.93 46.68 ± 1.54 50.29 ± 2.33 
500 mg/kg/day 32.78 ± 1.08 39.97 ± 1.12 46.27 ± 2.36 49.56 ± 3.06 
 
This table summarized the body weight of F1 females at different age. 
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Table 4.4 The effects of prenatal exposure to phthalate mixture on fertility at 3, 6, and 9 months of age. 
Age Treatment 
Total 
female 
Plugged 
female 
Pregnant 
females 
Delivered 
female 
Mating 
index 
Pregnancy 
rate 
Fertility 
index 
Gestational 
index 
3 Months 
Corn oil 11 11 11 10 100 100 100 91 
20 µg/kg/day 12 12 12 12 100 100 100 100 
200 µg/kg/day 11 11 11 11 100 100 100 100 
200 mg/kg/day 12 12 11 10 100 92 92 91 
500 mg/kg/day 11 11 10 10 100 91 91 100 
          
6 Months 
Corn oil 10 10 10 9 100 100 100 90 
20 µg/kg/day 11 11 10 10 100 91 91 100 
200 µg/kg/day 11 11 9 8 100 82 82 89 
200 mg/kg/day 12 12 10 8 100 83 83 80 
500 mg/kg/day 11 11 10 9 100 91 91 90 
          
9 Months 
Corn oil 7 7 6 6 100 86 86 100 
20 µg/kg/day 11 11 11 8 100 100 100 73 
200 µg/kg/day 10 10 10 7 100 100 100 70 
200 mg/kg/day 10 9 9 8 90 90 100 89 
500 mg/kg/day 9 9 9 8 100 100 100 89 
 
This table summarized the fertility-related indices of F1 female at different age.   
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Table 4.5 Summary of the effects of prenatal exposure to phthalate mixture on F1 females. 
Effects 
Treatments 
20 µg/kg/day 200 µg/kg/day 200 mg/kg/day 500 mg/kg/day 
Reduced AGD  √ (PND 60) √ (PND 60) √ (PND 8) 
Increased Uterine 
Weight 
√ (PND 8)   √ (PND 60) 
Induced Enlarged 
Cystic Ovaries 
√ (13 months) √ (13 months) √ (13 months) √ (13 months) 
Reduced Mating 
Index 
  √ (9 months)  
Reduced 
Pregnancy Rate 
√ (6 months) √ (6 months) √ (3, 6, and 9 months) √ (3 and 6 months) 
Reduced Fertility 
Index 
√ (6 months) √ (6 months) √ (3 and 6 months) √ (3 and 6 months) 
Reduced 
Gestational Index 
√ (9 months) √ (6 and 9 months) √ (3, 6, and 9 months) √ (6 and 9 months) 
Reduced Percent 
Fertile Female 
√ (9 months) √ (6 and 9 months) √ (3 and 6 months) √ (6 months) 
Disrupted Estrous 
Cyclicity 
√ (3 and 6 months) 
√ (after vaginal opening 
and at 3  months) 
√ (after vaginal opening 
and at 6 months) 
√ (after vaginal opening, 
and at 3 and 6 months) 
Increased Time to 
Pregnancy 
  √ (3 months)  
Decreased Litter 
Size 
 √ (6 months)   
 
This table summarized the effects on F1 female reproduction at different age.   
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Figure 4.1 Representative image of cystic ovary 
 
 
A representative photograph of a cystic ovary in the phthalate mixture exposed F1 mice at 13 
months of age. The cystic ovary is shown on the left and a normal ovary is shown on the right. A 
scale (in centimeters) was photographed along with the left uterine horn and ovary to indicate the 
sizes. 
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Figure 4.2 The effects of prenatal exposure to phthalate mixture on pubertal outcomes in 
F1 females.  
 
The effects of prenatal exposure to phthalate mixture on body weights at vaginal opening in F1 
females are shown in panel A. The effects of prenatal exposure to phthalate mixture on days 
between weaning and vaginal opening in F1 females are shown in panel B. The effects of prenatal 
exposure to phthalate mixture on days between vaginal opening and the presence of first estrus in 
F1 females are shown in panel C. Graphs represent means ± SEM from 10-12 dams per treatment 
group. Asterisk (*) indicates significant differences from the control (p < 0.05). ^ indicates 
borderline significance compared to control, p = 0.061. VO, vaginal opening.  
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Figure 4.3 The effects of prenatal exposure to phthalate mixture on estrous cyclicity after 
vaginal opening, and 3, 6, and 13 months of age in F1 females.  
 
Estrous cyclicity after vaginal opening in F1 females is shown in panel A. Estrous cyclicity at 3 
months in F1 females is shown in panel B. Estrous cyclicity at 6 months in F1 females is shown 
in panel C. Estrous cyclicity at 13 months in F1 females is shown in panel D. Graphs represent 
means ± SEM from 7-12 dams per treatment group. Asterisks (*) indicate significant differences 
from the control (p < 0.05). ^ indicates borderline significance compared to control (panel A, p = 
0.057 for estrus, p = 0.063 for metestrus/diestrus. Panel B, p = 0.077 for estrus, p = 0.059 for 
metestrus/diestrus).  
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Figure 4.4 The effects of prenatal exposure to phthalate mixture on time to pregnancy at 3, 
6, and 9 months of age in F1 females.  
 
The effects of prenatal exposure to phthalate mixture on time to pregnancy at 3 months of age in 
F1 females are shown in panel A. The effects of prenatal exposure to phthalate mixture on time to 
pregnancy at 6 months of age in F1 females are shown in panel B. The effects of prenatal exposure 
to phthalate mixture on time to pregnancy at 9 months of age in F1 females are shown in panel C. 
Graphs represent means ± SEM from 7-12 dams per treatment group. Asterisk (*) indicates 
significant differences from the control (p < 0.05). 
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Figure 4.5 The effects of prenatal exposure to phthalate mixture on F2 birth outcomes at the 
6 months F1 female fertility test.  
 
Litter size (including live and total F2 pup numbers) is shown in panel A. Average pup birth 
weights for F2 pups are shown in panel B. Percentages of female of F2 pups are shown in panel 
C. Graphs represent means ± SEM from 7-10 dams per treatment group. Asterisks (*) indicate 
significant differences from the control (p < 0.05). 
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CHAPTER V 
Exposure to an environmentally relevant phthalate mixture causes transgenerational 
effects on female reproduction in mice4 
5.1 Abstract 
Phthalates are used in consumer products and are known endocrine disrupting chemicals. Most 
previous studies on phthalates focus on single phthalates. However, it is important to study 
phthalate mixtures because females are constantly exposed to mixtures. Previously, we developed 
a phthalate mixture made of 35% diethyl phthalate, 21% di(2-ethylhexyl) phthalate, 15% dibutyl 
phthalate, 15% diisononyl phthalate, 8% diisobutyl phthalate, and 5% benzylbutyl phthalate that 
mimics human exposure. We tested the effects of prenatal exposure to this mixture on reproductive 
outcomes in F1 female mice and found that it impaired reproductive outcomes. However, the 
impact of this exposure on F2 and F3 females was unknown. Thus, we hypothesized that prenatal 
exposure to the phthalate mixture induces multigenerational and transgenerational effects on 
female reproduction. Pregnant CD-1 dams were orally dosed with vehicle (tocopherol-stripped 
corn oil) or a phthalate mixture (20 and 200 µg/kg/day, 200 and 500 mg/kg/day) daily from 
gestational day 10 to birth. Adult F1 females born to these dams were used to generate the F2 
generation and adult F2 females born to F1 females were used to generate the F3 generation. F2 
and F3 females were subjected to tissue collections and fertility tests. Prenatal phthalate mixture 
exposure increased uterine weights, anogenital distance (AGD), and body weight, induced cystic 
ovaries, and caused fertility complications in the F2 generation. It also increased uterine weight, 
4 Reprinted, with permission, from Zhou C. et al. Exposure to an environmentally relevant 
phthalate mixture causes transgenerational effects on female reproduction in mice. Endocrinology 
(Submitted). 
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decreased AGD, and caused fertility complications in the F3 generation. These data suggest that 
prenatal exposure to the phthalate mixture induces multigenerational and transgenerational effects 
on female reproduction. 
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5.2 Introduction  
Phthalates are a group of synthetic chemicals widely present in consumer products, 
including personal care products and plastic products [1, 2]. Humans are constantly exposed to a 
number of phthalates through their use of consumer products. This constant exposure to phthalates 
is supported by the frequent detection of multiple phthalate metabolites in various human fluid 
samples across regions and populations [3-5]. Phthalate exposure is of concern because studies 
have shown that it is associated with increased human health risks [6]. For example, urinary 
phthalate metabolite concentrations have been associated with high blood pressure [7, 8], diabetes 
[9], increased insulin resistance [10], pregnancy loss [11], and preterm birth [12]. Phthalates are 
also considered to be endocrine disrupting chemicals (EDCs). EDCs are defined as chemicals that 
disrupt normal endocrine hormone signaling at the receptor or signal transduction levels [13]. In 
animal studies, phthalates have been shown to act as EDCs to disrupt the reproductive system in 
both males and females [14, 15]. Phthalates are known to induce ‘”phthalate syndrome” in male 
rodents by disrupting the development and function of the male reproductive system [16, 17]. They 
are also capable of targeting the ovaries to disrupt the female reproductive system [18]. 
Recently, phthalates have been shown to have multigenerational or transgenerational 
effects [19-24]. Multigenerational effects occur when the effects of an EDC are observed in more 
than one generation and transgenerational effects occur when the effects of an EDC are transmitted 
to the generations that are not directly exposed to the EDC [13]. Studies have shown that  long-
term dietary exposure to diethyl phthalate (DEP) [19] and dibutyl phthalate (DBP) [20] induced 
multigenerational effects on body weight and reproductive outcomes in both male and female rats. 
Parental exposure to di-(2-ethylhexyl) phthalate (DEHP) caused adverse transgenerational effects 
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on stress hormones, behavior [21], and reproduction [22] in male mice in the F3 generation. 
Prenatal exposure to DEHP in mice accelerated follicle recruitment in both the F1 and F2 
generations [23]. In addition, prenatal exposure to DEHP caused multigenerational effects on male 
reproduction in the F1 and F2 generation, but not in the F3 and F4 generations [24]. However, 
information on the transgenerational effects of phthalates on females is limited. Moreover, little 
information exists on the transgenerational effects of a mixture of phthalates on female 
reproduction. One previous study examined the transgenerational effects of a mixture of bisphenol 
A (BPA), DEHP, and DBP in rats and found that this mixture induced pubertal abnormalities, 
ovarian disease, and obesity in the F3 generation in females [25]. Given that humans and animals 
are constantly exposed to mixtures of phthalates, it is important to further examine the effects of 
phthalate mixtures.   
In this study, we developed a phthalate mixture consisting of DEHP, DEP, DBP, 
benzylbutyl phthalate (BBzP), diisononyl phthalate (DiNP), and diisobutyl phthalate (DiBP). This 
phthalate mixture was based on the urinary phthalate metabolite levels detected in pregnant women 
in Illinois so that we could mimic human exposure to phthalates (unpublished iKids study). In our 
previous work, we showed that this phthalate mixture inhibited mouse antral follicle growth and 
steroidogenesis, reduced apoptosis, and induced oocyte fragmentation in vitro [26]. In addition, 
we reported that prenatal exposure to this phthalate mixture from gestational day 10 to birth 
induced reproductive disruption in female mice in the F1 generation [27]. The purpose of the 
current study was to expand our previous work by testing the hypothesis that exposure to an 
environmentally relevant phthalate mixture induces adverse transgenerational effects on female 
reproduction in mice. To test our hypothesis, we exposed pregnant mice to the phthalate mixture 
and we evaluated the female offspring born to these exposed dams in the next three generations. 
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In this current study, we focused on the female mice from F2 and F3 generations and compared 
the effects of the mixture with the results obtained from F1 generation [27]. 
5.3 Materials and Methods 
Chemicals 
All the phthalates used in this study, DEP, DEHP, DBP, DiBP, DiNP, and BBzP (>98% 
purity), were purchased from Sigma-Aldrich (St. Louis, MO). The phthalate mixture was made of 
21% DEHP, 35% DEP, 15% DBP, 8% DiBP, 5% BBzP, and 15% DiNP (see [27] for details). The 
mixture composition was derived from levels of phthalate metabolites measured in urine samples 
from pregnant women in Illinois (unpublished data from the iKids study). The phthalate mixture 
was diluted in tocopherol-stripped corn oil (vehicle control). The doses used for this study were 
20 µg/kg/day, 200 µg/kg/day, 200 mg/kg/day, and 500 mg/kg/day. This phthalate mixture and the 
selected doses were used in a previous study conducted by our laboratory on the effects of this 
phthalate mixture on female reproduction in F1 mice [27].  
Animals 
Adult cycling female and adult male CD-1 mice were purchased from Jackson Laboratory 
(Bar Harbor, ME) and allowed to acclimate to the facility for at least two weeks before use. The 
mice were housed at the University of Illinois at Urbana-Champaign, Veterinary Medicine Animal 
Facility in polysulfone cages. Food (Harlan Teklad 8604) and water (reverse osmosis filtered) were 
provided for ad libitum consumption. Temperature was maintained at 22±1 °C, and animals were 
subjected to 12-h light-dark cycles. The Institutional Animal Care and Use Committee (IACUC) 
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at the University of Illinois at Urbana-Champaign approved all procedures involving animal care, 
dosing, euthanasia, and tissue collection. 
Study Design 
At two months of age, 60 healthy and unexposed females were mated with untreated proven 
breeder male mice. The presence of a vaginal sperm plug was used as a sign of successful mating 
and gestational day (GD) 1 was considered as the day of the presence of vaginal sperm plug. 
Female mice were separated from males and singly housed once vaginal sperm plugs were 
observed. These dams were considered to be the F0 generation. On GD 10, F0 dams were randomly 
assigned to five different treatment groups (12 F0 dams/treatment group) and then were dosed 
every morning at the same time until the birth of pups. F0 mice were orally dosed by gently 
pipetting tocopherol-stripped corn oil (vehicle control) or different doses of phthalate mixture (20 
µg/kg/day, 200 µg/kg/day, 200 mg/kg/day, and 500 mg/kg/day) into their mouths. All the doses 
were administered based on the individual dam body weight (total volume delivered ranged from 
28 to 44 µl). The pups born to the F0 dams were considered as the first generation (F1). The F1 
generation was exposed to phthalate mixture as fetuses during dosing of the F0 dams. The F1 
females were used to generate the second generation (F2) by breeding F1 female mice (3 months 
of age) with non-exposed non-littermate adult proven male breeders. This F2 generation was 
exposed to phthalates as germ cells when the F0 dams were dosed with the mixture. The F2 females 
were then used to generate the third generation (F3) by breeding F2 female mice (3 months of age) 
with non-exposed non-littermate adult proven male breeders. This F3 generation was the first 
generation that was not exposed to phthalate mixture during the dosing of F0 dams. The F3 females 
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were then used to generate the fourth generation (F4) by breeding F3 female mice (3 months of 
age) with non-exposed non-littermate adult proven male breeders. 
Tissue Collection, Body Weights, and Organ Weights 
All pregnant mice were allowed to give birth naturally and the day of birth was considered 
as postnatal day (PND) 0 for the pups. On PNDs 1, 4, 8, and 21, at least one female F2 and F3 pup 
per litter (n = 3-11 dams/treatment group) was randomly chosen for tissue collections. On PND 60 
and 13 months of age, the remaining F2 and F3 female pups were euthanized and their tissues were 
collected during diestrus. At each time point, sera, ovaries, uteri, and livers were collected, organ 
weights and body weights were recorded, and anogenital distances (AGD) were measured. Organ 
weights were recorded as whole organ weights in grams, AGD was recorded in millimeters (mm), 
and ovaries from the same pup were measured together and recorded as one weight. At 13 months 
of age, due to the cystic ovaries in some treatment groups, ovarian weights were reported for one 
healthy ovary per mouse. AGD was normalized to cubic root of body weight to account for body 
size effects [28]. Sera were stored for measuring sex steroid hormone levels in future studies. 
Ovaries, uteri, and liver were snap-frozen or fixed for molecular or histological analyses in future 
studies. F4 pups born to the F3 mice at 3 months of age were kept until the day of weaning (PND 
21) and euthanized for the measurements of body weights and AGDs. AGDs to cubic root of body 
weight were calculated and compared to control for F4 female mice. 
Onset of Puberty  
After weaning (PND 21), one F2 and F3 female per litter (n = 11-12 litters/treatment group) 
was kept for analyses of onset of puberty, estrous cyclicity, and fertility. Vaginal opening was 
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monitored every morning as a sign of onset of puberty. Body weights were recorded on the day of 
weaning and on the day of vaginal opening. After vaginal opening, estrous cyclicity was monitored 
every morning by examining vaginal smears daily for 30 consecutive days. Days between vaginal 
opening and the presence of first estrus were calculated and compared to control. 
Fertility Tests 
One F2 and F3 female per litter (n = 7-12 litters/treatment group) was subjected to fertility 
tests at 3, 6, and 9 months of age. For each fertility test, estrous cyclicity was monitored every 
morning for 14 consecutive days prior to mating. Estrous cyclicity was also monitored for 14 
consecutive days at 13 months of age in the F2 generation. Then, female mice were housed with 
untreated proven breeder male mice for two weeks to evaluate fertility of the females. Successful 
mating was determined by the presence of a vaginal sperm plug. Body weights were recorded 
twice a week starting on the first day of estrous cyclicity examination until the birth of pups. 
Maintenance or loss of pregnancy were monitored by body weight gain. For every female, the 
presence of a vaginal sperm plug, days to pregnancy, the ability to become pregnant and maintain 
pregnancy, and pregnancy lengths were recorded. The ability to deliver live pups, the size of the 
litter, average live pup birth weight, and pup sex ratios were also recorded to evaluate the birth 
outcomes. To examine fertility, we used following equations based on our previous study [27] to 
calculate mating index, pregnancy rate, fertility index, gestation index, and percent females 
produced live pups:  
Pregnancy rate = number of pregnant females / number of breeding pairs × 100 
Mating index = number of females with vaginal sperm plugs / number of breeding pairs × 100 
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Fertility index = number of pregnant females / number of females with vaginal sperm plugs × 
100 
Gestational index = number of females who delivered / number of pregnant females × 100 
% females produced live pups = number of females who delivered live pups / number of 
breeding pairs 
Statistical Analyses 
Data analyses were conducted using SPSS statistical software (SPSS Inc., Chicago, IL). 
One-way analysis of variance (ANOVA) was used to conduct multiple comparisons between 
normally distributed experimental groups, then followed by Dunnett post-hoc comparisons if equal 
variances were assumed, or Games-Howell post-hoc comparisons if equal variances were not 
assumed. Kruskal-Wallis H tests were used for comparison between groups if data were not 
normally distributed, followed by Mann-Whitney U two-independent sample tests. Statistical 
significance was assigned at p < 0.05. 
5.4 Results 
Effect of Phthalate Mixture Exposure on F2 and F3 Female Pup Tissue and Body Weights 
In the F2 generation, prenatal exposure to the phthalate mixture significantly increased 
body and liver weights compared to controls on PND 1 (200 µg/kg/day), did not affect body and 
liver weights on PND 4, but decreased AGD (500 mg/kg/day) and increased uterine weights (200 
and 500 mg/kg/day) on PND 8 compared to control (Table 5.1, n = 5-10 dams/treatment, * p < 
0.05). On PND 21, the mixture increased body and liver weights (200 µg/kg/day and 200 
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mg/kg/day), increased AGD (200 µg/kg/day and 200 mg/kg/day), and increased ovary weights 
(200 mg/kg/day) compared to control (Table 5.1, n = 5-10 dams/treatment, * p < 0.05, ^ 0.05 < p 
< 0.1, borderline significance). On PND 60, the phthalate mixture did not affect body and tissue 
weights or AGD compared to controls (Table 5.1, n = 3-8 dams/treatment). As the mice aged, the 
phthalate mixture at 200 µg/kg/day significantly increased body weights in the F2 pups at 6, 9, and 
13 months of age compared to control (Table 5.2, n = 5-13 female mice/treatment, * p < 0.05). 
However, phthalate mixture did not affect organ weights or AGD at 13 months of age compared 
to control (Table 5.1, n = 3-9 dams/treatment).  
In addition, the phthalate mixture increased the number of enlarged cystic ovaries at 13 
months of age in F2 generation (Table 5.3). Specifically, 2 of 7 animals (28.6%) in the control 
group, 8 of 11 animals (72.7%) in the 20 µg/kg/day group, 3 of 7 animals (42.9%) in the 200 
µg/kg/day group, 3 of 9 animals (33.3%) in the 200 mg/kg/day group, and 2 of 6 animals (33.3%) 
in the 500 mg/kg/day group had at least one enlarged cystic ovary (Table 5.3). Of these animals, 
three animals in 20 µg/kg/day group and one animal in 200 µg/kg/day had 2 enlarged cystic ovaries. 
Moreover, two animals in the 200 µg/kg/day group had blood filled cysts, and other animals in 
this group had clear fluid filled cysts (Table 5.3). 
In the F3 generation, the phthalate mixture significantly increased body weights on PND 1 
(200 mg/kg/day), but it did not affect body and tissue weights or AGD on PND 4 and 8 compared 
to controls (Table 5.4, n = 5-10 dams/treatment, * p < 0.05). The phthalate mixture significantly 
decreased AGD (200 mg/kg/day) on PND 21. Further, it increased uterine weights (200 µg/kg/day 
and 200 mg/kg/day) and decreased ovarian weights (200 mg/kg/day) on PND 60 compared to 
controls (Table 5.4, n = 3-8 dams/treatment, * p < 0.05, ^ 0.05 < p < 0.1, borderline significance). 
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The phthalate mixture did not affect body weights of F3 females at 3, 6, and 9 months of age 
compared to control (Table 5.2, n = 5-10 female mice/treatment).  
In the F4 generation at PND 21, the phthalate mixture did not affect body weight of the 
females, but it significantly decreased AGD (20 and 200 µg/kg/day and 200 mg/kg/day) compared 
to control (Table 5.5, n = 2-7 dams/treatment, * p < 0.05). Although the body weight and AGD of 
the F4 females in 500 mg/kg/day group appeared to be lower than controls, we could not perform 
statistical analyses on this group because there were only 2 litters in this group (Table 5.5). 
Effect of Phthalate Mixture Exposure on F2 and F3 Pubertal Outcomes 
To monitor puberty, we recorded the age at vaginal opening, body weight at vaginal 
opening, and days between vaginal opening to first estrus in both F2 and F3 generations. Our 
results indicate that the phthalate mixture did not affect body weight at vaginal opening, days 
between weaning and vaginal opening, or days between vaginal opening and first estrus in F2 and 
F3 females compared to control (Figure 5.1A, 5.1B, and 5.1C, n = 7-10 females/treatment for F2. 
Figure 5.1C, 5.1D, and 5.1E, n = 5-9 females/treatment for F3).  
Effect of Phthalate Mixture Exposure on F2 and F3 Cyclicity over Time 
Estrous cyclicity was monitored for 14 consecutive days during adulthood at selected ages 
in both the F2 and F3 generations. The phthalate mixture did not affect estrous cyclicity in either 
the F2 or F3 generation at the selected ages (Figure 5.2A and 5.2B, n = 6-10 females/treatment for 
F2. Figure 5.2C, n = 5-10 females/treatment for F3). However, in the F2 females at 13 months of 
age, one animal in control and two animals in the 20 µg/kg/day group were not cycling and were 
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in persistent diestrus; and one animal in the 20 µg/kg/day group was not cycling and in persistent 
estrus.  
Effect of Phthalate Mixture Exposure on F2 and F3 Fertility over Time 
Fertility tests were performed at 3, 6, and 9 months of age for the F2 and F3 female mice. 
In the F2 generation, the phthalate mixture at 20 µg/kg/day and 500 mg/kg/day significantly 
increased the time female mice needed to mate with males at 3 months (Figure 5.3A, n = 7-13 
females/treatment, * p < 0.05). It did not affect the days to mate with males at 6 months of age 
(Figure 5.3B, n = 6-13 females/treatment), and it (500 mg/kg/day) borderline significantly 
increased the days to mate at 9 months of age in the F2 generation compared to control (Figure 
5.3C, n = 6-12 females/treatment, ^ p = 0.06). In the F3 generation, the phthalate mixture did not 
affect the days female mice needed to mate with males at 3 and 6 months of age (Figure 5.3D and 
5.3E, n = 5-10 females/treatment), but it (200 mg/kg/day) borderline significantly increased the 
days to mate at 9 months of age compared to control (Figure 5.3F, n = 4-8 females/treatment, ^ p 
= 0.07).  
Different fertility indices were calculated based on breeding and pregnancy complications. 
In the F2 generation during the fertility tests at the 3 month time-point, one female in the control, 
20 and 200 µg/kg/day, and 200 mg/kg/day groups successfully mated with males, but did not 
become pregnant; one female in the 200 µg/kg/day group did not mate with the male; and one 
female in the 500 mg/kg/day group had dystocia. These breeding, pregnancy, and delivering 
complications resulted in reduced fertility-related indices, however, all the fertility-related indices 
were similar in phthalate mixture treated groups compared to control (Table 5.6, n = 7-13 
females/treatment). In the F2 generation during the fertility test at the 6 month time-point, all the 
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control females were fertile and maintained their pregnancies; two females in the 20 µg/kg/day 
group and one female in the 200 and 500 mg/kg/day group successfully mated, but did not become 
pregnant; one female in the 200 µg/kg/day group did not mate with the male, resulting in the 
reduction of some fertility-related indices in the phthalate mixture treated group (Table 5.6, n = 6-
13 females/treatment). In the F2 generation during the fertility test at the 9 month time-point, one 
female in the control group and 500 mg/kg/day group experienced pregnancy loss; one female in 
200 µg/kg/day had dystocia; and two females in 200 mg/kg/day group never mated with males. At 
this age, fertility-related indices were not significantly affected by phthalate mixture treatment 
compared to control (Table 5.6, n = 6-12 females/treatment). 
In the F3 generation during fertility tests at the 3 month time-point, one female in the 200 
µg/kg/day and 500 mg/kg/day groups successfully mated, but did not become pregnant; one female 
in the 200 mg/kg/day group did not mate with the male and another female in this group lost her 
pregnancy, whereas in controls and the 20 µg/kg/day group, all animals successfully delivered live 
pups. These complications led to several reduced fertility-related indices in the three highest 
treatment groups (Table 5.7, n = 5-10 females/treatment). In the F3 generation during the 6 month 
time-point fertility test, none of the animals in the control, 200 µg/kg/day, and 500 mg/kg/day 
groups had complications, however, one female in the 20 µg/kg/day group lost her pregnancy and 
another female never mated with male; and two females in 200 mg/kg/day group successfully 
mated with males, but never became pregnant. As a result, the 20 µg/kg/day and 200 mg/kg/day 
groups showed relatively lower fertility-related indices compared to other groups (Table 5.7, n = 
5-10 females/treatment). At the 9 month time-point in the F3 generation, two control females lost 
their pregnancy; one female lost her pregnancy and the other one never mated with the males in 
the 20 µg/kg/day group; one female successfully mated with a male, but did not become pregnant 
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in the 200 µg/kg/day group; one female never mated with a male, one animal successfully mated, 
but did not become pregnant, and another female lost her pregnancy in the 200 mg/kg/day group; 
and one animal successfully mated with a male, but did not become pregnant in the 500 mg/kg/day 
group. All these complications resulted in reduced fertility-related indices in all groups (Table 5.7, 
n = 4-10 females/treatment). 
Effect of Phthalate Mixture Exposure on the Ability of Producing Live Pups across Generations 
In the F1 generation, at the 3 month time-point, 91% of control females, 83% of the females 
in the 200 mg/kg/day group, and 91% of the females in the 500 mg/kg/day group produced live 
pups. Further, all females in the two lowest dose groups produced live pups (Table 5.8, n = 11-12 
females/treatment). At the 6 month time-point, all groups showed reduced percentages of females 
who produced live pups, with females exposed to the three highest doses of mixture producing 
fewer live pups compared to control (Table 5.8, n = 10-12 females/treatment). Similarly, at the 9 
month time-point, the percentages of females delivering live pups were reduced across all groups 
including controls. As a result, no treatment group produced fewer live pups compared to the 
control group (Table 5.8, n = 7-11 females/treatment).  
In the F2 generation, at the 3 month time-point, some animals in all phthalate mixture 
treated groups did not deliver live pups, resulting in reduced percentages of females producing live 
pups in all groups (Table 5.8, n = 6-13 females/treatment). At the 6 month time-point, all animals 
in the control group gave birth to live pups, but fewer females in the phthalate mixture-treated 
groups gave birth to live pups, indicated by the lower percentages (Table 5.8, n = 6-13 
females/treatment). At the 9 month time-point, several more animals in the control, 200 µg/kg/day, 
158 
 
200 and 500 mg/kg/day groups did not produce live pups, resulting in lower percentages of females 
producing live pups in these groups (Table 5.8, n = 6-12 females/treatment). 
In the F3 generation, at the 3 month time-point, all females in the control and 20 µg/kg/day 
groups produced live pups, however, females in the three highest dose groups produced fewer live 
pups compared to control, especially at the 500 mg/kg/day dose (Table 5.8, n = 5-10 
females/treatment). At the 6 month time-point, females in all phthalate mixture-treated groups 
produced fewer live pups compared to controls (Table 5.8, n = 5-10 females/treatment). However, 
at 9 months’ time-point, not all the animals in control group produced live pups. As a result, the 
percentage of females producing live pups in the phthalate mixture treated groups were comparable 
to the control group (Table 5.8, n = 4-10 females/treatment). 
Effect of Phthalate Mixture Exposure on F3 and F4 Pup Birth Outcomes 
Litter size, average live pup body weight, and percentages of female pups in F3 and F4 
generations were recorded and calculated at each fertility test in the F2 and F3 generations. After 
the fertility tests conducted at the 3 month time-point on the F2 and F3 generations, the phthalate 
mixture did not affect F3 and F4 litter size, average live pup body weight, or percentages of female 
pups compared to control (Figure 5.4A, 5.4B, and 5.4C, n = 7-13 dams/treatment for F2. Figure 
5.4D, 5.4E, and 5.4F, n = 5-10 dams/treatment for F3). After fertility tests conducted at the 6 month 
time-point on the F2 and F3 generations, the phthalate mixture did not affect F3 birth outcomes 
(Figure 5A, 5B, and 5C, n = 6-13 females/treatment), it only borderline significantly increased the 
percentage of female pups at 200 µg/kg/day dose in the F4 generation compared to control (Figure 
5.5F, n = 5-10 females/treatment, ^ p = 0.07). After fertility tests conducted at the 9 month time-
point on the F2 and F3 generations, the phthalate mixture did not affect F3 fertility test birth 
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outcomes compared to control (Figure 5.6A, 5.6B, and 5.6C, n = 6-12 females/treatment), but it 
reduced the litter size in the F4 generation compared to control (Figure 5.6D, n = 5-7 
females/treatment).  
5.5 Discussion  
In our previous study, we reported that prenatal exposure to an environmentally relevant 
phthalate mixture significantly decreased AGD, increased uterine weight, disrupted estrous 
cyclicity, reduced fertility-related indices, caused breeding complications, and induced cystic 
ovaries in the F1 generation of mice [27]. In this current study, we provided additional information 
on the effects of this phthalate mixture on female reproduction in the F2 and F3 generations and 
compared the effects caused by phthalate mixture exposure across generations. Our results showed 
that phthalate mixture exposure adversely affected tissue weights and AGD in both the F2 and F3 
generations. It also increased body weight and induced cystic ovaries in F2 generation, and it 
caused breeding and pregnancy complications at different ages in both the F2 and F3 generations. 
Phthalate mixture exposure also reduced the ability of dams to produce live pups and affected the 
pup AGD in all three generations.  
Our data showed the phthalate mixture consistently increased body weight in the F2 
generation at all ages, but not in the F3 generation. In the F2 generation, we observed that the 
phthalate mixture at 200 µg/kg/day increased body weight on PNDs 1 and 21, and 3, 6, 9, and 13 
months of age. This phthalate mixture-induced increase in body weight is similar to that observed 
in response to some other chemicals. Specifically, a mixture of BPA, DEHP, and DBP induced 
obesity in the F3 generation of female rats [25]. Interestingly, the overweight phenotype was 
observed at a low dose of the mixture (BPA 25 mg/kg/day, DEHP 375 mg/kg/day and DBP 33 
160 
 
mg/kg/day) [25]. This is similar to the findings in our study because we showed that one of the 
lower doses of our mixture (200 µg/kg/day) increased body weight. The mechanism by which 
phthalate mixture exposure increased body weight is unknown. However, phthalates have been 
shown to induce obesity by acting on peroxisome proliferator-activated receptors (PPARs) [29-
31]. It is also interesting that the phthalate mixture only increased body weight at the second lowest 
dose, indicating that different doses of the phthalate mixture may act differently to induce different 
effects. Further, we only observed a phthalate mixture-induced increase in body weight in the F2 
generation and not the F1 or F3 generations (except for at PND 1 in the F3 generation), but the 
reasons for this are unknown. Future studies should examine the mechanisms underlying the 
different effects of different doses and different outcomes in the F1, F2, and F3 generations.  
Our data also indicate exposure to the phthalate mixture increased uterine weight in both 
the F2 and F3 generations. In the F2 generation, the phthalate mixture increased uterine weight at 
PND 8, an age well before weaning.  In the F3 generation, the phthalate mixture increased uterine 
weight at PND 60, an age at which mice are adults. The reasons for phthalate mixture induced 
increase in uterine weight are unknown. Because uterine weight is affected by estrogen levels, we 
speculate that perhaps the phthalate mixture increased estrogen levels in the pups. It is also possible 
that in adult mice, the phthalate mixture-induced increased uterine weight may be the result of 
disrupted hormone levels or disrupted uterine development. Disrupted estrogen levels in both 
neonates and adults could be due to the phthalate mixture interfering with the steroidogenic 
pathway. A previous study has shown that acute early life exposure to DEHP resulted in long term 
disruption on steroidogenesis [32]. Moreover, in vitro exposure to this phthalate mixture 
dramatically disrupts steroidogenic pathway in cultured mouse antral follicles by disrupting 
hormone levels, enzyme expression, and receptor expression [26]. Further, studies have shown 
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that phthalates have the ability to cause epigenetic changes [33]. Thus, it is possible that the 
phthalate mixture disrupted the steroidogenic pathway through epigenetic changes, which persist 
across generations to affect uterine weights.  
Phthalate mixture exposure increased the incidence of enlarged cystic ovaries in the F2 
generation. This is similar to what we observed in response to the phthalate mixture in the F1 
females [27]. Our results are consistent with the results from studies on the transgenerational 
effects of a mixture of plastic derivatives (BPA, DEHP, and DBP) on reproduction [25, 34]. In 
those studies, female rats from both the F1 and F3 generations had several ovarian diseases at one 
year of age, including polycystic ovaries, with animals in the F3 generation experiencing more 
severe ovarian diseases than the F1 generation [25]. As suggested by Nilsson et al., it is possible 
that environmental toxicant-induced transgenerational ovarian disease is due to exposure during a 
critical exposure window, which is around sex determination; and due to an alteration in the 
transcriptome and epigenome of granulosa cells [34]. In our study, animals were exposed to 
phthalate mixture around sex determination; thus, our exposure window overlapped with the 
critical exposure window that is suggested by Nilsson et al. to cause ovarian diseases [34]. Further 
examination of the transcriptome and epigenome in phthalate mixture treated ovaries would 
provide more information to confirm our speculation. Future studies should also examine the 
ovaries in F3 generation at 13 months of age to determine if this effect is transgenerational. 
Exposure to the phthalate mixture differentially affected AGD in the F2, F3, and F4 
generations. Specifically, it increased AGD in the F2 generation, but decreased AGD in the F3 and 
F4 generations. AGD is determined by prenatal androgen levels. Therefore, it is possible that the 
phthalate mixture increased androgen levels in the F1 generation to increase the AGD in F2 pups. 
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In the F2 and F3 generations, it is likely that the phthalate mixture reduced androgen levels, leading 
to reduced AGD in the F3 and F4 pups. Future studies should examine the androgen levels in all 
four generations of females to provide more information on the causes of effects on AGD.  
Information on the transgenerational effects of phthalates on AGD is limited and 
inconsistent. One study focusing on the male lineage showed that DEHP exposure increased AGD 
in the F3 males compared to controls in mice [21]. Another similarly designed study showed that 
DEHP exposure only decreased AGD in the F1 generation, but showed no effect in the F2 and F3 
generations of male mice [22]. Differences among studies are probably due to the different lineages 
followed in each study. Our study focused on the female line and the other two studies focused on 
the male line. Differences could also be due to the differences between chemicals and the dosages 
used in the studies. Our study as well as other studies have shown that phthalates do not have linear 
dose response curves [18, 32]. Thus, it is possible that different doses can trigger different effects.  
Phthalate mixture exposure did not affect puberty outcomes (age at vaginal opening and 
age at first estrus) in F1 [27], F2 or F3 female mice. Most of the previous studies on the effects of 
phthalate exposure on puberty focused on direct exposure or the F1 generation and the results are 
inconsistent (reviewed in [14, 15]). However, in one DEHP transgenerational study on male 
puberty, exposure to DEHP delayed pubertal onset in the F1 generation, but not the F2 and F3 
generations [22]. Further, exposure to a mixture of BPA, DEHP, and DBP delayed pubertal onset 
in F1 female rats, but this exposure increased the incidence of early pubertal onset in F3 females 
compared to controls [25, 35]. Our findings are somewhat similar to the DEHP transgenerational 
study [22] because it also showed that phthalate exposure did not cause multigenerational or 
transgenerational effects on puberty onset. The differences between our findings and the other 
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mixture studies are probably due to the several factors. First, the animal species are different in 
that we used mice and the other study group used rats. Second, the dosing windows are different 
because we dosed the animals shortly after sex determination, but the other studies exposed rats 
during sex determination. Third, the mixture used in our study consisted only of phthalates, but 
the other studies used BPA and phthalates. BPA has been shown to cause transgenerational effects 
on puberty onset in mice [36]. Thus, it is possible that the transgenerational effects on puberty 
onset caused by the mixture of BPA, DEHP, and DBP were mainly due to the effects of BPA.  
Our results showed that phthalate mixture exposure did not affect estrous cyclicity in the 
F2 and F3 generations. In contrast, we reported a dramatic disruption of estrous cyclicity in the F1 
generation shortly after puberty onset [27]. Interestingly, we observed that 3 out of 11 animals in 
the lowest phthalate mixture treatment group in the F2 generation were not cycling at all by 13 
months of age. This observation is likely the result of earlier onset of reproductive senescence. 
This is also in accordance with our findings on cystic ovaries in the F2 generation, in which we 
observed the highest incidence of enlarged cystic ovaries in the lowest treatment group. Future 
hormone and ovarian follicle histological analyses are needed to examine whether these animals 
experienced early reproductive senescence. To our knowledge, other information on the 
transgenerational effects of phthalates on estrous cyclicity is unavailable.  
Phthalate mixture exposure increased time to pregnancy in the F2 and F3 generations. In 
our previous study, we observed that the phthalate mixture significantly increased the number of 
days that the F1 females needed to become pregnant at the 3 month time-point [27]. This increased 
time to pregnancy was also observed in the F2 generation at 3 and 9 months of age, as well as at 
the 9 month time-point in the F3 generation. It is likely that the reason for the increased time to 
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pregnancy observed in the F1 generation at the 3 month time-point was due to disrupted estrous 
cyclicity at this same time point [27]. In contrast to results obtained in the F1 generation, we did 
not observe disrupted estrous cyclicity in F2 or F3 generations. However, DEHP has been shown 
to have transgenerational effects on stress hormones and behaviors in female mice [21]. Thus, it is 
possible that phthalate mixture exposure may induce disruptions in behavior that affect the 
willingness of F2 and F3 females to mate with the males.  
Our data on F2 and F3 females also showed that phthalate mixture induced pregnancy 
complications, but to a lesser extent than observed in the F1 generation [27]. The reasons for the 
phthalate-induced pregnancy abnormalities are unknown. Exposure to DEHP disrupts ovarian 
functions in multiple generations [18, 23], and normal ovarian function is very important for 
pregnancy. Thus, disruption of ovarian function could lead to complications in maintaining 
pregnancy. Interestingly, the effects of the phthalate mixture on fertility gradually declined in the 
F2 and F3 generations compared to the F1 generation. This similar trend has been reported in a 
male transgenerational study [24]. Specifically, a study on male rats showed that DEHP exposure 
dramatically reduced conception rate in the F1 generation to 50% and it reduced conception rate 
in the F2 generation to 75%, but did not affect male fertility in F3 and F4 generations [24]. 
Differences among generations are likely due to the differences among the time of exposure in 
different generations. The F1 generation was directly exposed to the chemicals as developing 
fetuses, the F2 generation was directly exposed as germ cells in the F1 generation, and F3 and F4 
generations were not exposed to the chemicals. 
Our fertility tests in the F3 generation at the 9 month time-point showed that phthalate 
mixture significantly reduced litter size at highest dose. These results are consistent with previous 
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studies on single phthalates. DBP exposure through gestation reduced the number of live pups per 
litter in the rats [37]. DEHP exposure from PND 5 through weaning, mating and pregnancy at 20 
and 40 μg/kg/day significantly reduced litter size compared to control in mice [38]. DBP exposure 
at 500 mg/kg/day to pregnant rats reduced litter size in F1, F2, and F3 generations compared to 
control [39]. Interestingly, gestational exposure to DEHP at 20 mg/kg/day increased litter size in 
the F3 generation in rats [40]. The reduced litter size observed in our study could be due to 
disrupted ovarian and uterine function. It has been shown that DBP exposure decreases number of 
corpora lutea and the weight of placenta, it also increases resorptions and pre- and post-
implantation loss in F1, F2, and F3 generations of rats [39]. Moreover, DEHP exposure induces 
multigenerational acceleration of follicle recruitment in F1 and F2 mice [23]. It is possible that 
these effects could be passed down to the F3 generation, resulting in fewer follicles available at 9 
months of age and a reduction in litter size. However, future examination is needed to investigate 
the causes of this reduction in litter size, especially with regards to the effects of phthalate mixture 
on ovarian and uterine functions. 
Several female mice in both the F2 and F3 generations only gave birth to dead pups, but 
the percentage of females that produced dead pups was highest in the F3 generation. Reduced 
ability to produce live litters has been reported in single phthalate direct exposure studies. For 
example, dietary exposure to DEHP at 500 mg/kg/day induced 100% abortion rate in mice [41]. 
Further, two major types of dead litters were observed in our study: intact dead pups (either in 
nests or spread out in the cage) and damaged dead pups. Several scenarios could explain our 
observations. First, it is possible that more female mice experienced dystocia than we observed, 
and dystocia led to the death of pups. We only considered a female to have dystocia when we could 
detect she was in pain and was giving birth for more than 4 hours during the light cycle. It is likely 
166 
 
that some of the females experienced dystocia during the dark hours and we missed the opportunity 
to detect their condition. Second, it is possible that the phthalate mixture disrupted maternal 
behavior so that the dams neglected new born litters, leading to pups being found dead on the day 
of birth. Unlike live litters, pups from some of the dead litters were spread far apart from each 
other in the cage, or they were cannibalized by the dams. In both situations, no milk spots were 
observed, indicating the dams did not feed the pups. This maternal negligence hypothesis is 
supported by a study on DEHP, which showed that perinatal exposure to DEHP aggravated 
anxiety- and depression-like behaviors in mice [42]. Further, another study showed that DEHP 
induced transgenerational effects on stress hormones and behavior in mice [21]. Alternatively, it 
is possible that phthalate mixture disrupted fetal development to induce abnormalities in the fetus, 
resulting in deaths of the entire litter.  
In conclusion, our data show that exposure to an environmentally relevant phthalate 
mixture induced some multigenerational and transgenerational effects on female reproduction. We 
observed multigenerational effects on body weight and cystic ovaries and transgenerational effects 
on fertility and birth outcomes. Our study provided some of the first information on the 
multigenerational and transgenerational effects of a phthalate mixture on female reproductive 
health. Future studies should investigate the mechanisms underlying the phthalate mixture-induced 
effects on female reproduction. A limited number of studies on DEHP exposure suggest that the 
mechanisms that underlie the transgenerational effects in females involve epigenetic and/or 
imprinted genes. For example, prenatal DEHP exposure can affect DNA methylation of imprinted 
genes in the oocytes of F1 and F2 mice [43]. DEHP exposure through the diet causes 
transgenerational effects through estrogen receptor 1, which are mediated by PPARα-dependent 
pathways [44]. Further analyses on the animals from our study with a focus on DNA methylation, 
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imprinted genes, and the PPARs will help us understand the mechanisms involved in the toxicity 
of our phthalate mixture.  
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5.6 Tables and Figures 
Table 5.1 The effects of prenatal exposure to phthalate mixture on body and organ weights and AGD in F2 females.  
  Age of pups (F2)  
 Treatment          PND 1 PND 4          PND 8        PND 21       PND 60     13 Months 
Body 
weight (g) 
Control     1.72 ± 0.06     2.87 ± 0.21     5.12 ± 0.24   10.61 ± 0.81   28.17 ± 0.83   41.23 ± 1.39 
20 µg/kg/day     1.83 ± 0.04     3.17 ± 0.15     5.80 ± 0.26   13.03 ± 0.21*   26.86 ± 0.70   43.10 ± 1.29 
200 µg/kg/day     1.97 ± 0.07*     3.38 ± 0.17     5.79 ± 0.21   13.22 ± 0.65*   29.50 ± 0.84   47.99 ± 2.18* 
200 mg/kg/day     1.77 ± 0.03     2.96 ± 0.15     5.36 ± 0.30   12.40 ± 0.83   28.01 ± 0.50   41.15 ± 1.67 
500 mg/kg/day     1.71 ± 0.04     3.04 ± 0.16     5.01 ± 0.26   11.43 ± 0.78   28.65 ± 1.49   43.30 ± 2.57 
                  
Liver 
weight (g) 
Control 0.0728 ± 0.0028 0.1035 ± 0.0078 0.1573 ± 0.0076 0.5288 ± 0.0590 1.5989 ± 0.0822 2.3058 ± 0.1218 
20 µg/kg/day 0.0762 ± 0.0020 0.1188 ± 0.0067 0.1856 ± 0.0160 0.6727 ± 0.0280^ 1.3901 ± 0.0570 2.6565 ± 0.1273 
200 µg/kg/day 0.0830 ± 0.0024* 0.1240 ± 0.0072 0.1717 ± 0.0051 0.6820 ± 0.0370^ 1.6106 ± 0.0576 2.5465 ± 0.1483 
200 mg/kg/day 0.0716 ± 0.0010 0.0990 ± 0.0056 0.1613 ± 0.0103 0.6399 ± 0.0574 1.5455 ± 0.0513 2.4783 ± 0.1299 
500 mg/kg/day 0.0719 ± 0.0016 0.1052 ± 0.0067 0.1539 ± 0.0152 0.5272 ± 0.0432 1.5382 ± 0.0827 2.4591 ± 0.1202 
                  
AGD 
(mm)/ 
∛Body 
weight (g) 
Control       0.8241 ± 0.0680 1.5136 ± 0.0900 1.8492 ± 0.0353 1.6518 ± 0.0664 
20 µg/kg/day       0.8823 ± 0.0263 1.6543 ± 0.0717 1.7815 ± 0.0281 1.6079 ± 0.0403 
200 µg/kg/day       1.0170 ± 0.0618 1.8087 ± 0.0500* 1.8058 ± 0.0360 1.5544 ± 0.0498 
200 mg/kg/day       0.7251 ± 0.0457 1.7791 ± 0.0485^ 1.7307 ± 0.0597 1.5478 ± 0.0685 
500 mg/kg/day       0.5856 ± 0.0135* 1.6329 ± 0.1231 1.8522 ± 0.0978 1.5078 ± 0.0522 
                  
Uterine 
weight (g) 
Control       0.0033 ± 0.0002 0.0142 ± 0.0008 0.1172 ± 0.0084 0.2243 ± 0.0333 
20 µg/kg/day       0.0035 ± 0.0002 0.0192 ± 0.0014 0.1068 ± 0.0041 0.2354 ± 0.0125 
200 µg/kg/day       0.0037 ± 0.0002 0.0232 ± 0.0016 0.1002 ± 0.0066 0.2455 ± 0.0211 
200 mg/kg/day       0.0058 ± 0.0005* 0.0211 ± 0.0039 0.1011 ± 0.0043 0.1669 ± 0.0088 
500 mg/kg/day       0.0046 ± 0.0005* 0.0145 ± 0.0003 0.1040 ± 0.0046 0.2512 ± 0.0589 
                  
Ovary 
weight (g) 
Control        0.0033 ± 0.0003 0.0141 ± 0.0010 0.0090 ± 0.0010 
20 µg/kg/day        0.0040 ± 0.0002 0.0141 ± 0.0010 0.0117 ± 0.0014 
200 µg/kg/day        0.0041 ± 0.0003 0.0130 ± 0.0009 0.0115 ± 0.0007 
200 mg/kg/day        0.0046 ± 0.0004^ 0.0142 ± 0.0009 0.0091 ± 0.0009 
500 mg/kg/day        0.0039 ± 0.0003 0.0130 ± 0.0015 0.0112 ± 0.0011 
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Table 5.1 (cont.) 
Asterisks (*) indicate significant differences from the control (p < 0.05).  
^ indicates borderline significance compared to control, 0.05 < p < 0.1.  
This table summarized the body weight, liver weight, AGD, uterine weight, and ovary weight of F2 female mice at different age. 
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Table 5.2 The effects of prenatal exposure to phthalate mixture on body weight in F2 and F3 females. 
Treatments 
Age of pups (F2)  Age of pups (F3) 
3 months (g) 6 months (g) 9 months (g) 13 months (g)  3 months (g) 6 months (g) 9 months (g) 
Control 30.16 ± 1.23 38.93 ± 1.66 40.23 ± 1.04 41.23 ± 1.39  35.19 ± 1.27 40.87 ± 1.61 46.41 ± 3.27 
20 µg/kg/day 30.83 ± 1.04 41.74 ± 1.68 43.06 ± 1.37 43.10 ± 1.29  32.71 ± 1.16 39.11 ± 1.60 42.72 ± 2.21 
200 µg/kg/day 32.10 ± 0.77 45.83 ± 1.47* 50.72 ± 1.89* 47.99 ± 2.18*  36.26 ± 1.50 44.00 ± 1.77 52.91 ± 3.37 
200 mg/kg/day 30.46 ± 0.56 40.07 ± 1.49 42.41 ± 1.85 41.15 ± 1.67  36.01 ± 0.98 45.62 ± 1.87 51.54 ± 2.54 
500 mg/kg/day 31.23 ± 1.09 40.75 ± 2.83 43.53 ± 3.09 43.30 ± 2.57  33.44 ± 2.09 40.74 ± 2.22 41.35 ± 2.80 
 
Asterisks (*) indicate significant differences from the control (p < 0.05). 
This table summarized the body weight of F2 and F3 females at different age. 
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Table 5.3 The effects of prenatal exposure to phthalate mixture on the occurrence of cystic ovaries in F2 females at 13 months 
of age. 
Treatment 
Total number of 
females 
Number of 
females with 
cystic ovaries 
Number of females 
with blood filled 
cysts 
Number of females 
with clear fluid filled 
cysts 
Control 7 2 0 2 
20 µg/kg/day 11 8 0 8 
200 µg/kg/day 7 3 2 1 
200 mg/kg/day 9 3 0 3 
500 mg/kg/day 6 2 0 2 
 
This table summarized the information of cystic ovaries in the F2 females at 13 months of age. 
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Table 5.4 The effects of prenatal exposure to phthalate mixture on body and organ weights and AGD in F3 females.  
  Age of pups (F3) 
 Treatment PND 1 PND 4 PND 8 PND 21 PND 60 
Body weight (g) 
Control 1.74 ± 0.04 3.19 ± 0.09 5.68 ± 0.20      13.25 ± 0.75       30.49 ± 0.92 
20 µg/kg/day 1.73 ± 0.08 3.16 ± 0.07 5.77 ± 0.29      14.47 ± 0.57       29.55 ± 1.34 
200 µg/kg/day 1.78 ± 0.03 3.23 ± 0.09 6.03 ± 0.17      14.23 ± 1.34       31.37 ± 1.17 
200 mg/kg/day   1.89 ± 0.04* 2.94 ± 0.10 5.39 ± 0.35      14.81 ± 0.51       32.50 ± 2.02 
500 mg/kg/day 1.68 ± 0.04 3.25 ± 0.12 6.15 ± 0.13      14.82 ± 0.32       28.66 ± 1.06 
                 
Liver weight (g) 
Control 0.0715 ± 0.0020 0.1134 ± 0.0054 0.1934 ± 0.0159 0.7107 ± 0.0493 1.7779 ± 0.1205 
20 µg/kg/day 0.0700 ± 0.0025 0.1087 ± 0.0019 0.2027 ± 0.0159 0.7331 ± 0.0668 1.6777 ± 0.1048 
200 µg/kg/day 0.0730 ± 0.0023 0.1145 ± 0.0043 0.1970 ± 0.0085 0.7449 ± 0.0908 1.7668 ± 0.0694 
200 mg/kg/day 0.0747 ± 0.0028 0.1055 ± 0.0060 0.1833 ± 0.0128 0.7699 ± 0.0325 1.7646 ± 0.1464 
500 mg/kg/day 0.0677 ± 0.0032 0.1082 ± 0.0041 0.1972 ± 0.0061 0.7747 ± 0.0115 1.6424 ± 0.0683 
                 
AGD (mm)/ 
∛Body weight (g) 
Control       1.0628 ± 0.0436 1.6609 ± 0.0934 1.7181 ± 0.0660 
20 µg/kg/day       1.0371 ± 0.0491 1.4396 ± 0.0799 1.7576± 0.0571 
200 µg/kg/day       0.9964 ± 0.0495 1.5840 ± 0.1310 1.8220± 0.0627 
200 mg/kg/day       0.9482 ± 0.0543   1.3258 ± 0.0555* 1.7548 ± 0.0581 
500 mg/kg/day       0.9553 ± 0.0596 1.5925 ± 0.2694 1.7558 ± 0.0617 
                 
Uterine weight (g) 
Control       0.0047 ± 0.0002 0.0304 ± 0.0043 0.1087 ± 0.0047 
20 µg/kg/day       0.0044 ± 0.0003 0.0386 ± 0.0044 0.1124 ± 0.0041 
200 µg/kg/day       0.0041 ± 0.0003 0.0336 ± 0.0073   0.1353 ± 0.0076* 
200 mg/kg/day       0.0042 ± 0.0004 0.0272 ± 0.0026   0.1342 ± 0.0113* 
500 mg/kg/day       0.0051 ± 0.0003 0.0457 ± 0.0066 0.1265 ± 0.0070 
                 
Ovary weight (g) 
Control        0.0043 ± 0.0002 0.0158 ± 0.0014 
20 µg/kg/day        0.0045 ± 0.0005 0.0149 ± 0.0010 
200 µg/kg/day        0.0043 ± 0.0002 0.0138 ± 0.0011 
200 mg/kg/day        0.0047 ± 0.0004   0.0118 ± 0.0008^ 
500 mg/kg/day        0.0045 ± 0.0005 0.0135 ± 0.0012 
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Table 5.4 (cont.) 
Asterisks (*) indicate significant differences from the control (p < 0.05).  
^ indicates borderline significance compared to control, 0.05 < p < 0.1.  
This table summarized the body weight, liver weight, AGD, uterine weight, and ovary weight of F3 female mice at different age. 
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Table 5.5 The effects of prenatal exposure to phthalate mixture on body weight and AGD in F4 females at PND 21. 
Treatment Body Weight (g) AGD (mm)† 
Corn oil 9.90 ± 1.03 2.00 ± 0.05 
20 µg/kg/day 8.32 ± 0.85   1.75 ± 0.02* 
200 µg/kg/day 8.26 ± 0.78   1.75 ± 0.08* 
200 mg/kg/day 8.11 ± 0.78   1.70 ± 0.05* 
500 mg/kg/day  7.83 (n = 2)  1.66 (n = 2) 
 
† AGD, anogenital distance.  
Asterisks (*) indicate significant differences from the control (p < 0.05).  
This table summarized the body weight and AGD of F4 females at PND 21.  
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Table 5.6 The effects of prenatal exposure to phthalate mixture on fertility at the 3, 6, and 9 month time-points in the F2 
generation. 
 Treatment 
Total 
female 
Plugged 
female 
Pregnant 
females 
Delivered 
female 
Mating 
index 
Pregnancy 
rate 
Fertility 
index 
Gestational 
index 
3 month 
time-point 
Control 9 9 8 8 100 89 89 100 
20 µg/kg/day 13 13 12 12 100 92 92 100 
200 µg/kg/day 10 9 8 8 90 90 89 100 
200 mg/kg/day 12 12 11 11 100 92 92 100 
500 mg/kg/day 6 6 6 5 100 100 100 83 
          
6 month 
time-point 
Control 10 10 10 10 100 100 100 100 
20 µg/kg/day 13 13 11 11 100 85 85 100 
200 µg/kg/day 10 9 9 9 90 90 100 100 
200 mg/kg/day 11 11 10 10 100 91 91 100 
500 mg/kg/day 6 6 5 5 100 83 83 100 
          
9 month 
time-point 
Control 9 9 9 8 100 100 100 89 
20 µg/kg/day 12 12 12 12 100 100 100 100 
200 µg/kg/day 10 10 10 10 100 100 100 100 
200 mg/kg/day 10 8 8 8 80 80 100 100 
500 mg/kg/day 6 6 6 5 100 100 100 83 
 
This table summarized the fertility-related indices of F2 female at different age.   
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Table 5.7 The effects of prenatal exposure to phthalate mixture on fertility at the 3, 6, and 9 month time-points in the F3 
generation. 
 Treatment 
Total 
female 
Plugged 
female 
Pregnant 
females 
Delivered 
female 
Mating 
index 
Pregnancy 
rate 
Fertility 
index 
Gestational 
index 
3 month 
time-point 
Control 8 8 8 8 100 100 100 100 
20 µg/kg/day 10 10 10 10 100 100 100 100 
200 µg/kg/day 8 8 7 7 100 88 88 100 
200 mg/kg/day 10 9 9 8 90 90 100 89 
500 mg/kg/day 5 5 4 4 100 80 80 100 
          
6 month 
time-point 
Control 7 7 7 7 100 100 100 100 
20 µg/kg/day 10 9 9 8 90 90 100 89 
200 µg/kg/day 8 8 8 8 100 100 100 100 
200 mg/kg/day 10 10 8 8 100 80 80 100 
500 mg/kg/day 5 5 5 5 100 100 100 100 
          
9 month 
time-point 
Control 7 7 7 5 100 100 100 71 
20 µg/kg/day 10 9 9 8 90 90 100 89 
200 µg/kg/day 7 7 6 6 100 86 86 100 
200 mg/kg/day 9 8 7 6 89 78 88 86 
500 mg/kg/day 4 4 3 3 100 75 75 100 
 
This table summarized the fertility related-indices of F3 female at different age.   
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Table 5.8 The effects of prenatal exposure to phthalate mixture on the ability to produce live pups at the 3, 6, and 9 month 
time-points in the F1, F2, and F3 generations. 
  F1  F2  F3 
Age Treatment Total female 
% Produced 
Live Pups 
 Total 
female 
% Produced 
Live Pups 
 Total 
female 
% Produced 
Live Pups 
3 month 
time-point 
Control 11 91  9 89  8 100 
20 µg/kg/day 12 100  13 85  10 100 
200 µg/kg/day 11 100  10 80  8 88 
200 mg/kg/day 12 83  12 92  10 80 
500 mg/kg/day 11 91  6 83  5 40 
6 month 
time-point 
Control 10 90  10 100  7 100 
20 µg/kg/day 11 91  13 77  10 70 
200 µg/kg/day 11 64  10 90  8 88 
200 mg/kg/day 12 58  11 91  10 80 
500 mg/kg/day 11 82  6 83  5 60 
9 month 
time-point 
Control 7 57  9 89  7 71 
20 µg/kg/day 11 73  12 100  10 70 
200 µg/kg/day 10 60  10 90  7 86 
200 mg/kg/day 10 80  10 80  9 67 
500 mg/kg/day 9 56  6 83  4 75 
 
This table summarized the ability to produce live pups at the 3, 6, and 9 month time-points in the F1, F2, and F3 generations. 
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Figure 5.1 The effects of prenatal exposure to phthalate mixture on pubertal outcomes in 
F2 and F3 females. 
 
The effects of prenatal exposure to phthalate mixture on body weights at vaginal opening in F2 
and F3 females are shown in panel A and D, respectively. The effects of prenatal exposure to 
phthalate mixture on days between weaning and vaginal opening in F2 and F3 females are shown 
in panel B and E, respectively. The effects of prenatal exposure to phthalate mixture on days 
between vaginal opening and the presence of first estrus in F2 and F3 females are shown in panel 
C and F, respectively. Graphs represent means ± SEM from 7-10 females per treatment group for 
F2 and 5-9 females per treatment group for F3 dams. VO, vaginal opening.  
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Figure 5.2 The effects of prenatal exposure to phthalate mixture on estrous cyclicity at 
selected ages in F2 and F3 females. 
 
Estrous cyclicity after at 3 months of age in F2 females is shown in panel A. Estrous cyclicity at 
13 months in F2 females is shown in panel B. Estrous cyclicity at 6 months in F3 females is shown 
in panel C. Graphs represent means ± SEM from 6-10 females per treatment group for F2 females 
and 5-10 females per treatment group for F3 females. 
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Figure 5.3 The effects of prenatal exposure to phthalate mixture on time to pregnancy at 3, 
6, and 9 months of age in F2 and F3 females. 
 
The effects of prenatal exposure to phthalate mixture on time to pregnancy at 3 months of age in 
F2 and F3 females are shown in panel A and D, respectively. The effects of prenatal exposure to 
phthalate mixture on time to pregnancy at 6 months of age in F2 and F3 females are shown in 
panel B and E, respectively. The effects of prenatal exposure to phthalate mixture on time to 
pregnancy at 9 months of age in F2 and F3 females are shown in panel C and F, respectively. 
Graphs represent means ± SEM from 6-13 females per treatment group for F2 females and 4-10 
females per treatment group for F3 females. Asterisks (*) indicate significant differences from the 
control (p < 0.05). ^ indicates borderline significance compared to control, ^ p = 0.07.  
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Figure 5.4 The effects of prenatal exposure to phthalate mixture on F3 and F4 birth 
outcomes at the 3 month time-point in the F2 and F3 female fertility tests. 
 
Litter sizes of F3 and F4 are shown in panels A and D, respectively. Average pup birth weights for 
F3 and F4 pups are shown in panels B and E, respectively. Percentages of female of F3 and F4 
pups are shown in panels C and F, respectively. Graphs represent means ± SEM from 5-10 dams 
per treatment group for F3 pups and 5-10 dams per treatment group for F4 pups.  
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Figure 5.5 The effects of prenatal exposure to phthalate mixture on F3 and F4 birth 
outcomes at the 6 month time-point in the F2 and F3 female fertility tests. 
 
Litter sizes of F3 and F4 are shown in panels A and D, respectively. Average pup birth weights for 
F3 and F4 pups are shown in panels B and E, respectively. Percentages of female of F3 and F4 
pups are shown in panels C and F, respectively. Graphs represent means ± SEM from 6-13 dams 
per treatment group for F3 pups and 5-10 dams per treatment group for F4 pups. ^ indicates 
borderline significance compared to control, ^ p = 0.07. 
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Figure 5.6 The effects of prenatal exposure to phthalate mixture on F3 and F4 birth 
outcomes at the 9 month time-point in the F2 and F3 female fertility tests. 
 
Litter sizes of F3 and F4 are shown in panels A and D, respectively. Average pup birth weights for 
F3 and F4 pups are shown in panels B and E, respectively. Percentages of female of F3 and F4 
pups are shown in panels C and F, respectively. Graphs represent means ± SEM from 5-12 dams 
per treatment group for F3 pups and 5-7 dams per treatment group for F4 pups. Asterisk (*) 
indicates significant differences from the control (p < 0.05). 
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Chapter VI 
Summary, Conclusions, and Future Directions 
6.1 Summary, Conclusions, and Future Directions 
The overall goal of my doctoral dissertation work was to examine the developmental and 
reproductive toxicity of an environmentally relevant phthalate mixture in females. Phthalates are 
a category of structurally similar chemicals that are commonly used as plasticizers and additives 
in several common products, including various plastics, cosmetics, personal care products, 
polyvinyl chloride pipes, and vinyl flooring [1, 2]. Due to the ubiquitous presence of phthalates in 
daily life, exposure to phthalate is inevitable. Phthalate exposure is of concern because 
epidemiological studies have shown that it is associated with increased human health risks such as 
infertility and early reproductive senescence [3]. Many studies already have been conducted on 
the toxic effects of phthalate exposure. However, most of these previous studies have only 
examined a single phthalate, and it is well known that humans and animals are exposed to mixtures 
of phthalates [4-6]. The limited number of studies conducted with chemical mixtures either used 
very high doses (over 100 times higher than human daily exposure) or the mixtures were not made 
based on actual phthalates present in humans. It is important to examine environmentally relevant 
doses of a phthalate mixture that mimics human daily exposure so that we can better understand 
the potential risks of phthalates on human and animal health. My doctoral dissertation work 
provided research findings on the effects of an environmentally relevant phthalate to fill in this 
information gap. Collectively, my studies show that exposure to an environmentally relevant 
phthalate mixture decreases the growth and steroidogenic capacity of antral follicles and causes 
transgenerational fertility problems in female mice. 
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In Chapter III, I hypothesized that phthalate mixture exposure decreases antral follicle 
growth, compromises steroidogenic capacity, and induces atresia. My results showed that 
phthalate mixture at 100 and 500 µg/ml significantly reduced antral follicle growth compared to 
control in vitro. Further, I found that this phthalate mixture at the 10, 100, and 500 µg/ml doses 
significantly disrupted the steroidogenic pathway by reducing sex steroid hormone levels and 
adversely affecting steroidogenic enzyme and receptor gene expression after 96 hours of culture. 
The growth of antral follicles and the ability to produce sex steroid hormones are closely related 
to one another. Normal growth is the priority of normal steroidogenic capacity. However, normal 
antral follicle growth also relies on the normal levels of sex steroid hormones present in the 
steroidogenesis pathway. Future studies should perform a time course experiment to determine if 
phthalate mixture inhibited antral follicle growth first, then affected steroidogenesis, or if the 
mixture reduced steroidogenesis first and in turn reduced antral follicle growth. In addition, future 
studies should examine if supplementation of precursor sex steroid hormones could rescue the 
antral follicles exposed to the phthalate mixture.  
In Chapter III, I also hypothesized phthalate mixture exposure induces follicle atresia to 
cause inhibition of antral follicle growth and steroidogenic capacity. I found that the phthalate 
mixture increased the expression of anti-apoptotic factor Bcl2 and decreased apoptotic factor 
Casp8, indicating reduced apoptosis in the phthalate mixture treated follicles compared to control. 
This is the opposite of what I hypothesized, so I further conducted histological evaluations to 
confirm my apoptotic factor gene expression. I found that the phthalate mixture decreased antral 
follicle atresia and induced more oocyte fragmentation compared to control. Further investigation 
showed that phthalate mixture induced cell cycle arrest by increasing the expression of cell cycle 
inhibitor Cdkn2a. A previous study has shown that the cells at cell cycle arrest are resistant to 
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apoptosis [7]. Thus, it is possible that follicular cells in the phthalate mixture treated groups 
arrested in the cell cycle; therefore, were resistant to apoptosis, leading to reduced atresia ratings 
in the histology evaluation. However, future studies are needed to perform a cell cycle analyses on 
the mixture exposed follicles to test the cell cycle arrest hypothesis. In addition, the cell cycle 
arrest in the phthalate mixture treated follicles was likely the reason for mixture-induced inhibited 
antral follicle growth and steroidogenic capacity. Because antral follicles are very important for 
sex steroid hormone production and fertility, decreased steroidogenic capacity and induced oocyte 
fragmentation can compromise female reproductive health and reduce fertility. Future studies 
should investigate if the effects of this phthalate mixture on steroidogenic pathway are permanent. 
Oocyte fragmentation has been reported to occur because of disruption in intracellular Ca2+ 
concentrations, the PI3K/Akt/mTOR pathway, and cytoplasmic polyadenylation element [8-10]. 
Future studies should examine if the phthalate mixture interferes with these processes to cause 
oocyte fragmentation.  
In Chapter IV, I tested the hypothesis that prenatal exposure to an environmentally relevant 
phthalate mixture disrupts female reproductive health and fertility in the F1 offspring. I found that 
this prenatal phthalate mixture exposure significantly affected uterine weight and AGD in the F1 
females. Given that both uterine weight and AGD are sensitive to hormonal changes, future studies 
should examine the hormone levels at the time of tissue collection, including levels of estradiol, 
progesterone, and testosterone. It is also important to examine the gonadotropin hormones, for 
example FSH and LH, because sex steroid hormones are affected by the gonadotropin hormones 
as well. The other important finding from the tissue collected from in Chapter IV is that I found a 
lot of F1 females in the phthalate mixture treated groups had enlarged cystic ovaries. Future studies 
should focus on the cause of this observation. Similar phenotypes have been observed in aged mice, 
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transgenic mice, and ovarian diseases mouse models [11-13]. Further histological and molecular 
analyses on these cystic ovaries are important to identify the types of cysts and the mechanism 
underlying the mixture induced ovarian cysts. 
In Chapter IV, I also found that prenatal exposure to phthalate mixture reduced F1 female 
fertility. First, it significantly disrupted estrous cyclicity in F1 females at different ages. I found 
that in the phthalate mixture exposed females, estrous cyclicity was more severely disrupted at 
younger age (after puberty and 3 months of age) than at an older age (6 months), and it was not 
disrupted in aged females. Future studies should examine the cause of disrupted cyclicity and 
explain why phthalate mixture did not affect estrous cyclicity in older animals as much as it did 
on the younger animals. Second, the phthalate mixture caused breeding and pregnancy 
complications in F1 females at all tested time points. I found that the phthalate mixture induced 
failure to mate, failure to become pregnant after successful mating, loss of pregnancy, and dystocia. 
I also found that these breeding and pregnancy complications got worse with age. Future studies 
should examine the causes of these breeding and pregnancy complications. Possible causes of 
these complications include disruption of ovarian function, uterine function, hypothalamic-
pituitary function, hormone regulation, or fetal development. Future studies focusing on the 
histological evaluation, hormonal examination, and molecular analyses of the target tissues are 
crucial to elucidate the causes of reduced fertility. Moreover, because it is not common to observe 
dystocia in mice, future studies should also investigate the causes of dystocia and the effects of 
dystocia on pup survival.   
In Chapter V, I hypothesized that exposure to an environmentally relevant phthalate 
mixture induces adverse effects on female reproduction in F2 and F3 female mice. I found that the 
phthalate mixture induced multigenerational and transgenerational effects on body weights, tissue 
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weights, and AGD in both the F2 and F3 generations. The phthalate mixture induced changes were 
more frequently observed in F2 generation than F3 generation. Given that the F2 generation was 
exposed as germ cells and the F3 generation was not exposed to the mixture, the phthalate mixture 
induced changes might be through different mechanisms for F2 and F3 generations. Future studies 
should examine the mechanisms underlying these changes in two different generations and 
compare with the mechanisms with those in the F1 generation. I also found that the phthalate 
mixture at a lower dose in my study induced obesity in F2 generation. Phthalates have been 
characterized as EDCs and have shown to induce obesity by acting on nuclear receptors, such as 
the peroxisome proliferator-activated receptors (PPARs) [14-16]. Future studies should examine 
the causes of phthalate mixture induced obesity in the F2 generation, specifically focusing on the 
effects of the mixture on PPARs. It is also interesting that I only found phthalate mixture induced 
obesity in the second lowest dose, indicating different doses of the phthalate mixture could act 
differently to induce different effects. Future studies should also examine the dose response of the 
phthalate mixture at a wide range of doses and the different mechanisms involved for the mixture-
induced obesity. 
In addition, in Chapter V, I found that phthalate mixture did not affect estrous cyclicity in 
either the F2 or F3 generation at selected ages, but it reduced fertility in both generations. Unlike 
in F1 generation, the phthalate mixture did not affect estrous cyclicity in F2 or F3 generation at 
selected ages. However, I found that several females in F2 generation were not cycling at older 
age. Future studies should conduct a more comprehensive examination on the estrous cyclicity in 
the F2 and F3 generations similar to the examination performed in F1 generation. It is possible 
that phthalate mixture disrupted estrous cyclicity at other ages than the ages we tested in the current 
study. In addition, future studies should investigate the causes for the cessation of cycling in the 
194 
 
phthalate mixture treated group and examine whether this is a sign of early reproductive 
senescence. I also found that phthalate mixture induced similar breeding and pregnancy 
complications in the F2 and F3 generations, but to a lesser extent, than observed in the F1 
generation. It is possible that phthalate mixture disrupts fertility through different mechanisms in 
different generations. Future studies should examine the reproductive organs and hormone levels 
in F2 and F3 generations to explain the reduction in fertility, and also compare these findings with 
F1 generation to provide a better understanding on the transgenerational effects of this phthalate 
mixture on female fertility. 
In Chapter V, I compared the percentage of females who produced live pups from each 
generation and found that phthalate mixture reduce the ability of dams to produce live pups in all 
three generations compared to control. Producing dead litters can be the results of dystocia, lack 
of maternal care of the new born pups, or abnormal fetal development. Future studies should 
examine the causes of the death of the entire litter and the underlying mechanisms. I also found 
that the percentage of females producing live pups was dramatically reduced in F3 females. Given 
that the F3 generation is not exposed to the phthalate mixture directly, it is likely that the phthalate 
mixture induced some epigenetic changes. Future studies should focus on the epigenetic 
modifications caused by the phthalate mixture. In addition, I also compared the AGDs of the pups 
born from each of the fertility tests in all three generations. I found that phthalate mixture exposure 
induced different effects on AGD depending on the generation. AGD is an indicator of prenatal 
androgen levels. Thus, future studies should examine the androgen levels from different 
generations to determine if phthalate mixture affect androgen levels differently in each generation, 
as well as the different mechanisms involved. Moreover, I found several doses reduced AGD in 
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both F2 and F3 generations. Future study should examine if these effects will be carried on in 
future generations and how this will affect reproductive health.  
Future studies should also investigate the mechanisms underlying phthalate mixture 
induced effects on female reproduction. I observed that direct in vitro and systematic in vivo 
phthalate mixture exposure adversely affected female reproduction in mice. However, the 
mechanisms are not fully understood. Further examinations on the mechanisms involved in both 
in vitro and in vivo experiments are valuable to study the toxicity of this phthalate mixture. Future 
analyses should also be performed to determine if phthalate mixture exposure through different 
routes (in vitro organ culture or oral exposure) can induce similar adverse effects. Moreover, it is 
unknown whether the phthalate mixture would induce adverse effects on female reproduction if 
exposed during a different dosing window, such as neonatal development. One study has shown 
that the estimated DEHP exposure for neonatal intensive-care unit infants is much higher than 
daily human exposure and approaches the lowest observed adverse effect level in animal studies 
[17]. Currently, there is no information available on the effects of neonatal phthalate mixture 
exposure on reproductive health. Future investigation is needed to examine the effects and 
mechanisms of neonatal exposure of this mixture both in vitro and in vivo. Moreover, given that 
humans are constantly exposed to phthalates on a daily basis, a continuous phthalate mixture 
exposure study through diet or drinking water will provide a better understanding of the effects of 
phthalate exposure on human health. 
Overall, my doctoral dissertation work shows that an environmentally relevant phthalate 
mixture can disrupt female reproductive health. Specifically, direct exposure to this phthalate 
mixture in antral follicle culture reduced follicle growth, compromised steroidogenic capacity, 
arrested cell cycle, and induced oocyte fragmentation. Moreover, in vivo prenatal exposure to 
196 
 
phthalate mixture induced multigenerational and transgenerational disruptions on female fertility 
and reproductive health. These findings provide important new information on the effects of a 
phthalate mixture that mimics human exposure. This work is important to public health because 
humans and animals are constantly exposed to mixtures of chemicals. Further, the relatively low 
doses used in my doctoral dissertation work made the animal exposure model relevant to human 
exposure. 
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